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SUMMARY 
 
MHC class II-peptide multimers are important tools for the detection, enumeration and 
isolation of antigen-specific CD4+ T cells. However, their erratic and often poor performance 
impeded their broad application and thus in-depth analysis of key aspects of antigen-specific 
CD4+ T cell responses. In the first part of this thesis we demonstrate that a major cause for 
poor MHC class II tetramer staining performance is incomplete peptide loading on MHC 
molecules.  We observed that peptide binding affinity for “empty” MHC class II molecules 
poorly correlates with peptide loading efficacy. Addition of a His-tag or desthiobiotin (DTB) 
at the peptide N-terminus allowed us to isolate “immunopure” MHC class II-peptide 
monomers by affinity chromatography; this significantly, often dramatically, improved 
tetramer staining of antigen-specific CD4+ T cells. Insertion of a photosensitive amino acid 
between the tag and the peptide, permitted removal of the tag from “immunopure” MHC 
class II-peptide complex by UV irradiation, and hence elimination of its potential interference 
with TCR and/or MHC binding. Moreover, to improve loading of self and tumor antigen-
derived peptides onto “empty” MHC II molecules, we first loaded these with a 
photocleavable variant of the influenza A hemagglutinin peptide HA306-318 and subsequently 
exchanged it with a poorly loading peptide (e.g. NY-ESO-1119-143) upon photolysis of the 
conditional ligand. Finally, we established a novel type of MHC class II multimers built on 
reversible chelate formation between 2xHis-tagged MHC molecules and a fluorescent 
nitrilotriacetic acid (NTA)-containing scaffold. Staining of antigen-specific CD4+ T cells 
with “NTAmers” is fully reversible and allows gentle cell sorting. 
In the second part of the thesis we investigated the role of the CD8  transmembrane domain 
(TMD) for CD8 coreceptor function. The sequence of the CD8 D but not the 
CD8 D, is highly conserved and homodimerizes efficiently. We replaced the 
CD8 D with the one of the interleukin-2 receptor chain (CD8 Tac) and thus ablated 
CD8 D interactions. We observed that T1 T cell hybridomas expressing CD8 Tacβ 
exhibited severely impaired intracellular calcium flux, IL-2 responses and K
d
/PbCS(ABA) 
P255A tetramer binding.  By means of fluorescence resonance energy transfer experiments 
(FRET) we established that CD8 Tacβ associated with TCR:CD3 considerably less efficiently 
than CD8 β, both in the presence and the absence of Kd/PbCS(ABA) complexes. Moreover, 
we observed that CD8 Tacβ partitioned substantially less in lipid rafts, and related to this, 
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associated less efficiently with p56
Lck
 (Lck), a Src kinase that plays key roles in TCR 
proximal signaling. Our results support the view that the CD8 TMD promotes the formation 
of CD8 β-CD8 β dimers on cell surfaces. Because these contain two CD8β chains and that 
CD8β, unlike CD8 mediates association of CD8 with TCR:CD3 as well as with lipid rafts 
and hence with Lck, we propose that the CD8 TMD plays an important and hitherto 
unrecognized role for CD8 coreceptor function, namely by promoting CD8 β dimer 
formation. We discuss what implications this might have on TCR oligomerization and TCR 
signaling.     
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RÉSUMÉ 
 
Les multimères de complexes MHC classe II-peptide sont des outils importants pour la 
détection, le dénombrement et l'isolation des cellules T CD4+ spécifiques pour un antigène 
d’intérêt. Cependant, leur performance erratique et souvent inadéquate a empêché leur 
utilisation généralisée, limitant ainsi l’analyse des aspects clés des réponses des lymphocytes 
T CD4+. Dans la première partie de cette thèse, nous montrons que la cause principale de la 
faible efficacité des multimères de complexes MHC classe II-peptide est le chargement 
incomplet des molécules MHC par des peptides. Nous montrons également que l'affinité du 
peptide pour la molécule MHC classe II “vide” n'est pas nécessairement liée au degré du 
chargement. Grâce à l’introduction d’une étiquette d’histidines (His-tag) ou d’une molécule 
de desthiobiotine à l'extrémité N-terminale du peptide, des monomères MHC classe II-
peptide dits “immunopures” ont pu être isolés par chromatographie d’affinité. Ceci a permis 
d’améliorer significativement et souvent de façon spectaculaire, le marquage des cellules T 
CD4+ spécifiques pour un antigène d’intérêt. L’insertion d’un acide aminé photosensible 
entre l’étiquette et le peptide a permis la suppression de l’étiquette du complexe MHC classe-
II peptide “immunopure” par irradiation aux UV, éliminant ainsi de potentielles interférences 
de liaison au TCR et/ou au MHC. De plus, afin d’améliorer le chargement des molécules 
MHC classe II “vides” avec des peptides dérivés d’auto-antigènes ou d’antigènes tumoraux, 
nous avons tout d’abord chargé les molécules MHC “vides” avec un analogue peptidique 
photoclivable issu du peptide HA306-318 de l’hémagglutinine de la grippe de type A, puis, sous 
condition de photolyse, nous l’avons échangé avec de peptides à chargement faible (p.ex. 
NY-ESO-1119-143). Finalement, nous avons construit un nouveau type de multimère 
réversible, appelé “NTAmère”, basé sur la formation chélatante reversible entre les molécules 
MHC-peptide étiquettés par 2xHis et un support fluorescent contenant des acides 
nitrilotriacetiques (NTA). Le marquage des cellules T CD4+ spécifiques pour un antigène 
d’intérêt avec les “NTAmères” est pleinement réversible et permet également un tri cellulaire 
plus doux. 
Dans la deuxième partie de cette thèse nous avons étudié le rôle du domaine 
transmembranaire (TMD) du CD8  pour la fonction coréceptrice du CD8. La séquence du 
TMD du CD8 , mais pas celle du TMD du CD8β, est hautement conservée et permet une 
homodimérisation efficace. Nous avons remplacé le TMD du CD8  avec celui de la chaine  
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du récepteur à l’IL-2 (CD8 Tac), éliminant ainsi les interactions du TMD du CD8 . Nous 
avons montré que les cellules des hybridomes T T1 exprimant le CD8 Tacβ présentaient une 
atteinte sévère du flux du calcium intracellulaire, des réponses d’IL-2 et de la liaison des 
tétramères K
d/PbCS(ABA) P255A. Grâce aux expériences de transfert d’énergie entre 
molécules fluorescentes (FRET), nous avons montré que l’association du CD8 Tacβ avec le 
TCR:CD3 est considérablement moins efficace qu’avec le CD8 β, et ceci aussi bien en 
présence qu’en absence de complexes Kd/PbCS(ABA). De plus, nous avons observé que le 
CD8 Tacβ se distribuait beaucoup moins bien dans les radeaux lipidiques, engendrant ainsi, 
une association moins efficace avec p56
Lck
 (Lck), une kinase de la famille Src qui joue un 
rôle clé dans la signalisation proximale du TCR. Nos résultats soutiennent l’hypothèse que le 
TMD du CD8  favorise la formation des dimères de CD8 β à la surface des cellules. Parce 
que ces derniers contiennent deux chaines CD8β et que CD8β, contrairement à CD8 , 
favorise l’association du CD8 au TCR:CD3 aussi bien qu’aux radeaux lipidiques et par 
conséquent à Lck, nous proposons que le TMD du CD8  joue un rôle important, jusqu’alors 
inconnu, pour la fonction coreceptrice du CD8, en encourageant la formation des dimères 
CD8 β. Nous discutons des implications possibles sur l’oligomerisation du TCR et la 
signalisation du TCR. 
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LIST OF ABBREVIATIONS 
 
ABA azidobenzoic acid 
Ahx ε-aminocaproyl 
AP alkaline phosphatase 
APC antigen-presenting cell 
APS ammonium persulfate 
β2m beta2-microglobulin 
BSA bovine serum albumin 
BSP biotinylation sequence peptide 
CD cluster of differentiation 
CDR complementarity determining region 
CTL cytotoxic T lymphocyte 
kD kiloDalton 
DMEM Dulbecco’s modified Eagle medium 
DNA deoxyribonucleic acid  
DMSO dimethylsulfoxide 
EBVB EBV-transformed lymphoblastoid B cell 
ECL enhanced chemoluminescence 
ELISA enzyme-linked immunosorbent assay  
ER endoplasmic reticulum 
FCS fetal calf serum 
FACS fluorescence activated cell sorting 
FPLC fast protein liquid chromatography 
FITC fluorescein isothiocyanate 
HA influenza A hemagglutinin  
HEPES N-2-hydroxyethylpoperazine-N-2-
ethansulfonic acid 
HPLC high pressure liquid chromatography 
HRP horseradish peroxidase 
ICS intracellular staining  
Ig immunoglobulin 
IP immunoprecipitation 
ITAM immunoreceptor tyrosine activation motif 
IMDM Iscove’s modified Dulbecco’s medium 
LB Luria-Bertani 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
MW molecular weight 
NPG nitrophenylglycine 
NPPA nitrophenylpropionic acid 
mAb monoclonal antibody 
OD optical density 
PAGE polyacrylamide gel electrophoresis 
PbCS Plasmodium berghei circumsporozoite 
PBMC peripheral blood mononuclear cell  
PCR polymerase chain reaction 
PE phycoerythrin 
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PHA phytohemagglutinin  
RPMI Roswell Park Memorial Institute medium 
RT room temperature 
SA streptavidin 
SDS sodium dodecyl sulfate 
TCR T cell receptor 
TMD transmembrane domain 
Temed N,N,N,N’ tetramethyl ethylenediamine 
Tris tris(hydroxymethyl)aminomethane 
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1. INTRODUCTION 
1.1 General introduction to immunity 
 
The immune system provides the body with protection against viral, bacterial and fungal 
pathogens, multicellular parasites, tumor cells and foreign transplanted tissue. Immune-
specific organs, cells and molecules are capable of efficiently eliminating interlopers 
recognized as non-self while minimizing damage to proper tissues. Epithelial surfaces are the 
first barriers to entry of pathogens, with mechanical (e.g. mucus), chemical (e.g. pH, 
enzymes, defensins) and microbiological (e.g. normal microbiota) mechanisms. Beyond this 
constitutive component of non-specific nature, the first cell-mediated line of defense is innate 
immune system, which is capable of mounting appropriate responses within the time span of 
minutes to hours. Innate immunity is armed with inducible mechanisms triggering 
phagocytosis, destruction and inflammation responses. The innate immune system is capable 
of recognizing and reacting to evolutionary conserved, broad non-self-features such as 
lipopolysaccharides present in the bacterial cell wall or unmethylated CpG DNA present in 
bacterial or viral genomes (Medzhitov, 2007).  
Recognition of pathogen-specific molecular signatures or antigens is pertinent to adaptive 
immunity in the medium to long term, and is present in vertebrates. A hallmark of adaptive 
immunity is memory, the ability to provide a long-lasting record of past encounters with an 
antigen in the form of specialized populations of cells which can rapidly elicit a recall 
response upon antigen re-encounter. The two cornerstones of adaptive immunity are B and T 
lymphocytes, constituting humoral and cellular immunity, respectively. In humans and mice, 
both types of cells arise from a common hematopoietic stem cell precursor from the bone 
marrow which can differentiate into mature, naive B cells in the bone marrow and three main 
subsets of T cells (CD4+, CD8+ and NKT) in a specialized organ, the thymus. After 
completing thymic development, T lymphocytes circulate through the blood stream and 
populate peripheral lymphoid organs such as the spleen, lymph nodes and other lymphatic 
tissues which are sites of antigen encounter.  
Both types of lymphocytes harbor specific receptors for recognition of antigens referred to as 
the B cell receptor (BCR) and the T cell receptor (TCR). TCRs can recognize antigens only 
in the form of peptides bound to major histocompatibility complex (MHC) proteins, a group 
of polygenic and highly polymorphic proteins. Fluorescent oligomeric recombinant MHC-
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peptide complexes, usually referred to as “tetramers”, are used to detect and sort antigen-
specific T cells by flow cytometry. The first subject of this thesis pertains to methods on how 
to improve the quality of MHC-peptide class II complexes, and therefore multimer binding to 
specific cells. The second subject of this thesis concerns the CD8 coreceptor molecule, where 
the importance of the CD8α chain transmembrane domain is investigated for its coreceptor 
function. 
1.2 T cell receptor 
1.2.1 Structural aspects of T cell receptors 
 
The T cell receptor (TCR) belongs to the immunoglobulin superfamily of proteins. Two 
forms have been identified: αβTCR and γδTCR. The αβTCR is expressed on CD4+, CD8+ T 
and NKT cells, while the γ TCR is expressed on a subset of intraepithelial lymphocytes, 
found predominantly in the skin and gut. The αβTCR is a membrane-bound heterodimeric 
protein composed of α and β chain, which are linked by a disulfide bond. The chains are 
encoded by genes formed by rearrangement of variable (V), diversity (D) (in β chain only), 
joining (J) and constant (C) segments that are highly similar to immunoglobulin chain 
formation. During T cell development, these segments are rearranged in a controlled and 
stepwise manner, resulting in 2x10
6
 and 2.5x10
8
 different TCR specificities in peripheral T 
cells of mice and humans, respectively (Casrouge et al., 2000; Robins et al., 2009). Structural 
studies of TCRs revealed four major differences from canonical immunoglobulin structures 
(Garboczi et al., 1996; Garcia et al., 1996a; Rudolph et al., 2006): i) a protruding, 13 residue 
long, FG loop in the constant domain of TCRβ; ii) rather flat surface of TCRα constant 
domain as a consequence of lacking several residues; iii) the absence of surface protrusions in 
the variable domain of TCRα because of a strand switch; iv) absence of flexibility in the 
hinge region of TCRβ. The TCR binds antigens in the form of peptides non-covalently bound 
to MHC proteins, known as MHC-peptide complexes. The binding site for MHC-peptide 
complexes is formed by six loops, called complementary determining regions (CDR). Each 
chain forms three CDRs. Two CDR loops are encoded by V gene segments (CDR1 and 
CDR2) and one by recombined V, (D on the β chain) and J segments (CDR3). Consequently, 
the CDR3 loop is the most polymorphic. While the CDR1 and CDR2 loops typically contact 
the helices of the MHC molecule, the highly polymorphic CDR3 loop interacts primarily with 
the MHC-bound peptide. TCRs tend to bind MHC-peptide complexes in a “diagonal” 
orientation, in which the peptide runs diagonally between the two CDR3 loops, extending 
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from CDR1α to CDR1β (Fig. 1.1). This orientation implies conserved atomic interactions 
between TCR V regions (mainly Vα) and residues of the MHC helices (mainly α2). However, 
binding modes of TCRs to MHC-peptide complexes vary considerably. In some cases CDR1 
and/or CDR2 loops make no or little contact and the orientation of TCR binding to MHC-
peptide is nearly perpendicular (Rudolph et al., 2006).  
                         
Figure 1.1 T cell receptor structure and diagonal ligand binding mode. A, Side view of the HA1.7 T cell 
receptor (TCR). The TCRα chain is in light blue and the TCRβ chain in light green. The constant and 
variable domains of both chains are labeled as Cα, Cβ and Vα, Vβ respectively. CDR loops from each 
chain are indicated by arrows. B, Top view of HA1.7 TCR with bound DR4/HA306-318. The TCRα is light 
blue and TCRβ is yellow-green. The HA306-318 peptide (PKYVKQNTLKLAT) is represented by a 
backbone in red and parts of the MHC (DR4) chains are shown in grey. Only residues Leu45 to Arg76 of 
MHCα (DRα) and Pro56 to Tyr96 (DR4β) are shown for clarity. The CDR3α loop (Glu94 to Leu104) is 
shown in dark blue and the CDR3β loop (Ser96 to Tyr106) in dark green. The protein backbone is 
represented as ribbons. Coordinates are from the PDB file ID code 1J8H. 
1.2.2 T cell receptor triggering 
 
Surface plasmon resonance studies on purified recombinant molecules showed that TCRs 
typically bind MHC-peptide complexes with low affinity (KD from 10
-4
 
to 10
-6
 
M)
 
and exhibit 
fast on-rates (10
3
 to 10
4
 s
-1
) and considerably slower off-rates (from 0.02 to 5 s
-1
) at room 
temperature. The rapid dissociation of TCR:MHC-peptide complexes allows the T cell to 
quickly scan MHC–peptide complexes on presenting cells and engage in TCR triggering in a 
rapid succession, which is usually referred to as serial triggering (Fremont et al., 1996b; 
Luescher et al., 1995b; Rudolph et al., 2002). Coordinate binding of CD8 to TCR-associated 
MHC-peptide greatly strengthens MHC-peptide binding to the TCR, mainly by decreasing  
TCR-MHC-peptide complex dissociation (Luescher et al., 1995b), allowing the recognition 
of weak and/or rare peptide ligands.   
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T cells are highly sensitive and can be triggered by just a few cognate MHC-peptide 
complexes (Irvine et al., 2002; Purbhoo et al., 2004). For CD4+ and CD8+ T cells it has been 
shown that MHC-peptide null ligands (i.e. ligands that bind to the TCR, but are too weak to 
trigger activation) significantly increase the sensitivity of antigen recognition (Cebecauer et 
al., 2005b; Krogsgaard et al., 2005; Wulfing et al., 2002). These and other findings support a 
model in which CD4 cross-links MHC-peptides engaged by TCRs by associating with one 
TCR and binding to the MHC-peptide engaging another TCR (Krogsgaard et al., 2005). 
A general mechanism to trigger receptors is dimerization (e.g. for erythropoietin receptor, 
growth hormone receptors and the pre-TCR) (Livnah et al., 1999; Yamasaki et al., 2006). 
There is also substantial evidence that TCR:CD3 can form dimers and higher aggregates 
(Minguet et al., 2007; Reich et al., 1997; Schamel et al., 2006; Yokosuka et al., 2005). 
Studies with soluble MHC-peptide complexes have shown that TCR triggering requires that 
these are at least dimeric, i.e. can induce TCR cross-linking (Cebecauer et al., 2005b; 
Cochran et al., 2001; Krogsgaard et al., 2005). TCR and coreceptor co-aggregation induces 
cross-linking mediated activation of Src kinases, such as coreceptor-associated Lck and TCR-
associated p59
fyn
 (Fyn). This initial tyrosine kinase activity mediates phosphorylation of CD3 
ITAMs, which allows docking of SH2 containing kinases like Syk-family ZAP-70, which 
upon activation phosphorylate diverse additional signaling molecules.  TCR micro clusters 
can be observed in APC-T cell contact areas as the sites where initial phosphorylation events 
and intracellular calcium flux emerge (Kane et al., 2000; Palacios and Weiss, 2004). The 
emerging view is that TCR aggregation elicits structural changes in CD3 complex (composed 
an εγ, an εδ and a ζζ dimer), which renders their ITAMs more amenable to kinases and 
adaptors (Minguet et al., 2007). Observations of T cell:APC synapses by confocal 
microscopy led to a third category of models which invoke segregation of large tyrosine 
phosphatases (e.g. CD45 or CD148) from the T cell:APC contact zones which would favor 
net phosphorylation of ITAMs by p56
Lck
. The exclusion of tyrosine phosphatases can be 
mediated purely on the basis of size of their ectodomains (the CD45 ectodomain is 540 
residue long in mice, Uniprot ID P06800) or by lipid-raft (also referred to as diffusional 
trapping) exclusion. Originally, this model was based on the observation that CD45 and 
CD148 are excluded from T cell:APC contact sites (Lin and Weiss, 2003; Varma et al., 
2006). Further support to this model is provided by experiments where the truncation of 
CD45 and CD148 ectodomains inhibits TCR triggering (Irles et al., 2003; Lin and Weiss, 
2003); elongation of MHC-peptide complexes inhibits TCR triggering (Choudhuri et al., 
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2009; Choudhuri et al., 2005); surface-bound MHC-peptide ligands induce TCR triggering 
better than soluble ones (Geppert and Lipsky, 1987; Ma et al., 2008) and the recognition of 
epitopes by engineered TCRs is better when they are positioned close to the target cell 
(Bluemel et al., 2010; James et al., 2008). The role of lipid rafts in T cell triggering has been 
subject to debate, as conflicting studies have been published. Nonetheless, it is recognized 
that they do play a role, albeit on a smaller scale than previously thought (Glebov and 
Nichols, 2004; Hashimoto-Tane et al., 2010; Pizzo et al., 2002; Zhu et al., 2005). 
1.2.3 T cell receptor signaling 
 
The TCR itself possesses no signal transduction capabilities (Fig. 1.2). Expression of a TCR 
on the cell membrane requires association with the CD3 complex. The intracellular tails of 
the CD3 chains contain immunoreceptor tyrosine activation motifs (ITAMs) crucial for 
initiation of TCR signaling. The CD3 complex consists of an εγ, an εδ and a ζζ dimer (Call 
and Wucherpfennig, 2004, 2005). The εδ and ζζ dimers associate with the TCRα chain and 
the εγ dimer with the TCRβ chain (Kuhns et al., 2010). Upon TCR triggering, the ITAM 
motifs (Y-x-x-L/I) on the long cytoplasmic tails of CD3 units are phosphorylated at their 
tyrosines by Src tyrosine kinases Lck and/or Fyn. Phosphorylated ITAMs bind SH2 domain 
containing kinases, such as ZAP-70 (ζ-chain-associated protein of 70 kDa) and Syk (Kane et 
al., 2000; Pitcher and van Oers, 2003). Lck can also phosphorylate ZAP-70 directly, thereby 
increasing its enzymatic activity (LoGrasso et al., 1996), as well as a negative regulator of 
ZAP-70 and Lck itself, SHP1, a tyrosine phosphatase (Kosugi et al., 2001). Activated ZAP-
70 phosphorylates tyrosines on LAT (linker of activation of T cells) which serves as a 
scaffold for organization of a proximal signaling complex consisting of PLCγ1, PI3K, GRB2, 
Gads and SLP-76. The activated plasma-membrane-associated PLCγ1 hydrolyzes PI(4,5)P2 
(phosphoinositol-4,5-diphosphate), a membrane constituent, whose products, IP3 (inositol-3-
phosphate) and DAG (diacyl-glycerol) activate downstream signaling pathways. IP3 triggers 
elevation of intracellular Ca
2+
 by activating IP3-dependent calcium channels in the 
endoplasmic reticulum (ER), thereby releasing Ca
2+
 from the ER into the cytosol. This influx 
of Ca
2+
 from intracellular stores triggers Ca
2+ 
channels in the cell plasma membrane aptly 
termed CRACs (Ca
2+
-release activated Ca
2+
 channels). Elevated concentration of Ca
2+
 
triggers release of cytotoxic granules, directly activates transcription factors MEF2 and 
DREAM, and signaling proteins calcineurin and CaMK (Ca
2+
/calmodulin-dependent protein 
kinase) which phosphorylates NFAT (nuclear factor of activated T cells), an important 
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transcription factor. The other signaling product of PI(4,5)P2 hydrolysis, DAG, activates the 
MAPK (mitogen-activated protein kinase) pathway through Ras. Another important pathway 
activated by DAG is the PKCθ-dependent pathway, with ends in activation of the NF-κB 
transcription factor and is mediated by the CARMA1/Bcl10/MALT1 complex, also referred 
to as the lymphocyte-specific activation complex. Negative regulation of TCR signaling is 
mediated by the Csk (C-terminal Src kinase) kinase that inactivates Lck by phosphorylation 
at Tyr505, and CD45 phosphatase that can directly dephosphorylate ITAMs. The end result 
of all this transcription factor activation is the production of cytokines (e.g. IL-2, IFNγ) and 
chemokines that activate long-range intercellular effector and signaling molecules of the 
immune system; reviewed in (Smith-Garvin et al., 2009). 
                      
Figure 1.2 T cell receptor proximal signaling pathways. T cell receptor (TCR) triggering induces a series of 
changes that activate ζ-chain associated protein of 70 kDa (ZAP-70) which phosphorylates linker of 
activaton of T cells (LAT) to assemble various components of the proximal signaling complex. A 
component of the complex, the phospholipase C γ1 (PLCγ1) breaks down PIP2 (phosphoinositol-4,5-
diphosphate) into two major small signaling molecules: inositol-triphosphate (IP3) and diacylglycerol 
(DAG). IP3 triggers Ca
2+
 channels in the ER and indirectly all Ca
2+
-dependent signaling pathways. DAG 
acts on the mitogen-activated protein kinase (MAPK) cascade via Ras. All these pathways end on 
transcription factors which relocate to the nucleus and activate transcription of target genes such as 
interleukin 2 (IL-2). Parts of these pathways branch out and act on cytoskeletal proteins, cell 
proliferation and survival. Proteins are represented by oval shapes. Small molecules are in rectangles or 
not associated by shapes. Activating receptors are blue; ligands in light green; structural, scaffold and 
regulatory proteins are shown in brown; kinases in blue-green; phosphatases in orange; GTP-exchange 
factors in yellow; GTP-ases in dark green and lipid modifying enzymes in purple. After (Huse, 2009).  
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1.3 MHC-peptide complexes 
1.3.1 Structural aspects of MHC-peptide complexes 
 
MHC-peptide complexes, ligands for αβTCRs, are non-covalent complexes composed of 
major histocompatibility proteins (MHC) and antigen-derived peptides. There are two classes 
of MHC proteins, encoded by genes clustered in the >4 million basepair MHC locus located 
on chromosome 6 in humans (HLA) and chromosome 17 in the mouse (H-2). There are 
multiple, highly polymorphic genes for human MHC class I and class II proteins. In humans, 
there are three main HLA class I loci, referred to as A, B and C and three HLA class II loci, 
called DR, DP and DQ; reviewed in (Kumanovics et al., 2003). According to the IMGT/HLA 
database at the European Institute for Bioinformatics (http://www.ebi.ac.uk/imgt/hla), release 
3.8.0 of April 12, 2012, there are 5880 HLA class I alleles (including minor E, F and G loci) 
coding for 4291 different proteins and 1647 HLA class II alleles (including DM and DQ loci) 
coding for 1208 different proteins (Fig. 1.3). In laboratory inbred strains of mice, the 
diversity of H-2 proteins is much smaller (Table 1.1). Both classes are comprised of non-
covalently associated protein chains and share common structural features, i.e. a TCR-facing 
peptide-binding cleft formed by two -helices and a β-sheet on the bottom, variable and 
constant immunoglobulin domains, transmembrane helices and short intracellular tail(s). 
Bound peptides interact with MHC protein primarily via a network of hydrogen bonds (Fig 
1.4). Some peptide amino acid residues with bulky side chains are buried in deep, frequently 
hydrophobic, pockets. MHC class I proteins consist of a heavy and a light chain, also referred 
to as 2-microglobulin, and bind peptides usually of 8 to 10 amino acid residues, whereas 
MHC class II proteins are comprised of two equally sized membrane-bound chains and bind 
larger peptides, from 9 to >20 amino acid residues in length, in an extended, poly-proline 
helix II-like conformation. Whereas MHC class I proteins have at least two prominent 
binding pockets accomodating peptide’s amino acid side chains, MHC class II proteins have 
typically four binding pockets at positions P1, P4, P6 and P9, where the pocket P1 is the 
primary with the other being secondary binding pockets. Amino acid residues whose side 
chains bind into these pockets are termed anchor residues. Residues at positions P2, P3, P5 
and P8 are typically solvent-exposed, i.e. available to contact the TCR. In many HLA-DR 
molecules, the pocket 1 is occupied by a bulky, hydrophobic side chain (F, Y or W) and 
defines the peptide binding register. Because MHC class II molecules do not impose any 
length constraints to bound peptides and the binding pockets can accommodate multiple 
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amino acid residues as anchors, a single peptide can bind in different registers giving rise to 
various conformers of the MHC class II-peptide complex (Lovitch and Unanue, 2005). The 
best studied examples of such conformers are those of I-A
k
/HEL48-62 and I-A
g7
/B9-23 
complexes (Mohan and Unanue, 2012). Following immunization of mice with hen egg-white 
lysozyme (HEL), two types of CD4+ T cells specific for the dominant HEL48-62 peptide are 
induced: type A, which react against APCs pulsed with the HEL protein or the HEL48-62 
peptide, whereas the type B cells react only with the APCs pulsed with the HEL48-62 peptide 
(Pu et al., 2002; Viner et al., 1996). In the non-obese diabetic (NOD) mouse, CD4+ T cells 
specific for the insulin beta chain (B) are key for the initiation of diabetes (Nakayama et al., 
2005). As in the HEL system, CD4+ T cells specific for the dominant B9-23 peptide can be 
found as type A and type B. In this case, it has been demonstrated that type A cells recognize 
the strongly binding B13-21 register and type B cells the weakly binding B12-20 register 
(Levisetti et al., 2007; Mohan et al., 2010; Mohan et al., 2011). Peptide-pulsed APCs present 
peptide loaded in early endosomes where H2-M is not present (see section 1.3.2) that would 
normally edit out the B9-23 peptide bound in the weakly binding register (Pu et al., 2004). The 
existence of type A and B cells has been linked to autoimmunity where the type B cells for 
self-antigens, able to escape thymic negative selection and present in the periphery, could be 
activated by APCs presenting extracellularly-generated peptides and trigger autoimmune 
reactions. 
These features of MHC class II molecules related to peptide binding have several important 
consequences for the design of fluorescent MHC-peptide class II multimers (section 1.6).  
 
                           
Figure 1.3 Human leukocyte antigen diversity in populations of the world. Bar charts representing the 
number of different proteins encoded by class I genes (A) or class II genes (B). Minor class I genes E, F, G 
and class II genes DM and DQ are not shown. Data are from the IMGT/HLA database, release 3.8.0, 
April 12, 2012. 
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Figure 1.4 Structural features of MHC-peptide complexes. A, Structure of the K
d
 in complex with the 
influenza nucleoprotein peptide 147-155 (TYQRTRALV). The β2-microglobulin (β2m) is in red and the 
H-2K
d
 heavy chain in blue. The peptide is shown in yellow. Coordinates are from the PDB file ID code 
2FWO. B, Structure of the DR4/HA306-318 complex. The DRα chain is shown in red, the DR4β in blue and 
the peptide in yellow. Coordinates are from the PDB file ID code 1J8H. Backbones of protein chains are 
represented as ribbons and peptide backbones with side chains as sticks. 
 
 
Table 1.1 Murine H-2 proteins in common strains of laboratory mice. Due to inbreeding, laboratory mice 
(Balb/c, C57BL/6, C3H/He, CBA) have a limited number of alleles in the H-2 class I (K, D and L) and 
class II (I-A and I-E) genes. 
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1.3.2 Pathways of antigen presentation 
 
The pathways of antigen presentation by MHC molecules have been extensively reviewed in 
(Neefjes et al., 2011). MHC class I molecules present peptides derived from 
(immuno)proteasomal degradation of intracellular proteins (Fig. 1.5A). Two ATP-dependent 
peptide transporters, TAP1 and TAP2, pump these peptides into the ER lumen where newly 
synthesized empty MHC class I proteins are present. Nascent MHC class I heavy chains are 
stabilized in association with calreticulin, tapasin and ERp57. Upon successful binding of a 
peptide ligand, MHC-peptide class I complexes bind β2-microglobulin and are exported and 
displayed on the cell surface. MHC class I proteins can also present peptides derived by 
extracellular antigens by a process termed cross-presentation.  
While all cells are able to express MHC class I molecules in a constitutive manner, MHC 
class II expression is under control of the MHC class II transactivator (CIITA), being 
constantly expressed only in DCs, macrophages, monocytes and B-cells (termed professional 
APCs) and is inducible under certain conditions, e.g. exposure to IFNγ, in all other cell types. 
MHC class II molecules present peptides derived from extracellular proteins degraded by 
endosomal cysteine proteases known as cathepsins (Fig. 1.5B). Extracellular antigens are 
taken up via IgG or Fc receptor-mediated endocytosis in B cells and DCs respectively, or by 
phagocytosis in macrophages. Recently, autophagy has been identified as a mechanism that 
also allows MHC class II proteins to present peptides derived from intracellular antigens 
(Klein et al., 2010). Cathepsins are activated by acidification of endosomal vesicles and/or 
fusion with acid lysosomes.  
Nascent MHC class II molecules are first associated with the invariant chain (Ii) that is 
degraded by cathepsins and other proteases to leave a fragment referred to as CLIP 
(PVSKMRMATPLLMQA), bound to the peptide-binding groove of the MHC protein. 
Exchange of CLIP with an antigen-derived peptide is favored by acidic pH and is catalyzed 
by an MHC class II homologue referred to as HLA-DM in humans and H2-M in the mouse, 
in specialized multi-vesicular and/or multilamellar compartments termed MIICs (MHC class 
II compartments). Another MHC class II-like molecule, HLA-DO in humans and H2-O in 
mice, can prevent interaction with MHC class II-CLIP complexes by physical association 
with HLA-DM/H2-M thereby acting as a negative regulator (Porter et al., 2011; Xiu et al., 
2011). To date, the exact role of HLA-DO/H2-O in antigen presentation is still unclear. 
 INTRODUCTION 
18 
 
 
Figure 1.5 Antigen presentation pathways. A, Basic pathway of antigen presentation by MHC class I 
molecules. Cytosolic antigens are degraded by the proteasome and pumped by peptide transporters 
associated with antigen presentation (TAP) into the endoplasmic reticulum (ER) where nascent MHC 
class I molecules are loaded. Defective or denatured intra-ER proteins are degraded by ER-associated 
protein degradation mechanisms (ERAD). Upon stable peptide binding, MHC class I molecules bind β2-
microglobulin (β2m) and are released from the ER and transported through the Golgi to the plasma 
membrane for binding to T cell receptors (TCRs) on CD8+ T cells. B, Basic pathway of antigen 
presentation by MHC class II molecules. MHC class II α-and β-chains assemble with the invariant chain 
(Ii) into a heterotrimeric complex in the endoplasmic reticulum (ER) of an antigen-presenting cell (APC). 
Subsequently, the MHC class II-Ii complexes are transported via the Golgi to the MHC class II 
compartment (MIIC) directly or passing by the plasma membrane. Endocytosed antigens and the MHC 
class II-associated Ii are degraded by resident proteases in the MIIC and the Ii fragment CLIP is 
exchanged for an antigenic peptide at acidic pH with the help of the HLA-DM (H2-M in mice). Such 
MHC class II-complexes are exported to the plasma membrane and presented as ligands to specific T cell 
receptors (TCRs) on CD4+ T cells. After (Neefjes et al., 2011). 
 
1.4 CD8 and CD4 coreceptors 
 
The developmental fate of T cells bearing the αβTCR depends on the surface expression of 
CD4 and CD8 molecules. T cells expressing CD4 are selected on MHC class II-peptide 
complexes while those expressing CD8 recognize their antigen in complex with MHC class I 
proteins. CD8 and CD4 are also referred to as coreceptors because they influence antigen 
recognition by the TCR.  
CD8 can occur in two forms. Homodimeric CD8αα consisting of disulfide-linked CD8α 
chains, is expressed on some intraepithelial lymphocytes (IEL), dendritic cells (DC), natural 
killer (NK) and NKT cells (Romero et al., 2005). Conversely, heterodimeric CD8αβ, 
consisting of a disulfide linked α and β chain, is expressed on some IEL in the gut and 
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importantly, on all αβTCR thymus-derived T cells (Fig. 1.6A). Both CD8 chains consist of an 
extracellular domain in which a long, heavily glycosylated stalk can be clearly distinguished 
from an N-terminal globular domain (Chang et al., 2005), a single transmembrane domain 
important for chain association and a cytoplasmic tail. The cytoplasmic tail of CD8β, but not 
of CD8α, contains the binding site for Lck, a Src tyrosine kinase that plays a crucial role in 
phosphorylation of the CD3 ITAMs, and hence initiating TCR signaling. While both CD8 
forms bind with comparable affinity (11-67 μM) (Garcia et al., 1996b; Kern et al., 1999) to 
the α3 constant domain of MHC class I molecules, they have completely different roles and 
activities. CD8αβ is the bona fide coreceptor, greatly increasing sensitivity and breadth of 
antigen recognition. By contrast, the biological role of CD8αα remains a matter of debate 
(Cheroutre and Lambolez, 2008; Romero et al., 2005) and when expressed on T cells tends to 
have an inhibitory role. The reasons for these differences include: i) the cytoplasmic tail of 
CD8β is palmitoylated, thereby promoting partitioning of CDαβ to lipid rafts and association 
with Lck and the linker of activation of T cells (LAT) ii) as a consequence lipid raft 
partitioning, there is about five times more Lck molecules associated with CD β than with 
CD8  (Bosselut et al., 2000); iii) differences in stalk length (Rettig et al., 2009) and 
flexibility between the two forms (the CD8β stalk is shorter than that of CD8α) and, iv) by 
co-ordinated binding  to TCR-associated MHC-peptide complexes, CD8 β, but not CD8 , 
strongly increases MHC-peptide binding activity (Arcaro et al., 2000).  
Acting as a coreceptor, CD8 associates with the TCR:CD3 complex and the MHC-peptide 
simultaneously. Immunoprecipitation experiments demonstrated that CD8 β but not CD8αα 
associates with the TCR:CD3 (Anel et al., 1997; Arcaro et al., 2001). Observations by FRET 
microscopy (Yachi et al., 2005) and micropipette adhesion frequency assay (Jiang et al., 
2011) revealed the inducible nature of this interaction. Interestingly, the anergic state of 
tumor-infiltrated human CD8+ CTLs can be at least partly explained by lack of association of 
TCR with CD8 (Demotte et al., 2008).  
 
 INTRODUCTION 
20 
 
 
Figure 1.6 CD8 and CD4 coreceptors in molecular context. A, CD8αβ immunoglobulin domain in complex 
with H-2D
d
/P18-I10 (RGPGRAFVTI) with murine β2-microglobulin (β2m) bound to a specific T cell 
receptor (TCR). CDαβ interacts with the acidic loop on the α3 domain of H-2Dd (residues 222-228). The 
CD8α chain is in ochre; CD8β in blue; H-2Dd in green; β2m in magenta; TCRα in rose and TCRβ in gold. 
Protein backbones represented as ribbons. The peptide is in light blue, represented as sticks.  Distance in 
angstroms between the antigen presenting cell and the CD8+ T cell as a sum of heights of the TCR (68 Å) 
and the MHC-peptide (60 Å) is represented. After (Wang et al., 2009). B, Ternary complex between the 
extracellular part of CD4 (domains D1-D4) bound to the HLA-DR4/MBP114-126 (FSWGAEGQRPGFG) 
and the MS2-3C8 TCR. The CD4 is a high-affinity variant which harbors two point mutations in the D1 
domain (Gln40Tyr/Thr45Trp) increasing its avidity to HLA-DR4 to 10.1 μM. Most of the contacts 
between CD4 and the HLA-DR4 are with β2 domain (residues 104, 114, 116, 142-145, 148, 158, 160, 162) 
with some in the α1 domain (residues 88, 90, 176). It is notable that the structure has an inverted V-shape. 
The TCR:MHC-peptide axis is tilted to 60
o
 against the plasma membrane and the CD4, the apical angle is 
70
o. CD4 is shown in magenta, the MHCα in grey, MHCβ in gold, TCRα in blue, TCRβ in green. Peptide 
backbone is shown in red. After (Yin et al., 2012). 
CD8αβ can also function as an adhesion molecule. As first demonstrated in a plate adhesion 
assay, CD8+ CTLs avidly adhere to plastic coated with non-cognate MHC-peptide complexes 
after sub-optimal TCR triggering, e.g. by low concentrations of a soluble anti-TCR or CD3 
antibody (O'Rourke et al., 1990). Subsequent studies showed that CD8-mediated adhesion is 
driven by partial TCR signaling. It has been shown that CD8 is associated with the actin 
cytoskeleton (Geppert and Lipsky, 1991; O'Rourke et al., 1991), arguing that cytoskeletal 
rearrangements are important for CD8-mediated adhesion. A recent finding indicates that 
kinetically, CD8 adhesion events precede engagement by the TCR by approx. 1 second (Jiang 
et al., 2011). 
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CD8 coreceptor function can be modulated during T cell development and differentiation by 
changes in CD8 glycosylation and silalylation. In particular the O-linked glycosylation and 
sialylation of CD8β increases when CD4, CD8 double positive thymocytes convert into CD8 
single positive thymocytes and T cells and decreases again upon T cell activation (Moody et 
al., 2001; Shore et al., 2005). CD8 coreceptor function can also be regulated by tuning the 
CD8 surface expression and perhaps by over expression of CD8α (or down-modulation of 
CD8β) (Maile et al., 2005).  
CD4 consists of four immunoglobulin domains (D1 to D4), a transmembrane and 
cytoplasmic domain, similar to that of CD8β, can be palmitoylated (Fig. 1.6B). The 
interaction of CD4 with the constant domains of MHC class II molecules is nearly 10-fold 
lower as compared to the interaction of CD8 with MHC class I molecules (KD>200 µM 
versus 50-150 µM for CD8 β) (Fremont et al., 1996b). Whereas CD8 substantially 
strengthens the binding of MHC class I-peptide complexes to cell-associated TCR, CD4 has 
no influence on the MHC class II-peptide binding.  CD4 can form dimers and tetramers, 
which are highly active as coreceptors (Maekawa et al., 2006). Moreover, CD4 and CD8 can 
both associate with TCR:CD3, which involves CD3δ and enhances MHC-peptide binding 
and T cell activation (Doucey et al., 2003). 
1.5 T cells 
1.5.1 Origin and development of T cells 
 
T cell development, reviewed extensively in (Koch and Radtke, 2011), originates from 
hematopoetic stem cells (HSC) precursors, which are located in the bone marrow. As 
multipotent stem cell (MSCs) progenitors leave the bone marrow and enter the thymus, they 
lose self-renewal potential and start their differentiation pathways, circulating through 
distinct anatomical parts: cortex, subcapsular zone, medulla and back to the cortex. Thymic 
seeding progenitors (TSPs), derived from MSCs, pass through four developmental stages 
termed double negative (DN1 to DN4) where cells do not express coreceptor proteins, i.e. are 
CD8- CD4-. The DN stages can be differentiated by their differential expression of CD44 and 
CD25. During that time, T cell precursors rearrange their TCRβ chains and express them on 
the cell surface along with an invariant pTα chain and the CD3 complex, forming a pre-TCR. 
It is only after productive pre-TCR triggering and cellular expansion that both coreceptors are 
expressed and cells acquire a double positive (CD8+ CD4+) phenotype (DP). The TCRα 
chain then rearranges and such cells express clonotypic fully mature αβTCRs and are ready to 
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engage in a selection process, (also referred to as “central tolerance”) to finally become single 
positive (SP) and commit to CD8+ or CD4+ T cell lineages. 
During positive selection, DP thymocytes interact with MHC-self-peptide complexes 
expressed on the surface of thymic epithelial cells (TECs). In the case of successful 
engagement in low avidity interactions with presented MHC-self-peptide complexes, DP 
thymocytes receive a survival signal and continue their differentiation program further. Those 
that cannot engage die passively, i.e. undergo “death-by-neglect”. By contrast, in the case of 
overly strong interactions, the stimulatory signal received results in apoptosis. This process, 
called negative selection, is extensively reviewed in (Palmer, 2003). It is extremely important 
as it prevents harmful, autoreactive T cells from reaching body tissues where they would 
potentially trigger autoimmune reactions. Substantial evidence from experiments using 
altered peptide ligands on S14, T1 and OT-I transgenic TCRs showed that there is an affinity 
threshold of  ~6 μM between positive and negative selection (Naeher et al., 2007; Palmer and 
Naeher, 2009). Above this threshold, for TCR:MHC-peptide affinities of <6 μM, negative 
selection occurs. It is estimated that because of death-by-neglect and apoptosis during 
negative selection only 5% of initial DP thymocytes reach maturity.  
1.5.2 Activation and differentiation of T cells 
 
After exit from the thymus, naïve T cells populate defined areas of secondary lymphoid 
organs and recirculate back through body tissues via the bloodstream. Upon their very first 
antigen encounter, in addition to TCR:CD3 signaling triggered by recognition of cognate 
MHC-peptide class I or class II complexes, a second signal is needed. This additional 
requirement is termed costimulation, namely productive triggering of CD28 expressed on the 
surface of the T cell by CD80 (B7.1) and CD86 (B7.2) on the APC. In the absence of this 
second signal, T cells fail to activate and enter a non-functional state termed anergy.  
Activated cells upregulate CD25, the alpha chain of the receptor for IL-2 (a key growth-
promoting factor), and downregulate CCR7, a receptor important for homing in secondary 
lymphoid organs. IL-2 is produced in a paracrine fashion as well. Furthermore, a common 
surface antigen, CD45 changes to a shorter splicing isoform (from CD45RA to CD45RO). 
Activated cells can further differentiate into short-lived effectors and long-lived memory 
cells. Memory cells are antigen-experienced and can rapidly respond to antigen in a 
costimulation-independent way. 
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1.5.3 CD8+ T cells 
 
The main function of CD8+ T cells consists in killing pathogen infected or transformed cells, 
so they are therefore known as cytotoxic T cells (CTLs), which display antigenic peptides 
derived from endogenously produced antigens bound to MHC class I molecules, as reviewed 
in (Harty et al., 2000). Activated CD8+ CTLs kill target cells primarily by releasing perforin 
and granzymes, which in a synergistic manner induce target cell death via caspase-dependent 
apoptosis. CTL can also kill other cells by expressing FasL, which binds to Fas on target cells 
and induces apoptosis. Fas-dependent killing can also be used by helper T cells (Th) and 
other cells, e.g. to maintain homeostasis and to regulate development. Activated CTLs also 
release cytokines, such as TNF, IFNγ and variable amounts of other interleukins. Perforin-
dependent killing is rapid (from a few minutes to a few hours) and can be elicited by a few 
MHC–peptide complexes on target cells. By contrast, cytokine production and FasL synthesis 
involve gene transcription, which requires sustained TCR signaling for extended periods of 
time. Fas-dependent cytolysis is slower than perforin dependent cytolysis (6–18 h) and TNF-
mediated killing is slower still (after 16 h). In some cases Fas–FasL-dependent killing 
involves translocation of preformed, intracellular FasL to the cell surface or release of soluble 
FasL. 
1.5.4 CD4+ T cells – subsets and functions 
 
The principal function of CD4+ T cells is to support and regulate cellular and humoral 
immune responses. Th cells control B cell antibody class switching and support antibody 
production (Lederman et al., 1996). They also promote proliferation, differentiation and 
activation of cytotoxic T cells (CTLs), and increase bactericidal activity of macrophages 
(Constant and Bottomly, 1997; Dong and Flavell, 2001; Tato et al., 2006) and produce 
cytokines. Originally Th cells were divided into Th1 and Th2 cells (type 1 and type 2 Th) 
(Dong and Flavell, 2001; Reinhardt et al., 2006; Susan L, 1999). Th1 cells produce 
proinflamatory cytokines, mainly interferon-γ (IFNγ) and tumor necrosis factor-β  (TNFβ). 
Th1 cytokines augment the cytotoxicity of macrophages and proliferation of cytotoxic CD8+ 
T cells. Th1 cells also express CD40 ligand (CD154) and Fas ligand (CD178) on cell surface, 
thereby mediating costimulation and apotosis, respectively. Differentiation of Th1 is driven 
by IL-12, IL-18 and IL-27, cytokines produced by APCs such as macrophages and DCs. 
Activated Th2 cells produce IL-4, IL-5, IL-6 and IL-13. These cytokines stimulate B cells to 
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proliferate, to induce antibody class switching, and to increase antibody production, i.e. are 
crucial for humoral immunity, including IgE-mediated allergic reactions. Many of the Th2 
cytokines also act on CD4+ T cells and other immune cells and can be part of regulatory 
mechanisms (e.g. IL-4 promotes the production of Th2 cytokines (including itself), and Th1 
cytokines (IFNγ, TNFβ) inhibit differentiation into Th1. It was proposed to separate a 
specific subset, referred to as Th9, which arises from Th2 cells and secretes broadly 
inhibitory cytokines IL-9 and IL-10, previously assigned to the Th2 subset itself (Dardalhon 
et al., 2008; Veldhoen et al., 2008). These cytokines negatively affect secretion of IL-2 and 
IFNγ by Th cells and IL-12 by DC and macrophages). Th1 and Th2 cells express different 
sets of chemokine receptors, which govern their migration to different sites (Dong and 
Flavell, 2001). Th1 cells preferentially express CCR5, CXCR3 and CCR1, which allow them 
to migrate to inflammatory sites. By contrast Th2 cells express CCR3, CCR4 and CCR8, 
which are important for recruitment to site of allergic reactions. Th1 and Th2 cells are well 
characterized at the level of specific transcription factors driving their distinct gene 
expression programs. Th1 cells express Stat1, Stat4 and T-bet and Th2 cells express Stat5, 
Stat6 and GATA3 transcription factors. T-bet and GATA3 are master transcription factors 
and de facto represent their lineage markers. Additional CD4+ Th cell subsets were recently 
defined, such as Th3, which produce mainly TGFβ (transforming growth factor β); Th17, 
which by secreting IL-17A and other cytokines, promoting protective immunity against 
extracellular bacteria and fungi, mainly at mucosal surfaces. They also promote autoimmune 
and inflammatory diseases. Further subsets are Tfh (follicular helper cells) which due to 
CXCR5 expression migrate to B cell follicles to support B cell development by secreting IL-
21 and Th22 cells which secrete IL-22 and were identified in inflammatory skin diseases. 
Under certain conditions leading to expression of eomesodermin (EOMES), such as repeated 
exposure to antigen (e.g. EBV, HIV-1, CMV infections), Th1 cells can acquire full cytolytic 
machinery (Qui et al., 2011). Regulatory T cells comprise thymus-derived nTreg cells 
(natural regulatory T cells), and iTreg (induced regulatory T cells) that arise from naïve Th 
cells in the periphery. nTregs express constitutively high levels of CD25, secrete TGFβ and 
IL-10 inhibitory cytokines (Bacchetta et al., 2005; Grazia Roncarolo et al., 2006). A distinct 
subset of iTregs, Tr1 cells, are suppressive cells generated under experimental conditions in 
vitro from naïve T cells in the presence of TGFβ and IL-27 or in the presence of the 
immunosuppressive drugs vitamin D3 and dexamethasone. These cells do not undergo 
negative thymic selection and therefore have relatively high affinities for self-antigens. The 
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transcription factor FoxP3 is required for regulatory T cell development and is a master 
regulator of the genetic program for this lineage, along with the transcription factors Smad3 
and Stat5. iTregs are also CD25+ and FoxP3+ and differentiate from naïve peripheral CD4+ 
cells, namely under the influence of TGFβ and IL-2. 
Regulatory T cells play a crucial role in T cell homeostasis and in suppressing T cell 
mediated immunity against self-antigens (Randolph and Fathman, 2006; Wahl and Chen, 
2005). A major mechanism of inhibition is via secretion of inhibitory cytokines, namely IL-
10 and TGFβ. IL-10 inhibits CD28-mediated tyrosine phosphorylation and hence CD28-
mediated co-stimulation. TGFβ suppresses the activity of most immune cells. Regulatory T 
cells also express high levels of inhibitory coreceptors such as CTLA-4 (cytotoxic T-
lymphocyte associated molecule-4), GITR (glucocorticoid-induced TNF receptor) and PD-1 
(programmed cell death-1) inhibitory coreceptors (Yamazaki et al., 2006), acting negatively 
on T cells by contact inhibition. Treg have a greater TCR diversity than effector T cells, with 
recognition biased towards self-peptides (Föhse et al., 2011). Regulatory T cells actively 
suppress activation of immune responses against self-antigens and thus prevent autoimmune 
disease. Genetic deficiency in Tregs results in severe autoimmune syndromes. The balance in 
the differentiation of the various CD4+ effector and regulatory T cells is controlled to a large 
extent by DCs (de Jong et al., 2005). Immature DCs reside in different tissues and in the 
blood and can be activated by pathogens, e.g. via Toll-like receptors (TLR), which are 
members of the IL-1 receptor/TLR superfamily. Upon activation DCs acquire effector 
functions, including production of proinflamatory cytokines and support local innate immune 
responses; they also up-regulate MHC class II, CD80 and CD86 thereby efficiently 
promoting the differentiation of CD4+ T cells into effector cells.  
1.6 Fluorescent MHC-peptide oligomers (“tetramers”) 
 
The invention of MHC-peptide tetramers (Altman et al., 1996) revolutionized CD8+ T cell 
immunology (Klenerman et al., 2002). Tetramers made possible enumeration and isolation of 
antigen-specific T cells. MHC-peptides are natural ligands for T cell receptors (TCRs). 
Because TCR:MHC-peptide interactions are of low affinity (micromolar dissociation 
constants) and relatively short lived (off-rates in the range of seconds) (Merwe and Davis, 
2003), fluorescently labeled monomeric MHC-peptide complexes cannot be used to stain T 
cells. Oligomerization of biotinylated MHC-peptides on fluorescent streptavidin provides 
such conjugates with sufficiently stable binding to allow detection of cell-bound complexes 
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by flow cytometry. Streptavidin-phycobiliprotein conjugates (e.g. phycoerythin or 
allophycocyanin) are most commonly used because of their intense fluorescence. Because of 
the large size of these fluorochromes, such conjugates are typically heterogeneous and hence 
the resulting staining reagents are multimeric (Guillaume et al., 2003).  
Applying the same strategy to MHC class II-peptide complexes encountered numerous 
difficulties, only some of which have been solved (Guillaume et al., 2009; Kwok, 2003; 
Vollers and Stern, 2008). Soluble recombinant MHC class II monomers proved more difficult 
to produce than their class I counterparts. While MHC class I heavy chains can be readily 
refolded from heavy and light chains produced in E. coli in the presence of a given binding 
peptide, this method is generally not applicable to the production of MHC class II-peptide 
complexes, except for rare cases such as for HLA-DR1 (Frayser et al., 1999). The most 
successful expression system proved to be based on Drosophila S2 cells, probably at least in 
part because of their ability to grow between 20 and 28 
o
C (optimum at 26 
o
C) which favors 
thermolabile MHC class II proteins. Naturally, transmembrane domains (TMDs) have an 
important role in the formation and stabilization of the MHC class II heterodimer. In soluble 
recombinant MHC II molecules, acidic and basic leucine zippers replace the TMDs to 
promote chain pairing. One of the leucine zippers is C-terminally fused with an Avi-Tag (also 
referred to as BSP tag), which is recognized and biotinylated by the E. coli BirA enzyme in 
the presence of ATP. There are two approaches to produce MHC-class II peptide complexes. 
One is to encode the peptide fused via a flexible (often thrombin-cleavable) linker to the 
MHC class II β chain and the other is to load the “empty” molecules with the peptide in vitro. 
The so-called “peptide tethered-on” approach is sometimes necessary if “empty” MHC class 
II molecules of a particular allele are very unstable, and is favored by crystallographers; such 
complexes are more amenable to crystallization. Disadvantages are that a separate β chain 
construct is required for every different MHC-peptide complex and that linker length imposes 
constraints on the peptide (Cunliffe et al., 2002). To prepare MHC-class II peptide complexes 
by loading is a more flexible strategy.  
While it is possible to detect antigen-specific CD8+ T cells directly ex vivo, for most 
specificities frequencies of effector CD4+ T cells are at or just above 0.02%, i.e. detection 
limit of flow cytometers (Vollers and Stern, 2008). Higher frequencies of specific cells can be 
found in diseased tissues (e.g. lung parenchyma of mice infected by Sendai virus (Cauley et 
al., 2002) or human synovial fluid from individuals affected by Lyme disease (Meyer et al., 
2000)). CD4+ memory cells are very rare; their frequencies in peripheral blood are estimated 
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at 1/100,000 or lower (Vollers and Stern, 2008). Naïve cells counts are also well below flow 
cytometric detection limits (Moon et al., 2007). Usually strategies such as peptide-stimulated 
expansion in vitro or tetramer-guided MACS (Day et al., 2003) are required to visualize 
antigen-specific CD4+ T cells by flow cytometry. 
It is not clear why antigen-specific CD4+ T cells are at least an order of magnitude less 
frequent than CD8+ T cells in blood. A possible explanation could be the way peptides are 
presented by MHC class II molecules. Because their peptide-binding grooves are open-ended, 
MHC class II molecule-bound peptides are not of defined length. Peptides are presented as 
nested truncates (Chicz et al., 1992; Rudensky et al., 1991) with a common nonamer core 
binding sequence flanked by residues of variable length. Such core peptide-flanking residues 
have been shown to play a role in TCR recognition, MHC binding and MHC-peptide 
conformation (Arnold et al., 2002; Durinovic-Bello et al., 2006; Lovitch et al., 2006; 
Rötzschke et al., 1999). Changes in peptide-dependent conformation can be observed by 
NMR (Schmitt et al., 1999), mass spectrometry (Carven and Stern, 2005), differences in 
SDS-resistance (Natarajan et al., 1999b), measurements of hydrodynamic radii (Zarutskie et 
al., 1999), differential antibody reactivity (Carven et al., 2004) or T cell recognition (Lovitch 
and Unanue, 2005).  
Another reason is that in CD8+ T cells, epitope immunodominance is highly pronounced, 
leading to high frequencies of CD8+ T cells specific for immunodomainant epitopes. This is 
less so in the CD4+ T cell compartments, along with more limited burst sizes than CD8+ T 
cells. 
Coordinate binding of CD8 to TCR-associated MHC class I-peptide complexes provides a 
substantial increase in avidity of MHC class I-peptide multimer binding (Merwe and Davis, 
2003). This is not the case for MHC class II-peptide multimer binding, mainly because 
CD4:MHC class II-peptide interactions are very weak (KD>200 µM) (Xiong et al., 2001). 
Moreover, data comparing binding of several class I and class II MHC-peptide binding to 
their cognate TCRs showed on average weaker interactions of class II MHC-peptide:TCR 
(Cole et al., 2007). As those data are limited, it is not possible to generalize to all TCR:MHC 
class II-peptide interactions, but it is conceivable that MHC class II multimers can efficiently 
bind only to CD4+ T cells expressing TCRs of sufficiently high avidity. 
Refolding of MHC class I heavy chains in the presence of β2-microglobulin and peptide is an 
“all-or-none” process. Preparations of purified MHC class I-peptide complexes are highly 
molecularly homogenous. Conversely, register sliding has been demonstrated in mouse and 
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human recombinant MHC class II-peptide complexes, even with covalently bound long 
peptides (Cecconi et al., 2010; Landais et al., 2009; Stadinski et al., 2010). Adoption of 
alternate binding registers consequently yields heterogeneous mixtures of MHC class II-
peptide conformers giving multimers with suboptimal avidity. Heterogeneity arises as well 
when “empty” MHC molecules are loaded with peptides of interest, which is investigated in 
this thesis. 
1.7 Thesis aims 
 
The objectives of the thesis research include : 1) establishment of methods to reliably produce 
molecularly defined MHC class II-peptide multimers to further analysis of antigen-specific 
CD4+ T cells, 2) to invent a novel type of reversible MHC class II-peptide multimers for 
special applications, 3) elucidation of the role of the CD8  transmembrane domain for CD8 
coreceptor function.  
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2. MATERIALS AND METHODS 
2.1 General materials and methods 
2.1.1 Reagents and consumables 
 
β-mercaptoethanol Gibco/Invitrogen Life Technologies, US 
DMEM Gibco/Invitrogen Life Technologies, US 
RPMI 1640 Gibco/Invitrogen Life Technologies, US 
IMDM Gibco/Invitrogen Life Technologies, US 
Sf900 II SFM Gibco/Invitrogen Life Technologies, US 
Fetal calf serum Omnilab, CH 
Human serum Swiss Blood Bank, CH 
Mouse recombinant IL-2 Peprotech, UK 
Human recombinant IL-2 Peprotech, UK 
Polybrene Sigma, US 
Human β2-microglobulin courtesy of Dr. P. Guillaume 
GelCode Blue Stain reagent Pierce, US 
Precision Plus Protein Standards All Blue Bio-Rad, US 
Centrifugal filter devices (Amicon Ultra-
4/Ultra-15 ; Amicon concentration cell) 
Merck Millipore, US 
NHS-Cy5 GE Healthcare Life Sciences, SE 
CnBr Sepharose 4B GE Healthcare Life Sciences, SE 
PD-10 columns GE Healthcare Life Sciences, SE 
SigmaFAST pNPP substrate Sigma, US 
Amersham Hyperfilm ECL GE Healhcare Life Sciences, SE 
ECL detection solutions GE Healhcare Life Sciences, SE 
16% formaldehyde, MetOH free PolySciences, US 
 
All other chemicals were from Sigma, if not otherwise mentioned. 
2.1.2 Antibiotics 
 
Ampicillin Applichem, DE 
Penicillin/streptomycin Gibco/Invitrogen Life Technologies, US 
Puromycin Sigma, US 
 
2.1.3 Enzymes 
 
V. cholerae neuraminidase Roche, CH 
Restriction enzymes and accompanying 
buffers 
New England Biolabs or Promega, US 
T4 DNA polymerase Klenow fragment New England Biolabs, US 
Quick DNA ligase  Promega, US 
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2.1.4 Kits 
 
MaxiPrep, MiniPrep, RNAeasy Mini, 
QiaPrep, OmniScript RT, Qiashredder kits 
Qiagen, DE 
Mouse IL-2 and human IFN-γ ELISA Mabtech, SE 
2.1.5 Solutions and cell culture media 
 
TBE 
45 mM Tris-borate 
1 mM EDTA 
PBS 
 137 mM NaCl 
 2.7 mM KCl 
 8.0 mM Na2HPO4 
 1.5 mM KH2PO4 
TBS  
 20 mM Tris pH 8.0 
 100 mM NaCl 
 
Stacking gel solution 
 
 30% acrylamide solution 
 1 M Tris pH 6.8 
 10% SDS 
 10% APS 
 0.25% TEMED 
 
Separating gel solution 
 
 30% acrylamide solution 
 1.5M Tris pH 8.8 
 10% SDS 
 10% APS 
 0.25% TEMED 
 
SDS-PAGE running buffer 
 
 25 mM Tris pH 8.3 
 250 mM glycine pH 8.3 
 0.1% SDS 
 
SDS gel loading buffer 
 
 50 mM Tris pH 6.8 
 100 mM β-mercaptoethanol 
 2% SDS 
 10% glycerol 
 0.1% bromophenol blue 
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Semi-dry transfer buffer 
 
 38 mM glycine 
 48 mM Tris pH 8.3 
 0.4% SDS 
 20% methanol 
 
Western Blocking solution 
 
 5% fat-free dry milk 
 0.05% Tween 20 
 1xPBS 
 
ELISA incubation buffer 
 
 0.1% BSA 
 0.05% Tween 20 
 1xPBS 
 
ELISA wash buffer 
 
 0.05% Tween 20 
 1xPBS 
 
FACS buffer 
 
 0.5% BSA 
 2 mM EDTA 
 0.02% NaN3 
 
LB medium 
 
 1% peptone 
 0.5% yeast extract 
 90 mM NaCl 
 
LB freezing medium 
 
 LB medium 
 40% glycerol 
 
TSS solution 
 
 10% w/v PEG 3350 
5% v/v DMSO 
20 mM MgCl2  
pH 6.5 in LB broth 
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5xKCM buffer 
 
 0.5 M KCl 
 0.15 M CaCl2 
 0.25 M MgCl2 
 
Cell lysis buffer  
 
 1% Triton X-100 or Brij96 
 50 mM HEPES pH 7.4 
 150 mM NaCl 
 1x complete protease inhibitors 
 1x PHOStop complete phosphatase inhibitors 
 
Cell freezing medium 
 
 Sf900 II SFM/DMEM/RPMI 
50% FCS 
10% DMSO 
 
T cell hybridoma medium 
 
 DMEM 
 5% FCS 
 50 μM β-mercaptoethanol 
 100 U/ml penicillin 
 100 μg/ml streptomycin 
 
Murine CD4+ T cell medium 
 
 IMDM 
 10% FCS 
 50 U/ml rmIL-2 
 100 U/ml penicillin 
 100 μg/ml streptomycin 
 
Human CD4+ T cell medium 
 
 RPMI 1640 
 8% human serum 
 100 U/ml rhIL-2 
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2.1.6 Instruments 
 
ÄKTA FPLC system GE Healthcare Life Sciences, SE 
Biometra Thermocycler T3 Chatel-St. Denis, CH 
FACSCalibur Becton Dickinson, US 
BD LSR II Becton Dickinson, US 
BD Aria Becton Dickinson, US 
HPLC system (1525 Binary HPLC pump 
and 2998 Photodiode Array Detector) 
Waters, US 
Centrifuge 5810R Eppendorf, DE 
Centrifuge 5415D Eppendorf, DE 
Centrifuge 5417R Eppendorf, DE 
Mini-Protean 3 system Bio-Rad, US 
Ultracentrifuge Discovery M150SE Thermo Scientific Sorvall, US 
Ultrospec 3000 spectrophotometer GE Healthcare Life Sciences, US 
Epoch plate reader Bio-Tek, CH 
Countess cell counter Invitrogen/Life Technologies, US 
Semi-dry transfer unit Hoefer TE-70 GE Healthcare Life Sciences, US 
UV lamps (312 and 365 nm) Vilber Lourmat, FR 
 
2.1.7 FPLC columns 
 
Superdex S200 GE Healthcare Life Sciences, SE 
HiPrep 26/10 GE Healthcare Life Sciences, SE 
HisTrap HP 1ml GE Healthcare Life Sciences, SE 
MonoQ HR 5/5 1 ml GE Healthcare Life Sciences, SE 
Strep-Tactin Superflow high capacity 5 ml IBA, DE 
2.1.8 HPLC columns 
 
Reverse phase C18, Grace Vydac, Hesperia CA, USA 
2.1.9 Software 
 
FlowJo 7.6 TreeStar flow cytometry data analysis 
ImageJ 1.46k NIH image analysis 
Gen5 1.10 BioTek ELISA data analysis 
Prism 5 GraphPad Software data analysis 
Axiovision LE 4.8 Zeiss image analysis 
Unicorn 5.20 GE Healthcare Life Sciences FPLC chromatogram data 
analyses 
Vector NTI Advance 11 Invitrogen DNA construct management 
DeepView/Swiss PDB 
viewer v4.0.4 
Swiss Institute for 
Bioinformatics 
visualization of protein 
structure 
EndNote X5 ThomsonReuters reference manager 
Word 2010 Microsoft writing 
Excel 2010 Microsoft data storage 
Photoshop CS3 Adobe image analysis 
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2.1.10 Molecular biology methods 
 
Preparation of chemically competent bacteria 
E. coli XL-1 Blue cells were grown in 500 ml LB medium at 37 
o
C shaken at 250 rpm until 
mid-log phase was reached (OD600=0.6-0.8). Cells were cooled on ice and harvested by 
centrifugation at 4000 rpm for 30 min at 4 
o
C. Bacterial pellets were resuspended in 25 ml 
ice-cold TSS solution, frozen in aliquots of 100 μl in liquid nitrogen and stored at -80 oC.  
Transformation of competent bacteria 
Frozen competent XL-1 Blue bacteria (100 μl) were thawed on ice and mixed with 5xKCM 
buffer and 1 μg plasmid DNA or 5 μl ligation mix, incubated 5 min at 37 oC and then 
incubated for 2 min on ice. Subsequently, 1 ml LB medium was added and the cells incubated 
for 1 h at 37 
o
C. Bacteria were plated on LB agar plates containing 100 μg/ml ampicillin and 
then incubated overnight at 37 
o
C.  
Plasmid preparation 
For plasmid maxipreps (150 ml) or plasmid minipreps (3 ml), the appropriate volume of LB 
broth with 100 μg/ml ampicillin was inoculated with transformed bacteria and allowed to 
grow overnight at 37 
o
C, while being shaken at 250 rpm. Bacterial cells were harvested by 
centrifugation at 4000 rpm for 30 min at 4 
o
C. Plasmids were purified with the MaxiPrep or 
MiniPrep kits according to the manufacturer’s instructions. Plasmid preparations for 
transfections were dissolved in sterile EB buffer at 1-2 mg/ml. 
Restriction enzyme digestion of plasmid DNA 
Typically 10 μg of plasmid DNA was digested in 50 μl with appropriate restriction enzyme(s) 
and suitable 10x restriction buffer as recommended by the manufacturer, for 1 h at 37 
o
C. 
Digested plasmid DNA was loaded in the presence of loading buffer onto 1% agarose gels 
with 0.1 μg/ml ethidium bromide and the appropriate DNA fragments isolated using the 
QiaQuick gel extraction kit according to the manufacturer’s instructions. 
DNA ligation 
DNA ligation was carried out in 20 μl containing 1 μg digested and purified vector DNA, and 
an appropriate quantity of digested and purified insert DNA to achieve a 1:1 molar ratio. The 
Quick ligation kit (New England Biolabs) was used to perform the ligation in 5 min at room 
temperature. 5 μl of this ligation mix was used for transformation of competent bacteria.  
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2.2 Materials and methods, Chapter I 
 
Peptides 
Sequence Designation 
PKYVKQNTLKLAT HA306-318 
PGVLLKEFTVSGNILTIRLTAADHR NY-ESO-1119-143 
GFVFTLTVPSER Flu-MP61-72 
KKYFAATQFEPLAA Oxy272-284 
biotin-Ahx-CPKYVKQNTLKLAT biotin-HA306-318 
RQLQLSISSCLQ NY-ESO-1143-154 
HHHHHHSGSGPKYVKQNTLKLAT His-HA306-318 
HHHHHHSGSGPGVLLKEFTVSGNILTIRLTAADHR His-NY-ESO-1119-143 
HHHHHHSGSG-βNPPA-PKYVKQNTLKLAT His-SGSG-βNPPA-
PKYVKQNTLKLAT 
PKYVKQNTLKLAT-βNPPA-SGSGHHHHHH PKYVKQNTLKLAT-βNPPA-
SGSG-His 
DTB-Ahx-CPKYVKQNTLKLAT DTB-HA306-318 
DTB-Ahx-CPGVLLKEFTVSGNILTIRLTAADHR DTB-NY-ESO-1119-143 
pY-DDDDSGSGPKYVKQNTLKLAT pY-D
4
-SGSG-HA
306-318
 
sY-DDDDDDSGSGPKYVKQNTLKLAT sY-D6-SGSG-HA306-318 
pY-DDGGDDGGDDSGSGPKYVKQNTLKLAT pY-(DDGG)2DD-SGSG-HA306-318 
pY-EEEEEEEESGSGPKYVKQNTLKLAT pY-E8-SGSG-HA306-318 
pY-EEEEEEEESGSGPKYVKQNTLKLAT pY-E8-SGSG-HA306-318 
FNNFTVSFWLRVPK TT947-960 
DTB-Ahx-CFNNFTVSFWLRVPK DTB-TT947-960 
HHHHHHSGSGPKY-βNPG-KQNTLKLAT HA*2 
HHHHHHSGSGPKYV-βNPG-QNTLKLAT HA*3 
HHHHHHSGSGPKYVKQ-βNPG-TLKLAT HA*5 
HHHHHHSGSGPKYVKQNTL-βNPG-LAT HA*8 
 
MALDI-TOF of peptides 
 
On a clean MALDI target plate, 0.8 µl of peptide in 50% water (0.1% TFA in water)/50% 
acetonitrile was applied per spot and allowed to air-dry. 0.8 μl of saturated methanol solution 
of α-cyano-4-hydroxycinnaminic acid was added onto the spotted peptide and air-dried. Data 
were acquired with 200 pulses of the 337 nm laser; signals below 700 Da were excluded from 
the analysis due to species originating from matrix molecules. 
Synthesis of NTA4 biotin and SA-PE NTA4 
 
Tetra-NTA biotin was obtained by alkylation of the tetra-NTA peptide precursor, which was 
synthesized by conventional solid phase chemistry using chlorotrityl resins. Biotin-ε-
aminocaproyl (Ahx) was used to incorporate biotin. Detailed protocols are reported in 
(Schmidt et al., 2011). Commercial SA-PE conjugates (Invitrogen Life Technologies) were 
saturated with a 10-fold molar excess of NTA4 biotin and incubated with 100 mM NiSO4 for 
30 min at RT. Prior to use, excess reagents were removed with gel filtration spin columns and 
the concentration adjusted based on absorbance at 595 nm. 
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Antibodies 
 
Mouse anti-human DR mAb L243 (ExBio, Czech Republic), mouse anti-human DP mAb 
B7.21.7, biotinylated mouse anti-BSP mAb 1.4.2.7 (a gift from G. De Libero, University 
Hospital Basel), FITC-labeled anti-CD4 mAb RPA-T4 (BD Pharmingen), mouse anti-
phosphotyrosine mAb PY20 alkaline phosphatase conjugate (Calbiochem), mouse anti-
sulfotyrosine mAb 1C-A2 (Merck Millipore).  
Cells 
 
10
6
 PBMCs from a DRB1*0401
+
 healthy donor were stimulated with 2 µM HA306-318 and 
cultured in complete medium with 100 U rhIL-2/ml for at least 10 days before analysis. 
DR4/HA306-318-specific clones were obtained by limiting dilution cloning of peptide-
stimulated PBMC of the same donor after day 10 and cultured in RPMI 1640 medium 
supplemented with 8% human serum and 150 U/ml of rhIL-2 (complete medium). T2-DR4 
cells were cultured in RPMI 1640 supplemented with 10% FCS. CD4+ T cells from DR1 
transgenic mouse (referred to as AJ123 line) were maintained in IMDM supplemented with 
10% FCS and 50 U/ml of recombinant mouse IL-2 (rmIL-2) (Peprotech). D.mel-2 were 
grown in Sf900 II SFM medium (Life Technologies/Invitrogen) in closed flasks at 26 
o
C 
without CO2 or humidity. Puromycin-resistant lines and clones derived from original D.mel-
2, used for the production of recombinant MHC class II molecules were maintained in Sf900 
II SFM supplemented with 10 µg/ml puromycin (Sigma).  
Plasmids 
 
MHC class II expression plasmids were derived from the pMT\BiP\V5-His A vector 
(Invitrogen). The restriction map of the plasmids containing the beta chain is shown in Fig. 
2.1. The coding sequence for the human CLIP peptide (PVSKMRMATPLLMQA) was 
cloned between the BglII and NheI sites. The coding sequence for the thrombin cleavage site 
(LVPRGS), flanked on each side by linkers (GGGGS) was cloned between NheI and KpnI. 
The extracellular region of the mature beta chain (without the signal peptide) was cloned 
between KpnI and EcoRI. Alternatively, the extracellular region of the alpha chain was 
cloned between BglII and EcoRI, as the constructs for the alpha chains do not have the 
peptide and the thrombin cleavage site. Finally, coding sequences for acidic and basic leucine 
zippers were cloned between EcoRI and EcoRV sites. The alpha chain construct harbors the 
acidic leucine zipper, which in some cases was terminated by a tandem His-tag 
(HHHHHHGGGSGGGSGSHHHHHH). The beta chain construct contains the basic leucine 
zipper and terminates with a biotinylation sequence peptide (BSP) tag, known also as Avi-
Tag (LNDIFEAQKIEWHE).  
The BglII-KpnI fragment was constructed by joining the CLIP-F and LTL-R oligonucleotides 
by PCR. The extracellular parts of the DRα (DRA1*0101) and DPα (DPA1*0103) chains 
were PCR amplified from plasmid constructs containing those chains cloned using the 
primers DRA-F and DRA-R for the DRα and DP4A-F and DP4A-R for DPα. The 
extracellular parts of the DRB1*0401 (DR4), DRB3*0202 (DR52b) and DPB1*0401 (DP4) 
were PCR amplified from respective plasmid constructs using primers DR4B-BglII-F (for 
DR4 with no covalently bound peptide) or DR4B-KpnI-F (with covalent CLIP peptide) and 
DR4B-R (DR4), DR4B-KpnI-F and DR4B-R (DR52b), and DP4B-F and DP4B-R (DP4). 
The coding sequences for the acidic and basic leucine zipper were PCR amplified from 
plasmid constructs with primers ALZ/BLZ-F (common primer for both leucine zippers) and 
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ALZ-R for acidic and BLZ-R for basic leucine zipper, respectively. The fragment containing 
the ALZ was extended with ALZ-His6-R and further with 2xHis-R to provide for the tandem 
His-tag.  
For primer design, allele sequence data publicly available in the NIH dbMHC database 
(http://www.ncbi.nlm.nih.gov/projects/gv/mhc) were used. 
The pBS-hs.PURO plasmid was a gift from K. Karjalainen (Seidl et al., 2001). 
 
Figure 2.1 Schematic representation of the insert restriction map of the pMT plasmid constructs. The 
coding sequence for the peptide is cloned between BglII and NheI sites (blue). The thrombin cleavage site 
flanked by two linkers in cloned between NheI and KpnI (green). The extracellular region of the MHC 
class II α or β chain are between Kpn I or BglII and EcoRI. Note that for empty molecules the NheI and 
KpnI sites are omitted and the MHC chain is cloned into BglII/EcoRI. Finally, the acidic or basic leucine 
zipper (red) is cloned between EcroRI and EcoRV. 
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Primers and sequences 
Primers 
CLIP-F 
5’CTTTAGATCTCCTGTGAGCAAGATGCGCATGGCCACCCCGCTGCTGATGCAGGCGGCTAG
CGGAGGTGGA3’ 
LTL-R 
5’CTTTGGTACCTGAACCTCCACCTCCAGAGCCTCGGGGCACTAGTGAGCCTCCACCTCCGC
TAGCCGCCTGCAT3’ 
DRA-F 
5’CTTTAGATCTATCAAAGAAGAACATGTGATC3’ 
DRA-R 
5’CTTCGAATTCGTTCTCTGTAGTCTCTGGG3’ 
DP4A-F 
5’CTTTAGATCTGCTGGAGCCATCAAGGCGGAC3’ 
DP4A-R 
5’CTTTGAATTCCTCCGTTGTCTCAGGCATC3’ 
DR4B-BglII-F 
5’CTTTAGATCTCGACCACGTTTCTTGGAGC3’ 
DR4B-KpnI-F 
5’CTTTGGTACCCGACCACGTTTCTTGGAGC3’ 
DR4B-R 
5’CTTTGAATTCCTTGCTCTGTGCAGATTCAG3’ 
DP4B-F 
5’CTTTAGATCTCCAGAGAATTACCTTTTCC3’ 
DP4B-R 
5’CTTTGAATTCCTTACTCCGGGCAGAATCAG3’ 
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ALZ/BLZ-F 
5’CTTTGAATTCGGTGGTGGATCAGGAGGTTCAACTACAGCTCCATCAGCTC3’  
ALZ-R 
5’CTTTGATATCTTACTGAGCCAGTTCCTTTTCC3’ 
BLZ-BSP-R 
5’GATGTCGTTCAGACCGCCACCACTGCCTCCCTGGGCGAGTTTCTTCTTGAG3’ 
ALZ-His6-R 
5’CTTTGATATCTCAATGATGGTGATGATGGTGGCCGGTGCGCTGAGCCAGTTCCTTTTCC3
’ 
ALZ-His6LinkerHis6-R 
5’CTTTGATATCTCAGTGGTGGTGGTGGTGGTGGCTGCCGCTGCCGCCGCCGCTGCCGCCGC
CATGATGGTGATGATGGTGGCCGGTGCG3’ 
Sequences 
DRα   
5’AGATCTATCAAAGAAGAACATGTGATCATCCAGGCCGAGTTCTATCTGAATCCTGACCAA
TCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGATTTTCCATGTGGATATGGCAAAGAA
GGAGACGGTCTGGCGGCTTGAAGAATTTGGACGATTTGCCAGCTTTGAGGCTCAAGGTGCAT
TGGCCAACATAGCTGTGGACAAAGCCAACCTGGAAATCATGACAAAGCGCTCCAACTATACT
CCGATCACCAATGTACCTCCAGAGGTAACTGTGCTCACGAACAGCCCTGTGGAACTGAGAGA
GCCCAACGTCCTCATCTGTTTCATCGACAAGTTCACCCCACCAGTGGTCAATGTCACGTGGC
TTCGAAATGGAAAACCTGTCACCACAGGAGTGTCAGAGACAGTCTTCCTGCCCAGGGAAGAC
CACCTTTTCCGCAAGTTCCACTATCTCCCCTTCCTGCCCTCAACTGAGGACGTTTACGACTG
CAGGGTGGAGCACTGGGGCTTGGATGAGCCTCTTCTCAAGCACTGGGAGTTTGATGCTCCAA
GCCCTCTCCCAGAGACTACAGAGAACGAATTCGGTGGTGGATCAGGAGGTTCAACTACAGCT
CCATCAGCTCAGCTCGAAAAAGAGCTCCAGGCCCTGGAGAAGGAAAATGCACAGCTGGAATG
GGAGTTGCAAGCACTGGAAAAGGAACTGGCTCAGTAAGATATC3’ 
RSIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGAL
ANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVVNVTWL
RNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKHWEFDAPS
PLPETTENEFGGGSGGSTTAPSAQLEKELQALEKENAQLEWELQALEKELAQ 
DRα 2xHis 
5’AGATCTATCAAAGAAGAACATGTGATCATNCAGGCCGAGTTCTATCTGAATCCTGACCAA
TCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGATTTTCCATGTGGATATGGCAAAGAA
GGAGACGGTCTGGCGGCTTGAAGAATTTGGACGATTTGCCAGCTTTGAGGCTCAAGGTGCAT
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TGGCCAACATAGCTGTGGACAAAGCCAACCTGGAAATCATGACAAAGCGCTCCAACTATACT
CCGATCACCAATGTACCTCCAGAGGTAACTGTGCTCACGAACAGCCCTGTGGAACTGAGAGA
GCCCAACGTCCTCATCTGTTTCATCGACAAGTTCACCCCACCAGTGGTCAATGTCACGTGGC
TTCGAAATGGAAAACCTGTCACCACAGGAGTGTCAGAGACAGTCTTCCTGCCCAGGGAAGAC
CACCTTTTCCGCAAGTTCCACTATCTCCCCTTCCTGCCCTCAACTGAGGACGTTTACGACTG
CAGGGTGGAGCACTGGGGCTTGGATGAGCCTCTTCTCAAGCACTGGGAGTTTGATGCTCCAA
GCCCTCTCCCAGAGACTACAGAGAACGAATTCGGTGGTGGATCAGGAGGTTCAACTACAGCT
CCATCAGCTCAGCTCGAAAAAGAGCTCCAGGCCCTGGAGAAGGAAAATGCACAGCTGGAATG
GGAGTTGCAAGCACTGGAAAAGGAACTGGCTCAGCGCACCGGCCACCATCATCACCATCATG
GCGGCGGCAGCGGCGGCGGCAGCGGCAGCCATCACCATCACCACCATTGAGATATC3’ 
RSIKEEHVIXQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGAL
ANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVVNVTWL
RNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKHWEFDAPS
PLPETTENEFGGGSGGSTTAPSAQLEKELQALEKENAQLEWELQALEKELAQRTGHHHHHHG
GGSGGGSGSHHHHHH 
DR4β CLIP 
5’AGATCTCCTGTGAGCAAGATGCGCATGGCCACCCCGCTGCTGATGCAGGCGGCTAGCGGA
GGTGGAGGCTCACTAGTGCCCCGAGGCTCTGGAGGTGGAGGTTCAGGTACCCGACCACGTTT
CTTGGAGCAGGTTAAACATGAGTGTCATTTCTTCAACGGGACGGAGCGGGTGCGGTTCCTGG
ACAGATACTTCTATCACCAAGAGGAGTACGTGCGCTTCGACAGCGACGTGGGGGAGTACCGG
GCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGA
GCAGAAGCGGGCCGCGGTGGACACCTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCA
CAGTGCAGCGGCGAGTCTATCCTGAGGTGACTGTGTATCCTGCAAAGACCCAGCCCCTGCAG
CACCACAACCTCCTGGTCTGCTCTGTGAATGGTTTCTATCCAGGCAGCATTGAAGTCAGGTG
GTTCCGGAACGGCCAGGAAGAGAAGACTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAG
ACTGGACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACC
TGCCAAGTGGAGCACCCAAGCCTGACGAGCCCTCTCACAGTGGAATGGAGAGCACGGTCTGA
ATCTGCACAGAGCAAGGAATTCGGTGGTGGATCAGGAGGTTCAACTACAGCTCCATCAGCTC
AGTTGAAAAAGAAATTGCAAGCACTGAAGAAAAAGAACGCTCAGCTGAAGTGGAAACTTCAA
GCCCTCAAGAAAAAACTCGCCCAGGGAGGCAGTGGTGGCGGTCTGAATGACATCTTCNAGGC
TCAAAAAATCGAATGGCACGAATGAGATATC3’ 
RSPVSKMRMATPLLMQAASGGGGSLVPRGSGGGGSGTRPRFLEQVKHECHFFNGTERVRFLD
RYFYHQEEYVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQKRAAVDTYCRHNYGVGESFT
VQRRVYPEVTVYPAKTQPLQHHNLLVCSVNGFYPGSIEVRWFRNGQEEKTGVVSTGLIQNGD
WTFQTLVMLETVPRSGEVYTCQVEHPSLTSPLTVEWRARSESAQSKEFGGGSGGSTTAPSAQ
LKKKLQALKKKNAQLKWKLQALKKKLAQGGSGGGLNDIFEAQKIEWHE 
DR1β 
5’AGATCTCGACCACGTTTCTTGTGGCAGCTTAAGTTTGAATGTCATTTCTTCAATGGGACG
GAGCGGGTGCGGTTGCTGGAAAGATGCATCTATAACCAAGAGGAGTCCGTGCGCTTCGACAG
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CGACGTGGGGGAGTACCGGGCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACA
GCCAGAAGGACCTCCTGGAGCAGAGGCGGGCCGCGGTGGACACCTACTGCAGACACAACTAC
GGGGTTGGTGAGAGCTTCACAGTGCAGCGGCGAGTTGAGCCTAAGGTGACTGTGTATCCTTC
AAAGACCCAGCCCCTGCAGCACCACAACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAG
GCAGCATTGAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACA
GGCCTGATCCAGAATGGAGATTGGACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCG
GAGTGGAGAGGTTTACACCTGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGG
AATGGAGAGCACGGTCTGAATCTGCACAGAGCAAGGAATTCGGTGGTGGATCAGGAGGTTCA
ACTACAGCTCCATCAGCTCAGTTGAAAAAGAAATTGCAAGCACTGAAGAAAAAGAACGCTCA
GCTGAAGTGGAAACTTCAAGCCCTCAAGAAGAAACTCGCCCAGGGAGGCAGTGGTGGCGGTC
TGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAATGAGATATC3’ 
RSRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGEYRAVTELGRPDAEYWNS
QKDLLEQRRAAVDTYCRHNYGVGESFTVQRRVEPKVTVYPSKTQPLQHHNLLVCSVSGFYPG
SIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVE
WRARSESAQSKEFGGGSGGSTTAPSAQLKKKLQALKKKNAQLKWKLQALKKKLAQGGSGGGL
NDIFEAQKIEWHE 
DR4β 
5’AGATCTCGACCACGTTTCTTGGAGCAGGTTAAACATGAGTGTCATTTCTTCAACGGGACG
GAGCGGGTGCGGTTCCTGGACAGATACTTCTATCACCAAGAGGAGTACGTGCGCTTCGACAG
CGACGTGGGGGAGTACCGGGCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACA
GCCAGAAGGACCTCCTGGAGCAGAAGCGGGCCGCGGTGGACACCTACTGCAGACACAACTAC
GGGGTTGGTGAGAGCTTCACAGTGCAGCGGCGAGTCTATCCTGAGGTGACTGTGTATCCTGC
AAAGACCCAGCCCCTGCAGCACCACAACCTCCTGGTCTGCTCTGTGAATGGTTTCTATCCAG
GCAGCATTGAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGAAGACTGGGGTGGTGTCCACA
GGCCTGATCCAGAATGGAGACTGGACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCG
GAGTGGAGAGGTTTACACCTGCCAAGTGGAGCACCCAAGCCTGACGAGCCCTCTCACAGTGG
AATGGAGAGCACGGTCTGAATCTGCACAGAGCAAGGAATTCGGTGGTGGATCAGGAGGTTCA
ACTACAGCTCCATCAGCTCAGTTGAAAAAGAAATTGCAAGCACTGAAGAAAAAGAACGCTCA
GCTGAAGTGGAAACTTCAAGCCCTCAAGAAGAAACTCGCCCAGGGAGGCAGTGGTGGCGGTC
TGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAATGAGATATC3’ 
RSRPRFLEQVKHECHFFNGTERVRFLDRYFYHQEEYVRFDSDVGEYRAVTELGRPDAEYWNS
QKDLLEQKRAAVDTYCRHNYGVGESFTVQRRVYPEVTVYPAKTQPLQHHNLLVCSVNGFYPG
SIEVRWFRNGQEEKTGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSLTSPLTVE
WRARSESAQSKEFGGGSGGSTTAPSAQLKKKLQALKKKNAQLKWKLQALKKKLAQGGSGGGL
NDIFEAQKIEWHE 
DR52b  
5’AGATCTCGACCACGTTTCTTGGAGCTGCTTAAGTCTGAGTGTCATTTCTTCAATGGGACG
GAGCGGGTGCGGTTCCTGGAGAGACACTTCCATAACCAGGAGGAGTACGCGCGCTTCGACAG
CGACGTGGGGGAGTACCGGGCGGTGAGGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACA
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GCCAGAAGGACCTCCTGGAGCAGAAGCGGGGCCAGGTGGACAATTACTGCAGACACAACTAC
GGGGTTGGTGAGAGCTTCACAGTGCAGCGGCGAGTCCATCCTCAGGTGACTGTGTATCCTGC
AAAGACCCAGCCCCTGCAGCACCACAACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAG
GCAGCATTGAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACG
GGCCTGATCCAGAATGGAGACTGGACCTTCCAGACCCTGGTGATGCTAGAAACAGTTCCTCG
GAGTGGAGAGGTTTACACCTGCCAAGTGGAGCACCCAAGCGTAACGAGCCCTCTCACAGTGG
AATGGAGTGCACGGTCTGAATCTGCACAGAGCAAGGAATTCGGTGGTGGATCAGGAGGTTCA
ACTACAGCTCCATCAGCTCAGTTGAAAAAGAAATTGCAAGCACTGAAGAAAAAGAACGCTCA
GCTGAAGTGGAAACTTCAAGCCCTCAAGAAGAAACTCGCCCAGGGAGGCAGTGGTGGCGGTC
TGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAATGAGATATC3’ 
RSRPRFLELLKSECHFFNGTERVRFLERHFHNQEEYARFDSDVGEYRAVRELGRPDAEYWNS
QKDLLEQKRGQVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPG
SIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVE
WSARSESAQSKEFGGGSGGSTTAPSAQLKKKLQALKKKNAQLKWKLQALKKKLAQGGSGGGL
NDIFEAQKIEWHE 
DPα 
5’AGATCTGCTGGAGCCATCAAGGCGGACCATGTGTCAACTTATGCCGCGTTTGTACAGACG
CATAGACCAACAGGGGAGTTTATGTTTGAATTTGATGAAGATGAGATGTTCTATGTGGATCT
GGACAAGAAGGAGACCGTCTGGCATCTGGAGGAGTTTGGCCAAGCCTTTTCCTTTGAGGCTC
AGGGCGGGCTGGCTAACATTGCTATATTGAACAACAACTTGAATACCTTGATCCAGCGTTCC
AACCACACTCAGGCCACCAACGATCCCCCTGAGGTGACCGTGTTTCCCAAGGAGCCTGTGGA
GCTGGGCCAGCCCAACACCCTCATCTGCCACATTGACAAGTTCTTCCCACCAGTGCTCAACG
TCACGTGGCTGTGCAACGGGGAGCTGGTCACTGAGGGTGTCGCTGAGAGCCTCTTCCTGCCC
AGAACAGATTACAGCTTCCACAAGTTCCATTACCTGACCTTTGTGCCCTCAGCAGAGGACTT
CTATGACTGCAGGGTGGAGCACTGGGGCTTGGACCAGCCGCTCCTCAAGCACTGGGAGGCCC
AAGAGCCAATCCAGATGCCTGAGACAACGGAGGAATTCGGTGGTGGATCAGGAGGTTCAACT
ACAGCTCCATCAGCTCAGCTCGAAAAAGAGCTCCAGGCCCTGGAGAAGGAAAATGCACAGCT
GGAATGGGAGTTGCAAGCACTGGAAAAGGAACTGGCTCAGTAAGATATC3’ 
RSAGAIKADHVSTYAAFVQTHRPTGEFMFEFDEDEMFYVDLDKKETVWHLEEFGQAFSFEAQ
GGLANIAILNNNLNTLIQRSNHTQATNDPPEVTVFPKEPVELGQPNTLICHIDKFFPPVLNV
TWLCNGELVTEGVAESLFLPRTDYSFHKFHYLTFVPSAEDFYDCRVEHWGLDQPLLKHWEAQ
EPIQMPETTEEFGGGSGGSTTAPSAQLEKELQALEKENAQLEWELQALEKELAQ 
DPα 2xHis 
5’AGATCTGCTGGAGCCATCAAGGCGGACCATGTGTCAACTTATGCCGCGTTTGTACAGACG
CATAGACCAACAGGGGAGTTTATGTTTGAATTTGATGAAGATGAGATGTTCTATGTGGATCT
GGACAAGAAGGAGACCGTCTGGCATCTGGAGGAGTTTGGCCAAGCCTTTTCCTTTGAGGCTC
AGGGCGGGCTGGCTAACATTGCTATATTGAACAACAACTTGAATACCTTGATCCAGCGTTCC
AACCACACTCAGGCCACCAACGATCCCCCTGAGGTGACCGTGTTTCCCAAGGAGCCTGTGGA
GCTGGGCCAGCCCAACACCCTCATCTGCCACATTGACAAGTTCTTCCCACCAGTGCTCAACG
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TCACGTGGCTGTGCAACGGGGAGCTGGTCACTGAGGGTGTCGCTGAGAGCCTCTTCCTGCCC
AGAACAGATTACAGCTTCCACAAGTTCCATTACCTGACCTTTGTGCCCTCAGCAGAGGACTT
CTATGACTGCAGGGTGGAGCACTGGGGCTTGGACCAGCCGCTCCTCAAGCACTGGGAGGCCC
AAGAGCCAATCCAGATGCCTGAGACAACGGAGGAATTCGGTGGTGGATCAGGAGGTTCAACT
ACAGCTCCATCAGCTCAGCTCGAAAAAGAGCTCCAGGCCCTGGAGAAGGAAAATGCACAGCT
GGAATGGGAGTTGCAAGCACTGGAAAAGGAACTGGCTCAGCGCACCGGCCACCATCATCACC
ATCATGGCGGCGGCAGCGGCGGCGGCAGCGGCAGCCATCACCATCACCACCATTGAGATATC 
3’ 
RSAGAIKADHVSTYAAFVQTHRPTGEFMFEFDEDEMFYVDLDKKETVWHLEEFGQAFSFEAQ
GGLANIAILNNNLNTLIQRSNHTQATNDPPEVTVFPKEPVELGQPNTLICHIDKFFPPVLNV
TWLCNGELVTEGVAESLFLPRTDYSFHKFHYLTFVPSAEDFYDCRVEHWGLDQPLLKHWEAQ
EPIQMPETTEEFGGGSGGSTTAPSAQLEKELQALEKENAQLEWELQALEKELAQRTGHHHHH
HGGGSGGGSGSHHHHHH 
DP4β 
5’AGATCTCCAGAGAATTACCTTTTCCAGGGACGGCAGGAATGCTACGCGTTTAATGGGACA
CAGCGCTTCCTGGAGAGATACATCTACAACCGGGAGGAGTTCGCGCGCTTCGACAGCGACGT
GGGGGAGTTCCGGGCGGTGACGGAGCTGGGGCGGCCTGCTGCGGAGTACTGGAACAGCCAGA
AGGACATCCTGGAGGAGAAGCGGGCAGTGCCGGACAGGATGTGCAGACACAACTACGAGCTG
GGCGGGCCCATGACCCTGCAGCGCCGAGTCCAGCCTAGGGTGAATGTTTCCCCCTCCAAGAA
GGGGCCCTTGCAGCACCACAACCTGCTTGTCTGCCACGTGACGGATTTCTACCCAGGCAGCA
TTCAAGTCCGATGGTTCCTGAATGGACAGGAGGAAACAGCTGGGGTCGTGTCCACCAACCTG
ATCCGTAATGGAGACTGGACCTTCCAGATCCTGGTGATGCTGGAAATGACCCCCCAGCAGGG
AGATGTCTACACCTGCCAAGTGGAGCACACCAGCCTGGATAGTCCTGTCACCGTGGAGTGGA
AGGCACAGTCTGATTCTGCCCGGAGTAAGGAATTCGGTGGTGGATCAGGAGGTTCAACTACA
GCTCCATCAGCTCAGTTGAAAAAGAAATTGCAAGCACTGAAGAAAAAGAACGCTCAGCTGAA
GTGGAAACTTCAAGCCCTCAAGAAGAAACTCGCCCAGGGAGGCAGTGGTGGCGGTCTGAATG
ACATCTTCGAGGCTCAGAAAATCGAATGGCACGAATGAGATATC3’ 
RSPENYLFQGRQECYAFNGTQRFLERYIYNREEFARFDSDVGEFRAVTELGRPAAEYWNSQK
DILEEKRAVPDRMCRHNYELGGPMTLQRRVQPRVNVSPSKKGPLQHHNLLVCHVTDFYPGSI
QVRWFLNGQEETAGVVSTNLIRNGDWTFQILVMLEMTPQQGDVYTCQVEHTSLDSPVTVEWK
AQSDSARSKEFGGGSGGSTTAPSAQLKKKLQALKKKNAQLKWKLQALKKKLAQGGSGGGLND
IFEAQKIEWHE 
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Preparation of cDNA from EBVB cells 
Total RNA was extracted from DR52b
+
 EBVB cells with RNAeasy Mini kit (Qiagen) and 
QIAshredder (Qiagen) according to manufacturer’s instructions. cDNA was synthesized from 
1 μg of total RNA using the OmniScript RT kit (Qiagen).  
Liposomal transfection of insect cells  
The day before transfection, D.mel-2 cells were plated at a subconfluent concentration of 0.5-
1x10
6 
cells per well of a 24-well plate (Corning) in 0.5 ml of Sf900 II SFM medium. For 
transfection, in a well of a v-bottom 96-well plate, in 200 µl Sf900 II SFM medium, 20 µl of 
Cellfectin (Invitrogen) was added and 2.2 µg of plasmid DNA (1 µg of each pMT plasmid 
construct and 0.2 μg of pBS-hs.PURO plasmid to confer puromycin resistance) and mixed 
well. After 20 minutes at room temperature, the transfection mixture was pipetted dropwise 
onto the cells and after 24 hours puromycin was added. After 7 to 10 days, a puromycin-
resistant cell line was obtained. 
Generation of stably transfected insect cells for recombinant protein production 
The day before plating, cells were split and diluted to 5x10
5
-10
6 
cells/ml. For limited dilution 
cloning a puromycin-resistant cell line is “spiked” (100 cells/ml) into untransfected D.mel-2 
cells (3x10
5
 cells/ml) in Sf900 II SFM supplemented with 10% FCS and distributed by 
pipetting in flat-bottom 96-well plates (Corning) at 100 μl per well. Plates were wrapped in 
Saran wrap to prevent medium evaporation. After 24 hours, puromycin was added to the 
wells. Growth medium containing FCS and puromycin was replaced after 7 days and colonies 
scored after a further 7 days in culture. Colonies were transferred with a sterile pipette and 
expanded. Expression of recombinant MHC class II protein was tested by induction with 1 
mM CuSO4 and an ELISA assay after 3 to 5 days. Typically, clones obtained by this 
procedure were screened twice: first at an early stage to exclude all clones not expressing 
MHC class II protein and then a second selection where clones are induced at equal cell 
density to compare their specific productivity and choose the best producers for large scale 
supernatant production and protein purification. At least 10
7
 cells per vial were frozen in 
Sf900 II SFM-based freezing medium and kept in liquid nitrogen vapor phase for long term 
storage. 
MHC class II ELISA 
High-protein binding flat-bottom 96-well plates (Nunc Maxisorp) were coated with anti-DR 
L243 or anti-DP B7.21.7 antibodies (2 µg/ml) in 100 mM sodium carbonate buffer pH 8.3. 
Plates were blocked with incubation buffer and samples applied for 1 hour. For 
quantification, purified recombinant HLA-DR or DP protein were applied in a dilution series 
from 5000 ng/well in incubation buffer. After washes, bound recombinant MHC class II 
protein was detected with biotinylated anti-BSP antibody (0.2 μg/ml) and streptavidin-
alkaline phosphatase (SA-AP) (Sigma). 100 µl of pNPP substrate was allowed to develop 
yellow color at room temperature, and color development stopped with equal volume of 1 M 
NaOH and read at 405 nm in a plate reader. 
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Scale-up of insect cell supernatants for protein purification 
Roller bottles (Falcon) with closed caps were inoculated with 2x10
6
/cell in 500 ml of Sf900 II 
SFM without antibiotics. Cells were grown at room temperature (22-25 
o
C) turning at 6 rpm.  
Upon reaching densities from 0.5-1x10
7
 cells/ml, cultures were induced with 1 mM CuSO4 
for 3 to 5 days. Supernatant was harvested by centrifugation at 2000 rpm for 5 min and 
filtered through a 0.22 μm filter and stored at 4 oC with 0.05% sodium azide and 2-
iodoacetamide (4 mM). 
Preparation of MHC class II-peptide complexes 
Filtered supernatants from stably transfected insect cells containing soluble recombinant 
MHC class II molecules were purified on Chelating Sepharose FF columns if the molecules 
carried single or tandem His-tags. Alternatively, in the absence of His-tags, they were 
purified on CnBr Sepharose columns (20 ml) conjugated with anti-DR or anti-DP antibodies. 
Chelating Sepharose FF columns were washed with 10 mM imidazole in PBS and eluted with 
200 mM imidazole in PBS. From anti-DR conjugated Sepharose columns, proteins were 
eluted with 50 mM glycine pH 11.5 and from anti-DP conjugated columns with 100 mM 
citrate pH 3.2. Chelating Sepharose FF columns were subsequently stripped of Cu
2+
 ions with 
20 mM EDTA in PBS. Both types of columns were equilibrated in PBS with 0.05% sodium 
azide before the next purification cycle. The pH of eluates was corrected to neutral and 
concentrated in a nitrogen-pressurized Amicon concentration cell. Samples were further 
buffer-exchanged on a HiPrep 26/10 column into 100 mM sodium citrate, pH 6.0 and loaded 
with 100 μM peptide at 37 °C for 24 h in 1xprotease inhibitor mixture (Roche) and 0.2% 
octyl β-D-glucopyranoside. Excess unbound peptide was removed by buffer-exchange on a 
HiPrep 26/10 column. MHC class II-peptide complexes with untagged peptides were 
concentrated to < 2 ml and purified by gel filtration on a Superdex S200 column. MHC class 
II-peptide complexes containing peptide-bound His-tags were purified on a HisTrap HP 1 ml 
column and subsequently on a Superdex S200 column. Alternatively, MHC class II-peptide 
complexes with N-terminal polyanion tags were purified on MonoQ HR 5/5 columns over a 
20 CV 0-1 M NaCl gradient. Complexes were eluted at 400-500 mM NaCl. Desthiobiotin-
labeled complexes were purified on a 5 ml Strep-Tactin Superflow High-Capacity column 
(IBA). After elution with pH 7-buffered 50 mM desthiobiotin, excess desthiobiotin was 
eliminated with several concentration and dilution cycles in PBS. The streptactin column was 
regenerated with 1 mM 2-(4-hydroxyphenylazo)benzoic acid) (HABA) in PBS and 
equilibrated with PBS to remove bound HABA and prepare the column for the next 
purification cycle. 
Photocleavable peptides and generation of UV-exchangeable multimers 
MHC class II complexes with peptides containing photocleavable amino-acid derivatives 
(βNPG) (1 μg in 100 μl PBS/well), were irradiated with a 30 W UV lamp (365 nm) on ice for 
10 minutes (if not specified otherwise) in v-bottom 96-well plates. The amount of complexes 
harboring the tag is measured by an ELISA (see under Peptide binding assays). To make 
multimers from biotinylated photocleavable MHC class II complexes, UV irradiation was 
performed in 100 mM citrate pH 6.0 in the presence of 10 μM peptide (if not specified 
otherwise) and incubated overnight at 37 
oC. Samples were brought to neutral pH with 10 μl 
Tris HCl pH 9.0. Subsequently, 3 μl (1 μg) of streptavidin-phycoerythrin (Invitrogen) were 
added and mixed and after 1h incubation, samples were used for staining cells. 
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Peptide binding assays 
In a peptide competition assay, for each peptide, eight wells of a v-bottom 96-well plate 
(Greiner Bio-One) were filled with 50 µl each of recombinant “empty” DR4 or DR52b 
protein (1 µg) in a citrate saline buffer (100 mM citrate pH 6.0), with 0.2% β-octyl-
glucopyranoside (Calbiochem), 1xcomplete protease inhibitors (Roche) and 2 µM biotin-
HA306-318. Competitor peptides (10 mM DMSO solution) were added to each well to a final 
concentration of 100, 30, 10, 3, 1, 0.3 and 0.1 µM. After incubation at 37 
o
C overnight, each 
reaction was diluted with a fourfold volume of 1xPBS pH 7.4, 0.1% BSA and 0.05% Tween 
20 (PBT) and 100 µl applied to a plate coated with anti-DR mAb L243 antibody (2 µg/ml) 
and previously blocked with PBT. After 1 h of incubation at RT and three washes with 
1xPBS pH 7.4, 0.05% Tween 20, streptavidin-alkaline phosphatase (SA-AP) conjugate 
(Sigma) was added as 1:10,000 in PBT. After 1 h, the plate was washed as previously 
described and developed with pNPP SigmaFAST substrate and absorbance read with the 405 
nm filter.  
To determine peptide occupancy, 500 µg of purified “empty” DR4 was loaded with His-
HA306-318 or His-NY-ESO-1119-143 peptides. For each time point, 0.5 ml was removed and 
subjected to gel filtration on a Superdex S200 column in PBS pH 7.4 to separate loaded DR4 
from free peptide. The percentage of loaded DR4 was determined with two parallel sandwich 
ELISAs – anti-DR capture//His-Detector and anti-DR capture//anti-BSP biotin/SA-AP. Ni2+-
NTA affinity chromatography was used to purify His-tagged DR4 complexes which were 
used as 100% standards in ELISA. Percentages of peptide occupancy were calculated as 
follows: peptide occupancy (%) = (amount of His-tagged DR4 complexes/amount of DR4 
complexes)*100.  
In a direct binding assay, 10 µg purified DR4 protein or DR4 HA*5 complex and was 
dissolved in 500 µl of 100 mM citrate buffer pH 6.0 with 10 µM DTB-NY-ESO-1119-143 
peptide, 0.2% octyl-glucoside and complete protease inhibitor mix and were exposed to UV 
light (354 nm) for 10 min and incubated for 0, 6, 12 and 24 hours at 37 
o
C. At each time 
point, 100 µl was withdrawn and frozen at -20 
o
C. After all samples were collected, they were 
diluted with an equal volume of the incubation buffer, captured on an anti-DR mAb L243 
coated plates and detected with His-Detector (KPL). 
Multimer binding assays 
For binding studies, CD4+ T cell clones (5x10
4
) or peptide-stimulated PBMCs (2x10
5
) were 
incubated for 1 hour at 37 
o
C with graded concentrations of DR4/HA306-318 multimers in 50 μl 
FACS buffer. Peptide-stimulated PBMCs were counter-stained with FITC-labeled anti-CD4, 
APC-labeled anti-CD3 and 7-aminoactinomycin (7AAD). After washing, fluorescence 
associated with living cells (CD3
+
 7AAD
-
 events) was analyzed on a FACSCalibur flow 
cytometer. In some experiments, washed cells were resuspended in FACS buffer 
supplemented with 100 mM imidazole and re-incubated for different periods of time.  
Neuraminidase treatment 
Prior to treatment, cells were washed in RPMI with 10% FCS and resuspended at 10
6
 
cells/ml. To a 50 μl aliquot, neuraminidase from Vibrio cholerae was added to 0.2 U/ml and 
cells incubated for 30 min at 37 
o
C.  After two washes in FACS buffer, cells were stained 
with multimers and analyzed by flow cytometry.  
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NTAmer dissociation kinetics 
PBMCs from a DRB1*0401
+
 healthy donor were stimulated with HA306-318 peptide for 10 
days in complete medium. 10
6
 cells were pre-cooled on ice, and then stained for 2 hours at 4 
oC with 4.5 μg/ml conventional or NTA-based multimers. Cells were analyzed on a 
FACSCalibur flow cytometer both prior to the addition of ice-cold 100 mM imidazole, and at 
1, 2, 5 and 10 minutes after imidazole addition. 
Fluorescence microscopy 
Aliquots of 200 μl DR4/HA306-318 clones (10
6
 cells/ml) were stained for 2 h at 4 
o
C, or for 1 h 
at 37 
oC with 5 μg/ml PE-labeled DR4/HA306-318 or DR4/Cy5-HA306-318 multimers, washed, 
and incubated in growth medium for a further 4 h at 37 
o
C. For some experiments, they were 
subsequently surface-labeled with 0.02 μg/ml NHS-Cy5 for 5 min at 4 oC. Cells were fixed in 
2% formaldehyde in PBS (v/v) for 10 min at room temperature and mounted on a microscope 
slide in 10 μl SlowFade medium (Invitrogen).  
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2.3 Materials and methods, Chapter II 
 
Peptides 
The Plasmodium berghei circumsporozoite 252-260 peptide (SYIPSAEKI) containing 
photoreactive 4-azidobenzoic acid on Lys-259 (PbCS(ABA)), its variant, PbCS(ABA) P255A 
and JAK1 non-receptor tyrosine kinase 355-363 (SYFPEITHI) (JAK1) peptides were 
synthesized using standard FMOC chemistry, purified by reverse-phase C18 HPLC and 
verified by MALDI TOF mass spectrometry. 
Antibodies 
Rat anti-mouse CD8α PE mAb 53.6.72, rat anti-mouse CD8β PE mAb H35, anti-CD3ε mAb 
17A2, mouse anti-mouse Vβ8.2 Alexa 647 mAb clone F23-2, rat anti-mouse anti-CD90.1 
(Thy1.1) mAb HIS51 were from the antibody fluorescent conjugate collection of the Flow 
Cytometry Facility of LICR@UNIL. Rat anti-mouse CD8α Cy5 mAb 53.6.72 and CD8β Cy5 
mAb KT112 were prepared from purified mAbs, conjugated with NHS-Cy5 at a dye/protein 
molar ratio 10:1 for 1 hour at RT and unreacted NHS-Cy5 removed with a PD-10 column 
(GE Healthcare Life Sciences/Amersham) previously equilibrated in 1xPBS. Final 
dye/protein ratios were 3.5 for anti-CD8α Cy5 and 4.3 for anti-CD8β Cy5 conjugate. For IP 
experiments, anti-CD8α 53.6.72 and anti-CD8β H35 were conjugated to CnBr Sepharose 4B 
beads according to manufacturer’s instructions. To detect p56Lck in Western blots, a primary 
rabbit polyclonal anti-Lck (sc-13, 2102) (Santa Cruz) was followed by HRP-conjugated goat 
anti-rabbit polyclonal antibody. To detect CD8α and CD8β in Western blots, a primary rat 
anti-mouse CD8α 53.6.72 or rat anti-mouse CD8β KT112 were followed by a secondary 
HRP-conjugated goat anti-rat polyclonal antibody (Southern Biotech). Supernatants 
containing rat anti-mouse CD16/32 mAb 2.4G2 were used to block Fc receptor binding 
(FcγRIII/II).  
Multimers  
PE-labeled K
d
 PbCS(ABA), K
d
 PbCS(ABA) 226/227, K
d
 PbCS(ABA) P255A multimers 
were kindly provided by Dr. Philippe Guillaume. 
Plasmids 
CD8β-YFP was designed as full-length fusion of murine CD8β (UniProt ID: P10300) with an 
enhanced variant of yellow fluorescent protein (eYFP) (Clonetech) linked by GGGSGGGS. 
The construct for CD8β-YFP was amplified from the PGK-driven pRRL vector with the 
primers for CD8B-EGFP-F and CD8B-EGFP-R and subcloned between BamHI and NotI 
sites of the pBMN-z vector. The pBMN-z CD3ζ-CFP plasmid was a gift from the Dr. Nicolas 
Gascoigne lab (The Scripps Research Institute, San Diego, USA). Constructs for CD8  
(UniProt ID: P01731) and the CD8 Tac mutant were cloned in the CMV promoter-driven 
pSD-3 vector. Coding sequences for full length CD8α were subcloned from the pLG449-2 
plasmid by digestion with HindIII, followed by Klenow blunting of the site and digestion 
with XhoI. The pSD-3 vector was cut with BamHI, the site blunted with Klenow and then 
digested with SalI. The two DNA fragments were subsequently ligated. The Tac coding 
sequence was synthesized by creating a first synthetic DNA fragment from BglII-tac-F and 
the tac-R primers, and then a with the tac-CD8a-F and SP6 primers. The two fragments were 
joined together, digested with BglII and SalI and ligated into the BglII and SalI digested 
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pLG449-2 plasmid. The fragment containing the CD8αTac coding sequence was subcloned 
into the pBMN-z vector by PCR amplification with CD8α-F and CD8α-R primers from the 
pLG449-2 plasmid, digestion with HindIII and NotI and then ligated with the HindIII/NotI 
digested and purified pBMN-z vector. 
Primers  
CD8α-F 
5’AGGGAGACCCAAGCTTGCCA3’ 
CD8α-R 
5’TTTTGCGGCCGCTCACACAATTTTCTCTGAAGGTCTGGGC3’ 
SP6  
5’ATTTAGGTGACACTATAG3’ 
BglII-tac-F 
5’GGATTAGATCTCTGCGTAGCAGTGGCCGCCTGCGTGTTCC3’ 
tac-R 
5’CCAGGTGAGGGCAGCCAGGAGGAGCACGGCGATGAGCAGGAACACGCAGGCGGCCA3’ 
tac-CD8a-F 
5’TCCTGGCTGCCCTCACCTGGCACAGGAGCCGAAAGCGTGT3’ 
CD8B-EGFP-F 
5’TTTAAGCTTTCTAGAGTCGACCTGCAGGG3’ 
CD8B-EGFP-R 
5’AGTCGCGGCCGCTTTAGCCGGACTTGTACAGC3’ 
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Sequences 
CD8β-YFP 
5’GGATCCTCTAGAGTCGACCTGCAGGGGGGGGGGGGGGGGGGGTTTCAGTTGACAGAGCAC
TGAGGGGAACAGTGTCCCCAAAAGCGCCAAGATGCAGCCATGGCTCTGGCTGGTCTTCAGTA
TGAAGCTGGCAGCTCTCTGGAGCAGCTCTGCCCTCATTCAGACCCCTTCGTCCCTGCTGGTT
CAAACCAACCATACGGCAAAGATGTCCTGTGAGGTTAAAAGCATCTCTAAGTTAACAAGCAT
CTACTGGCTGCGGGAGCGCCAGGACCCCAAGGACAAGTACTTTGAGTTCCTGGCCTCCTGGA
GTTCTTCCAAAGGAGTTTTGTATGGTGAAAGTGTGGACAAGAAAAGAAATATAATTCTTGAG
TCTTCAGACTCAAGACGGCCCTTTCTCAGTATCATGAATGTGAAGCCAGAGGACAGTGACTT
CTACTTCTGCGCGACGGTTGGGAGCCCCAAGATGGTCTTTGGGACAGGGACGAAGCTGACTG
TGGTTGATGTCCTTCCTACAACTGCCCCAACCAAGAAGACTACCCTGAAGATGAAGAAGAAG
AAGCAATGCCCGTTCCCCCACCCAGAGACCCAGAAGGGCCTGACATGCAGCCTTACCACCCT
CAGCCTGCTGGTAGTCTGCATCCTGCTTCTGCTGGCATTCCTCGGAGTGGCCGTCTACTTTT
ACTGTGTGCGGAGGAGAGCCCGAATTCACTTCATGAAACAGTTTCACAAAGGAGGTGGATCA
GGTGGAGGGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGA
CGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACG
GCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC
GTGACCACCTTCGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCA
CGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGG
ACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGC
ATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGA
ACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAG
AACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGTC
CGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCG
CCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAGCGGCCGC3’ 
MQPWLWLVFSMKLAALWSSSALIQTPSSLLVQTNHTAKMSCEVKSISKLTSIYWLRERQDPK
DKYFEFLASWSSSKGVLYGESVDKKRNIILESSDSRRPFLSIMNVKPEDSDFYFCATVGSPK
MVFGTGTKLTVVDVLPTTAPTKKTTLKMKKKKQCPFPHPETQKGLTCSLTTLSLLVVCILLL
LAFLGVAVYFYCVRRRARIHFMKQFHKGGGSGGGSKGEELFTGVVPILVELDGDVNGHKFSV
SGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGLQCFARYPDHMKQHDFFKSAMPEG
YVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIM
ADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKR
DHMVLLEFVTAAGITLGMDELYK 
CD8α HA 
5’AAGCTTGCCACCATGGCCTCACCGTTGACCCGCTTTCTGTCGCTGAACCTGCTGCTGCTG
GGTGAGTCGATTATCCTGGGGAGTGGAGAAGCTAAGCCACAGGCACCCGAACTCCGAATCTT
TCCAAAGAAAATGGACGCCGAACTTGGTCAGAAGGTGGACCTGGTATGTGAAGTGTTGGGGT
CCGTTTCGCAAGGATGCTCTTGGCTCTTCCAGAACTCCAGCTCCAAACTCCCCCAGCCCACC
TTCGTTGTCTATATGGCTTCATCCCACAACAAGATAACGTGGGACGAGAAGCTGAATTCGTC
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GAAACTGTTTTCTGCCATGAGGGACACGAATAATAAGTACGTTCTCACCCTGAACAAGTTCA
GCAAGGAAAACGAAGGCTACTATTTCTGCTCAGTCATCAGCAACTCGGTGATGTACTTCAGT
TCTGTCGTGCCAGTCCTTCAGAAAGTGAACTCTACTACTACCAAGCCAGTGCTGCGAACTCC
CTCACCTGTGCACCCTACCGGGACATCTCAGCCCCAGAGACCAGAAGATTGTCGGCCCCGTG
GCTCAGTGAAGGGGACCGGATTAGATCTCGCCTGTGATATTTACATCTGGGCACCCTTGGCC
GGAATCTGCGTGGCCCTTCTGCTGTCCTTGATCATCACTCTCATCTGCTACCACAGGAGCCG
AAAGCGTGTTTGCAAATGTCCCAGGCCGCTAGTCAGACAGGAAGGCAAGCCCAGACCTTCAG
AGAAAATTGTGGTCGACTATCCATATGACGTGCCAAACTACGCATGAACTAGTGCGGCCGCT
CGAG3’ 
MASPLTRFLSLNLLLLGESIILGSGEAKPQAPELRIFPKKMDAELGQKVDLVCEVLGSVSQG
CSWLFQNSSSKLPQPTFVVYMASSHNKITWDEKLNSSKLFSAMRDTNNKYVLTLNKFSKENE
GYYFCSVISNSVMYFSSVVPVLQKVNSTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKG
TGLDLACDIYIWAPLAGICVALLLSLIITLICYHRSRKRVCKCPRPLVRQEGKPRPSEKIVV
DYPYDVPNYA 
CDα tac HA 
5’AAGCTTGCCACCATGGCCTCACCGTTGACCCGCTTTCTGTCGCTGAACCTGCTGCTGCTG
GGTGAGTCGATTATCCTGGGGAGTGGAGAAGCTAAGCCACAGGCACCCGAACTCCGAATCTT
TCCAAAGAAAATGGACGCCGAACTTGGTCAGAAGGTGGACCTGGTATGTGAAGTGTTGGGGT
CCGTTTCGCAAGGATGCTCTTGGCTCTTCCAGAACTCCAGCTCCAAACTCCCCCAGCCCACC
TTCGTTGTCTATATGGCTTCATCCCACAACAAGATAACGTGGGACGAGAAGCTGAATTCGTC
GAAACTGTTTTCTGCCATGAGGGACACGAATAATAAGTACGTTCTCACCCTGAACAAGTTCA
GCAAGGAAAACGAAGGCTACTATTTCTGCTCAGTCATCAGCAACTCGGTGATGTACTTCAGT
TCTGTCGTGCCAGTCCTTCAGAAAGTGAACTCTACTACTACCAAGCCAGTGCTGCGAACTCC
CTCACCTGTGCACCCTACCGGGACATCTCAGCCCCAGAGACCAGAAGATTGTCGGCCCCGTG
GCTCAGTGAAGGGGACCGGATTAGATCTCTGCGTAGCAGTGGCCGCCTGCGTGTTCCTGCTC
ATCGCCGTGCTCCTCCTGGCTGCCCTCACCTGGCACAGGAGCCGAAAGCGTGTTTGCAAATG
TCCCAGGCCGCTAGTCAGACAGGAAGGCAAGCCCAGACCTTCAGAGAAAATTGTGGTCGACT
ATCCATATGACGTGCCAAACTACGCATGAACTAGTGCGGCCGCTCGAG3’ 
MASPLTRFLSLNLLLLGESIILGSGEAKPQAPELRIFPKKMDAELGQKVDLVCEVLGSVSQG
CSWLFQNSSSKLPQPTFVVYMASSHNKITWDEKLNSSKLFSAMRDTNNKYVLTLNKFSKENE
GYYFCSVISNSVMYFSSVVPVLQKVNSTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKG
TGLDLCVAVAACVFLLIAVLLLAALTWHRSRKRVCKCPRPLVRQEGKPRPSEKIVVDYPYDV
PNYA 
  
 MATERIALS AND METHODS 
52 
 
Cells 
Phoenix Eco packaging cells, 293T cells and P815 mastocytoma cells were grown in DMEM 
with 10% FCS, 50 U/ml penicillin and 50 μg/ml streptomycin. T cell hybridomas were grown 
in DMEM supplemented with 5% FCS, 50 μM β-mercaptoethanol, 50 U/ml penicillin and 50 
μg/ml streptomycin.  
Lentivirus production 
For production of lentiviral supernatants, HEK 293-derived cell lines were transfected with 
plasmid constructs by the calcium phosphate method. For constructs derived from the pRRL 
vector (CD8 , CD8αTac), 293T cells were used. Alternatively, for constructs derived from the 
pBMN-z vector (CD8β-eYFP, CD3ζ-eCFP), Phoenix Eco packaging cells were used. The 
day before transfection, 10 cm tissue culture dishes with 5x10
6
 cells were prepared in 8 ml of 
growth medium. At least 30 min prior to transfection, the old growth medium was exchanged 
for 4.5 ml fresh growth medium with chloroquine (25 μM).  To generate viral supernatants 
from pRRL-based constructs, 5 μg pMD2.VSVG, 15 μg pCMVΔR8.91 plasmids and 20 μg 
proper pRRL construct, or alternatively, 30 μg pBMN-z-based constructs were mixed well 
with 250 μl sterile water and 250 μl CaCl2 (0.5 M). To this solution, 500 μl 2xHeBS was 
added dropwise with vigorous agitation (pipette bubbling or vortexing). After 20 min 
incubation, the solution was added to the cell monolayer. After 24 hours, growth medium was 
exchanged and viral supernatant harvested 48 hours post-transfection. Supernatants were 0.22 
μm-filtered and used immediately or frozen at -80 oC.  
Infection, cloning and selection of hybridoma cells 
To infect the T1 TCR T cell hybridoma, 2x10
5 
cells/well were resuspended in 2 ml growth 
medium in a 6-well plate. Polybrene (4 μg/ml) was added before the addition of 2 ml viral 
supernatant. After 5 days of incubation, single cells were FACS sorted for high expression of 
a particular surface protein or fluorescent protein (CD8α/CD8α Tac/CD8β-YFP/CD8ζ-CFP) 
on BD Aria cell sorter in flat-bottom 96-well plates at 0.5 cells/well. After 7-10 days, clones 
were analyzed for 1) surface expression of T1 TCR, CD8α, CD8β and YFP/CFP fluorescence 
by flow cytometry, 2) morphology and localization of YFP and CFP fluorescence by 
fluorescence microscopy, 3) IL-2 production when stimulated with PbCS(ABA)-pulsed P815 
cells by IL-2 ELISA. Successive rounds of infection were used to introduce CD8α/CD8α 
Tac, CD8β-YFP and CD3ζ-CFP. Resulting cloned cells were named T1.wt, T1.tac, 
T1.wt.bYFP, T1.Tac.bYFP, T1.wt.bYFP.zCFP and T1.Tac.bYFP.zCFP. 
Conjugate formation assay 
One day before the assay, P815 cells were harvested, washed twice with 1xPBS, resuspended 
in PBS at 10
6/ml and labeled with 10 μg/ml NHS-Cy5 (Amersham/GE Healthcare Life 
Sciences) for 5 min. For conjugate formation, 2x10
5
 of P815 for each time point were loaded 
with 1 μM peptide for 1 h in a humidified incubator at 37 oC in DMEM, 0.5% FCS, 2 µg/ml 
hβ2m. Unbound peptide was removed by washing and cells were mixed with a T cell 
hybridoma at a 1:1 ratio in 200 µl of DMEM, 5% FCS, 50 µM β-mercaptoethanol. The time 
course was started after spinning at 1000 rpm for 1 min at room temperature. At each time 
point, cells were fixed with PBS buffered 2% formaldehyde and later analyzed on the 
FACSCalibur. Calculation of the percentage of conjugates was performed with the following 
formula: conjugate (%) = (2xYFP
+
Cy5
+
)/[(YFP
+
Cy5
-
+YFP
-
Cy5
+
+2xYFP
+
Cy5
-
)]. 
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Calcium flux 
P815 cells (10
6
 cells/ml) were pulsed with 1 μM PbCS(ABA) for 1 h at 37 oC in DMEM 
supplemented with 0.5% FCS and 2 µg/ml hβ2m. T1 TCR hybridomas (106 cells/ml) were 
incubated with 5 μM Indo-1 acetate ester (Sigma) at 37 oC for 45 min, washed in DMEM and 
mixed with peptide-loaded P815 cells at an E/T ratio of 1:4. After incubation in a waterbath 
at 37 
o
C for 1 min, calcium-dependent Indo-1 cell-associated fluorescence was measured on a 
LSR II flow cytometer equipped with a 355 nm solid-state laser. During acquisition, the 
sample temperature was maintained at 37 
o
C with a solid-state heating jacket around the 
sample tube. Emissions at 405 nm (E405) and 525 nm (E525) after excitation at 355 nm were 
recorded over time. Calcium flux was calculated as the E405/E525 ratio. 
TCR downregulation 
To measure TCR downregulation, P815 cells were pulsed with 1 µM peptide for 1 h at 37 
o
C 
in DMEM, 0.5% FCS, 2 µg/ml hβ2m. After the removal of unbound peptide with DMEM 
washes, 10
5
 of peptide-loaded P815 cells were brought into contact with an equal number of 
T cell hybridoma cells and centrifuged gently at 1000 rpm for 1 minute at RT. After different 
times of incubation at 37 
o
C, cells were fixed in ice-cold PBS-buffered 2% formaldehyde. 
Samples were treated with anti-CD16/32 mAb 2.4G2 supernatants before staining for the 
TCR receptor with PE-labeled anti-Vb8.2. Data were collected on FACSCalibur flow 
cytometer.  
FACS and FRET analysis 
For FACS analyses, aliquots of 5x10
5
 cells were incubated in 100 μl of FACS buffer in v-
bottom 96-well plates (Greiner Bio-One) with fluorescently labeled antibodies (20 μg/ml) for 
15 min at 4 
o
C; or with PE-labeled multimers of K
d
 PbCS(ABA), K
d
 PbCS(ABA) P255A, K
d
 
PbCS(ABA) 226/227 for 30 min at room temperature in the presence or absence of anti-
CD8β mAb H35 (20 μg/ml). After two washes, cell-associated fluorescence was assessed on 
a FACSCalibur. For FRET analyses, aliquots of 10
5
 cells were incubated in 100 µl FACS 
buffer in v-bottom 96-well plates with 20 µg/ml Cy5-labeled anti-CD8α 53.6.72, anti-CD8β 
KT112; PE-labeled anti-CD3ε mAb 17A2, anti-TCRβ mAb H57, anti-CD90.1 mAb HIS51 or 
PE-labeled K
d
/PbCS(ABA) multimers. After 45 min of incubation at 4 
o
C, cells were washed 
and fixed with formaldehyde (2% w/v in FACS buffer) for 10 min at room temperature, and 
cell-associated fluorescence was measured on a FACSCalibur at 580 nm upon excitation at 
488 nm (FL2), at 670 nm upon excitation at 630 nm (FL4) and at 670 nm after excitation at 
488 nm (FL3). The FRET intensity was calculated as “FRET units” as follows: FRET unit = 
[(FL3both-FL3none)-((FL3Cy5-FL3none)x(FL4both/FL4Cy5)]–[(FL3PE-FL3none)x(FL2both/FL2PE)] as 
previously described (Doucey et al., 2003). Mean fluorescence intensities were measured on 
unlabeled cells (FLnone), or cells labeled only with Cy5 (FLCy5), PE (FLPE), or Cy5 and PE 
(FLboth). 
IL-2 assay 
To measure IL-2 production, 10
4
 T cell hybridoma cells were mixed with peptide-pulsed 
P815 cells per well in a 1:4 E/T ratio and incubated in T cell hybridoma growth medium 
overnight in a v-bottom 96-well plate. 100 µl of supernatant was used in an IL-2 ELISA 
assay which was performed according to manufacturer’s instructions (Mabtech). 
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Isolation of detergent-insoluble membranes (DIMs), co-immunoprecipiation and 
immunoblotting 
T1 TCR hybridomas (1.5x10
7
 cells) were lysed on ice for 30 min in lysis buffer (TBS (20 
mM Tris HCl, pH 8.0, 100 mM NaCl) containing 1% Brij96 and 1x complete protease 
inhibitors (Roche Molecular Biochemicals)). The lysates were spun at 10,000 g for 10 min, 
and supernatants were immunoprecipitated using Sepharose-bound monoclonal antibodies 
specific for CD8α (53.6.72) or CD8β (H35). Alternatively, T cell hybridomas (5x107) were 
lysed in 1 ml cell lysis buffer with Triton X-100 for 30 min on ice. The samples were 
centrifuged at 100,000 x g for 60 min at 4°C, and the supernatant was collected (membrane 
(M) fraction). The pellet was homogenized in 1 ml cell lysis buffer with Brij96 and incubated 
for 60 min on ice. After centrifugation for 20 min at 12,000 x g and 4 °C, the supernatant was 
collected (DIM fraction), as described in (Arcaro et al., 2000). Membrane and DIM fractions 
were immunoprecipitated with anti-CD8α mAb 53.6.72 (20 µg) coupled to Sepharose. The 
samples were analyzed by SDS-PAGE and Western blotting with anti-CD8β Abs KT112 and 
goat anti-rat HRP secondary reagent.  
The immune complexes were washed twice with lysis buffer. Subsequently, they were boiled 
5 min at 95 
o
C in reducing Laemmli sample buffer and resolved on 4-15% gradient SDS-
PAGE (Bio-Rad), transferred onto a nitrocellulose membrane, and Western blotted using 
anti-CD3δ and anti-p56Lck antibodies. For detection the enhance chemiluminescence (ECL) 
kit (GE Healthcare Life Sciences) was used according to manufacturer’s instructions.  
FRET microscopy 
 
FRET microscopy was performed on the Axio Observer.Z1 (Zeiss) inverted fluorescence 
microscope with filters for Cy5, YFP, CFP and YFP/CFP FRET (Chroma). Samples were 
prepared in the same way as for conjugate formation but they were formaldehyde fixed after 
20 min of incubation at 37 
o
C. Samples were mounted after formaldehyde removal with PBS 
in the glycerol-based Slowfade medium (Invitrogen) on standard microscope slides. 
Coverslips were sealed with nail polish and slides used within a week of mounting. Images 
were processed with the AxioVision 4.8 (Zeiss) and ImageJ software and final FRET values 
calculated with MS Excel according to (Mallaun et al., 2008). Microscope setup G value was 
measured with CFP-YFP cells exposed to different levels of donor (CFP) bleaching by 
exposure to excitation light according to (Zal and Gascoigne, 2004). 
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Mathematical methods 
It is assumed that a streptavidin conjugate has four binding sites for biotin and that a 
biotinylated MHC-peptide complex is occupied with the desired peptide with a probability p 
or with any other peptide with a probability q=1-p. 
The probability of the formation of a tetramer with all four cognate MHC-peptide complexes 
is : 
1.        
404
4
4
pqp  
For the trimer, i.e. three right MHC-peptide and one irrelevant can be obtained in four 
different arrangements. Therefore, it is assigned the probability of : 
2.       qpqp
313 4
3
4
 
Because of the tetrahedral arrangement of MHC-peptides in a streptavidin conjugate, it can 
be considered that a tetramer and a trimer of the correct MHC-peptides are the proper 
staining reagents. This gives its probability as a sum of 1 and 2 or : 
3.        4334 344 ppqpp  
The distribution of streptavidin MHC-peptide oligomers obeys a binomial distribution where 
the probability of forming a dimer, monomer and a conjugate with no desired peptide-MHC 
(i.e. all four sites are occupied by irrelevant peptide-MHCs) is given by : 
dimer 
22
2
4
qp  , monomer 
31
1
4
qp , and  with all irrelevant MHC-peptides 
40
0
4
qp  
Sum over all probabilities of different oligomers is 1. 
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3. Detection of antigen-specific CD4+ T cells by novel types of MHC class 
II–peptide complexes 
3.1 Results 
3.1.1 State of the art of MHC-peptide multimer staining of specific CD4+ T cells   
Despite similarities in structural features, recombinant MHC class II-peptide complexes are 
characterized by more complex biochemistry and conformational dynamics than their  
MHC class I-peptide counterparts (Belmares et al., 2003; Georges et al., 2000; Lovitch and 
Unanue, 2005; Rötzschke et al., 1999; Schmitt et al., 1999). Therefore, it is necessary to 
validate MHC class II-peptide multimers on T cell lines or clones that are: i) specific for the 
peptide studied, and ii) stringently HLA typed. 
 
Figure 3.1 Production of conventional MHC class II-peptide multimers. Separate constructs for the MHC α 
and β chain in expression plasmids containing a metallothionein promoter are co-transfected with a 
plasmid conferring antibiotic resistance (e.g. puromycin) into S2 cells. After antibiotic selection, lines or 
clones were derived by limiting dilution, expanded and cultured in roller bottles at room temperature. 
After induction with 1 mM CuSO4 for 3-5 days, recombinant MHC class II proteins are purified from 
supernatants by immunoaffinity chromatography on an anti-MHC class II antibody column, loaded with 
a peptide of interest and enzymatically biotinylated with BirA. After gel filtration chromatography, 
MHC-peptide complexes are multimerized with a fluorescent streptavidin conjugate at a 4:1 ratio. 
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There are two main strategies to produce soluble recombinant MHC class II-peptide 
complexes: i) “Empty” (without a nominal peptide cargo) MHC molecules are loaded in vitro 
with a peptide of interest, and ii) The peptide of interest is tethered onto the MHC class II β 
chain via a long and flexible linker (Fremont et al., 1996a). This latter strategy is commonly 
used for the production of recombinant murine MHC class II–peptide complexes, mainly 
because “empty” mouse MHC class II molecules are not stable. The two strategies can be 
combined, by expressing MHC class II molecules with tethered on CLIP peptide and 
subsequent peptide exchange after proteolytic cleavage of the CLIP peptide (Day et al., 2003)     
With respect to MHC class II-peptide complexes obtained by peptide loading of “empty” 
MHC class II molecules, we and others have observed that efficient peptide binding is limited 
to native molecules (Carven et al., 2004; Natarajan et al., 1999a; Rabinowitz et al., 1998). By 
adding a low molecular weight tag N-terminally to the peptide, correct MHC class II-peptide 
complexes can be isolated by means of this peptide tag (Day et al., 2003; Demotz et al., 1991; 
Nag et al., 1994). This is a reliable method to ensure the biochemical integrity of MHC class 
II-peptide multimers. In the following sections of this chapter, several such strategies will be 
presented. Multimer staining of antigen-specific CD4+ T cells differs in several aspects from 
multimer staining of CD8+ T cells, such as: i) MHC class II-peptide multimer staining is 
preferably performed at elevated temperatures, usually 37˚C. Although some CD4+ T cells 
can also be efficiently stained in the cold, others are stained poorly or not at all (Fig. 3.2) 
(Reichstetter et al., 2000); ii) Longer incubation periods (1 hour or longer) are needed for  
 
Figure 3.2 Staining parameters of MHC class II-peptide multimers. DR4/HA306-318 clones were stained with 
the conventional SA-PE DR4/HA306-318 multimer for 30 min at 37 
o
C (A) or 3 hours at 4 
o
C (B), washed, 
and cell-associated fluorescence measured by flow cytometry. Data were fitted by nonlinear regression 
from two experiments. 
 CHAPTER I 
58 
 
efficient staining, which is explained, at least in part, by accumulation of MHC class II-
peptide multimers due to  endocytosis (Fig. 3.3) (Cameron et al., 2001) and iii) The avidity of 
MHC class II-peptide multimer binding is typically lower than the binding of MHC class I-
peptide multimers. Unlike CD8, the CD4 coreceptor does not significantly increase MHC-
peptide binding to the TCR (Xiong et al., 2001). Moreover, data comparing the binding 
avidity of MHC class I and class II-peptide complexes to their cognate TCR showed on 
average weaker binding for the latter (Cole et al., 2007). MHC class II-peptide multimers 
therefore have to be titrated up to high concentrations (e.g. 100 nM/approx. 50 µg/ml). Even 
then, some antigen-specific CD4+ T cells, namely those specific for self-antigens, remain un- 
or barely detectable by MHC class II-peptide multimer staining.  
 
Figure 3.3 MHC class II-peptide multimers are internalized at physiological temperatures. A, DR4/HA306-318 
clone was stained with 5 μg/ml SA-PE DR4/HA306-318 multimer for 1 hour at 4 
o
C (top) or 37 
o
C (bottom) - 
(pulse), washed and incubated at 37 
o
C for 4 hours (chase). B, DR4/HA306-318 clone was stained with 5 
μg/ml SA-PE DR4/HA306-318 multimer for 1 hour at 37 
o
C (red), washed and then surface labeled with 
NHS-Cy5 (blue). C, DR4/HA306-318 clone was stained with 5 μg/ml SA-PE DR4/Cy5-HA306-318 multimer for 
4 hours at 37 
o
C. Cells were fixed with formaldehyde and imaged by fluorescence microscopy. Red 
indicates signals from PE and blue from Cy5. White arrows indicate accumulation of Cy5 fluorescence 
without PE fluorescence. 
(Gebe et al., 2003; Kwok, 2003; Sabatino et al., 2011). This is explained, at least in part, by a 
combination of very low TCR avidity and rapid TCR down-modulation. Dasatinib, a Src 
kinase inhibitor, has been reported to inhibit TCR down-modulation and thus to increase 
multimer staining (Lissina et al., 2009). Moreover, we and others have observed that 
enzymatic desialylation with neuraminidase from Vibrio cholerae or Clostridium perfrigens 
can increase MHC class II-peptide multimer staining several-fold (Fig. 3.4) (Massilamany et 
al., 2011; Reddy et al., 2003). 
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Figure 3.4 Neuraminidase pre-treatment enhances multimer binding. A, B, DR4/HA306-318 clones 5-0.5 and 
9-0.5 were pretreated (squares) or not (circles) with 0.2 U/ml neuraminidase for 30 min at 37 
o
C, washed 
and stained with SA-PE DR4/HA306-318 multimer for 1 h at 37 
o
C. Experiments were performed at least 
twice. C, 18 DR4/HA306-318 clones were pretreated (squares) or not (circles) with 0.2 U/ml neuraminidase 
for 30 min at 37 
oC, washed and stained with 3.7 nM (2 μg/ml) SA-PE DR4/HA306-318 multimer for 1 h at 
37 
o
C and analyzed by flow cytometry. Non-specific binding was determined on a DR4/Flu-MP61-72-
specific clone and subtracted. Error bars represent SD. 
3.1.2 Loading of “empty” MHC class II molecules with specific peptides and impact of 
peptide loading efficiency on multimer staining 
 
Commonly used protocols to prepare human MHC class II-peptide multimers (Kwok et al., 
2002) involve loading of “empty” recombinant MHC class II molecules with high peptide 
concentrations (up to 100 μM) under acidic conditions (pH 5.2-6.0) for up to 72 hours at 
elevated temperatures (37 
o
C), followed by size exclusion chromatography to recover 
monomeric MHC class II-peptide complexes. To investigate whether peptide binding affinity 
correlates with the degree of loading, we compared relative affinities of DR4-binding 
peptides by means of a binding competition assay (Fig. 3.5A) and their loading efficiency 
after 6, 24 and 48 hours (Fig. 3.5B). The HA306-318 and NY-ESO-1119-143 peptides both 
exhibited high affinities for DR4 (DRA*0101, DRB1*0401), with IC50 values for half-
maximal binding of 4.43±1.22 μM for HA306-318 and 14.84±13.96 μM for NY-ESO-1119-143, 
respectively, which is in concordance with published data (Zarour et al., 2002). In contrast, 
when peptide occupancy was determined after 24 h of incubation with peptides on DR4 
complexes, >80% of monomeric DR4 had bound the HA306-318 peptide, but only 25% of 
monomeric DR4 had bound the NY-ESO-1119-143 peptide. 
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Figure 3.5 Extent of peptide loading and binding affinity are two separate parameters. A, Peptide binding of 
HA306-318 (orange triangles) and NY-ESO-1119-143 (inverted dark green triangles) peptides to recombinant 
soluble DR4 (10 μg/ml) was measured by competition with 2 μM biotin-HA306-318 peptide. Flu-MP61-72 
(olive green triangles) served as the positive control, and Oxy272-284 (magenta squares) as the negative  
control. Data were normalized to signals from the uncompeted samples, which were taken as 100%. Red 
dashed lines indicate 50% binding. Mean values and SD were calculated from three experiments. B, 
Peptide occupancy of DR4 with His-HA306-318 (black bars) or His-NY-ESO-1119-143 (white bars) for 6, 24 
and 48 hours at 37 
o
C at pH 6. Peptide occupancy was calculated as follows: (amount of His-peptide 
bound to the DR4 molecule)/(amount of total DR4). Samples were gel-filtered to remove unbound peptide 
and quantitated by ELISA using affinity-purified complexes as 100%. Mean values and SD were 
calculated from at least two experiments. 
Similar results were obtained with recombinant DR52b molecules (DRA*0101, 
DRB3*0202); in which case the affinities of the NY-ESO-1119-143 peptide were higher 
(0.62±0.06 μM for NY-ESO-1119-143 and 2.54±0.13 μM for HA306-318) (Fig. 3.8B). After 
loading of “empty” DR52b with Cy5-labeled NY-ESO-1119-143 under the same conditions and 
purification by gel filtration, the dye/protein (D/P) ratio of the MHC-peptide monomer was ≤ 
20% (data not shown). 
To investigate the correlation between peptide loading onto MHC class II molecules and 
multimer binding, we compared binding of mixed multimers to antigen-specific CD4+ T-cell 
clones. To form mixed multimers, cognate and non-specific MHC-peptide complexes were 
mixed and multimerized on a PE-labeled streptavidin conjugate. For the sake of simplicity, 
we assumed that all four binding sites on a streptavidin molecule were equally occupied. 
Fractions of cognate tetramers, trimers, dimers and monomers were calculated as a function 
of the proportion of cognate peptide-MHC complexes in tetramers are shown in Fig. 3.6A. If 
all MHC-peptide complexes are cognate, the resulting tetramer is bona fide. However, if half 
of the MHC-peptide monomers are cognate, the “tetramer” preparation consists mostly of 
dimers (37.5 %), equal proportions of trimers and monomers (25%) and only 6.25% bona 
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fide tetramers. If only 20% of MHC-peptide complexes are specific, the reagent consists 
mostly of monomers (41%), of dimers (~15%) and traces of true trimers (~3%) and tetramers 
(~0.2%).  
In tetramer binding to T cells, cell-associated fluorescence derives from molecular species of 
different valence. We defined the effective reagent fraction as the sum of fractions of 
different MHC-peptide species contributing to staining (Fig. 3.6A). Thus, four theoretical 
curves can be generated, depending on the binding avidity of the TCR. As shown in Fig. 
3.6B, when the avidity is low, only bona fide tetramers can stably bind (x=4). As the avidity 
gradually increases tetramers and trimers (x=4+3), then tetramers, trimers and dimers 
(x=4+3+2) and finally tetramers, trimers, dimers and even monomers (x=4+3+2+1) can bind 
stably. To determine whether there is a threshold, below which tetramer binding is negligible, 
i.e. where the effective reagent fraction is close to zero, mixed tetramers containing graded 
fractions of DR4/His-HA306-318 and DR4/CLIP monomers were prepared. Their binding 
profiles were assessed on seven DR4/HA306-318-specific CD4+ T cell clones (Fig. 3.6C). 
According to similarities of the binding profiles of clones with the theoretical binding curves 
(Fig. 3.6B), the observed binding data were grouped in three categories - very high avidity 
(Fig. 3.6D), high avidity (Fig. 3.6E) and low avidity (Fig. 3.6F).  These categories exhibit 
differently shaped binding curves; the very high avidity curves are concave, the high avidity 
nearly linear and the low avidity convex. On very high avidity clones tetramer binding stays 
relatively constant to about 50% of specific complexes and then rapidly decreases at higher 
fractions of non-specific complexes. For high-avidity clones this decrease starts already at 
~80% of specific complexes. For low-avidity clones, however, the monomer purity is 
paramount, as their staining strictly depends on the reagent’s content of bona fide tetramers, 
as seen by the nearly exponential decrease with the fraction of cognate complexes. 
This analysis highlights the importance of using affinity purified complexes for detection of 
low avidity CD4+ T-cells that are frequently those specific for self-antigens, including cancer 
antigens. Another important conclusion of our analysis is that binding diminishes 
dramatically when the fraction of specific complexes decreases to 20% or less (Figs. 3.6D-F, 
vertical light blue dashed line). As elaborated below, this explains why in the case of the NY-
ESO-1119-143 peptide, tetramers prepared by using conventional procedures exhibited no 
significant staining of clones or populations. 
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Figure 3.6 Dependence of tetramer staining on their cognate MHC-peptide content A, Cognate and 
irrelevant MHC-peptide monomers were mixed in different ratios (x-axis; fraction of specific monomers) 
and reacted with streptavidin to make tetramers. The binominal distributions of X-mers, i.e. complexes 
containing X=1,2,3 or 4 cognate monomers were calculated and plotted on the y-axis as fraction of 1. B, 
Theoretical effective reagent fraction, defined as the sum of the fractions of X-mers that bind stably to 
antigen-specific cells. Four curves were calculated reflecting different TCR avidities. C, Different PE-
labeled tetramers were prepared by reacting PE-streptavidin with mixtures of cognate biotinylated 
DR4/His-HA306-318 complexes and irrelevant biotinylated DR4/CLIP complexes. The fraction of cognate 
monomers is shown on the x-axis. The indicated DR4/HA306-318–specific CD4+ T cells clones were stained 
with the different tetramers (18.5 nM; i.e 10 μg/ml) for 1 hour at 37 oC, washed and analyzed by flow 
cytometry. The observed mean fluorescence intensities were normalized to the staining observed for bona 
fide DR4/His-HA306-318 tetramers, which was defined as 100% and represented at effective reagent 
fraction on the y-axis. Averages of two experiments are shown. D-F, DR4/HA306-318-specific clones from C) 
are grouped in three categories (very high avidity (D), high avidity (E), low avidity (F) based on their 
ability to bind X-mers. The vertical dashed line in light blue represents a critical staining threshold. One 
out of two-three experiments is shown. 
 
3.1.3 Purification of bona fide MHC class II-peptide complexes and impact on staining 
of antigen-specific CD4+ T cells 
3.1.3.1 Purification via a His-tag at the peptide N-terminus 
 
Purification of MHC class II-peptide monomers can be accomplished by means of a 
hexahistidine tag (His-tag) added to the peptide of interest via a SGSG linker. After peptide 
loading and biotinylation, MHC-peptide complexes were bound to a Ni
2+
-NTA chelating 
column and then eluted in a single sharp peak (Fig. 3.7A). Imidazole and eventual aggregates 
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were removed by subsequent gel filtration chromatography on a Superdex S200 column (Fig. 
3.7B). Purity and biotinylation state of the MHC-peptide monomers were verified by non-
denaturing SDS-PAGE (Fig. 3.7C) in the presence and absence of avidin. 
As peptide binding sites of MHC class II molecules are open-ended, permitting 
accommodation of peptide ligands of various lengths (Lippolis et al., 2002), we reasoned that 
the His-tag is located outside of the peptide binding groove and hence may not affect peptide 
binding to the MHC molecule. To verify this, N-terminally His-tagged NY-ESO-1119-143 
peptide was compared with the wild-type peptide in a binding competition assay. This assay 
was performed on soluble DR4 (Fig. 3.8A) and DR52b (Fig. 3.8B). Only modest differences 
were observed between the IC50 values of the His-tagged peptide and the unmodified peptide, 
with a tendency for the His-tagged peptide to exhibit slightly higher IC50 values.  
 
 
Figure 3.7 Purification and SDS-PAGE analysis of His-tagged MHC class II-peptide complexes. A, 
Representative Ni
2+
-NTA column chromatogram of a MHC class II-peptide complex with a N-terminal 
peptide His-tag (here DR4/His-NY-ESO-1119-143). His-tagged complexes elute in a sharp peak with 200 
mM imidazole. B, Representative gel filtration chromatogram of DR4/His-NY-ESO-1119-143 monomer 
eluted from the Ni
2+
-NTA column. C, Non-reducing SDS-PAGE (12%) of the DR4/His-NY-ESO-1119-143 
monomers after gel filtration. Molecular weight marker (lane 1) with the appropriate molecular weights 
in kDa shown on the left. Lanes 2, 4 and 6 were loaded with 2, 5 and 10 μg of monomers and lanes 3, 5 
and 7 likewise but with the addition of 10 μg avidin. Lane 8 contains avidin only. 
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Figure 3.8 N-terminal His-tag barely alters peptide binding to DR4 and DR52b. Peptide binding of NY-
ESO-1119-143 (triangles) and His-NY-ESO-1119-143 (diamonds) peptides to recombinant DR4 (A) and 
recombinant DR52b (B) was determined by competition against biotin-HA306-318. HA306-318 is the positive 
control (red circles) and NY-ESO-1143-154 is the negative control (pink circles). The red dashed line marks 
IC50 values as the competitor peptide concentration needed to reduce the amount of biotin-HA306-318-
containing complexes to 50%. The IC50 values were 1.6 μM and 3.0 μM for the wild-type and His-tagged 
NY-ESO-1119-143 peptides on DR4 and 3.6 μM and 5.9 μM for the wild-type and His-tagged NY-ESO-1119-
143 peptides on DR52b, respectively. Experiments were performed at least twice. Representative 
experiments are shown. 
To illustrate the impact of MHC-peptide monomer purity on the staining of fluorescent 
MHC-peptide tetramers, the binding of affinity purified DR4/His-NY-ESO-1119-143 
complexes was compared with the binding of conventional DR4/NY-ESO-1119-143 complexes 
on NY-ESO-1-specific CD4+ T cell line (Fig. 3.9A). Conventional DR4/NY-ESO-1119-143 
multimers failed to detect specific cells at any concentration tested. By contrast, DR4/His-
NY-ESO-1119-143 multimers detected up to 8.2% specific CD4+ T cells. We then analyzed a 
NY-ESO-1119-143-specific, DR52b-restricted CD4+ T cell clone and observed IFNγ 
production upon stimulation with the NY-ESO-1119-143 peptide (Fig. 3.9B). This clone was 
not significantly stained with conventional DR52b/NY-ESO-1119-143 multimers, but was 
stained avidly with multimers containing “immunopure” (molecularly defined) DR52b/His-
NY-ESO-1119-143 monomers (Fig. 3.9C).  
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Figure 3.9 Improved staining with “immunopure” DR4 and DR52b/His-NY-ESO-1119-143 multimers. A, 
Binding isotherm on a DR4/NY-ESO-1119-143-specific CD4+ T cell line stained with SA-PE multimers 
containing biotinylated affinity-purified DR4/His-NY-ESO-1119-143 monomers (circles), conventionally 
loaded DR4/NY-ESO-1119-143 monomers (squares) or DR4/CLIP monomers (triangles). Cells were stained 
with the indicated concentrations of multimers for 1 hour at 37 
o
C and analyzed by flow cytometry. B, 
Intracellular production of IFNγ in a DR52b/NY-ESO-1119-143-specific clone stimulated with 2 μM NY-
ESO-1119-143 peptide (ESO clone, top); nonspecific background was evaluated on a DR52b-restricted clone 
specific for the SSX2 antigen (Control clone, bottom). C, Staining of the clones as in B with 5.6 nM (3 
μg/ml) conventional (left) and “immunopure” DR52b/NY-ESO-1119-143 multimers (right).   
Moreover, “immunopure” DR52b/His-NY-ESO-1119-143 tetramers detected specific CD4+ T-
cells from vaccinated melanoma patients directly ex vivo (Fig. 3.10), i.e. without anti-PE 
based enrichment techniques or peptide stimulation of the T cells in vitro. This is of great 
significance, because for the first time this allowed conclusive analysis of tumor antigen-
specific CD4+ T cells without biasing the results and conclusions. 
 
Figure 3.10 Ex vivo detection of DR52b/NY-ESO-1119-143-specific CD4+ T cells from vaccinated cancer 
patients. A, CD4+ T cells purified from PBMC from DR52b+ healthy donors and from pre- and 
postvaccine samples from DR52b+ patients stained ex vivo with DR52b/His-NY-ESO-1119–143 tetramers 
(5.6 nM or 3 μg/ml) for 2 h at 37 °C and then stained with anti-CD45RA mAb HI100 and analyzed by 
flow cytometry. Dot plots for one HD, one pre-vaccine sample, and all postvaccine samples are shown in 
A and data for all samples tested are summarized in B. Numbers in dot plots correspond to the 
percentage of tetramer-positive cells among memory CD45RA− CD4+ T cells (from (Ayyoub et al., 
2010a)).  
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3.1.3.2 Reversible N-terminal peptide tags 
 
Our and others results support the notion that the binding of peptides to MHC class II 
molecules readily tolerates N- and C-terminal extensions from the binding nonamer core 
(Chicz et al., 1992; Hunt et al., 1992; Rudensky et al., 1991).  However, several reports have 
implicated N- and C-terminal residues adjacent to the nonamer core, termed “peptide-
flanking residues”, in modulating TCR binding (Arnold et al., 2002; Carson et al., 1997; 
Sant'Angelo et al., 2002), and influencing TCR repertoire selection (Cole et al., 2012). In 
view of the large diversity of TCR:MHC-peptide binding configurations, it is difficult to 
predict what effect modifications of peptide-flanking sequences might have on TCR 
recognition. We therefore established a strategy that allows easy removal of the peptide tag 
after its use for monomer purification, in order to avoid its potential interference with TCR 
recognition. To this end, we synthesized two variants of the HA306-318 peptide bearing a His-
tag either at the N- or the C-terminal end via a GSGS linker and a photocleavable residue, β-
nitrophenylglycine (βNPG) (Fig. 3.11A,B). The βNPG undergoes a photolytic reaction 
resulting in cleavage at its C-N bond. After cleavage, the indicated chemical entities (Fig. 
3.11B) remain on the N- and C-terminal portions. We prepared affinity-purified N- and C-
terminally tagged DR4 complexes and subjected them to irradiation with UV light at 365 nm 
for up to 60 minutes and observed the His-tag bound to the MHC molecules by ELISA. The 
half-lives of these complexes under these conditions were 0.51 min for the N-terminal and 
0.57 min for the C-terminal complex. In 10 minutes the photocleavage reaction was 
essentially complete (Figs. 3.11C-D). 
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Figure 3.11 Kinetics of photolytic tag removal. A, Sequences of HA306-318-peptide derivatives containing  a 
photolabile β-nitrophenylglycine residue between the His-tag on the N-terminus (peptide 1) or C-
terminus (peptide 2) of the MHC class II-binding peptide. B, Cartoon of the photocleavage reaction (top). 
Photochemical reaction of the β-nitrophenylglycine residue, induced by UV light at 365 nm (bottom), 
resulting in the cleavage of the adjacent peptide bond. C-D, Kinetics of His-tag photocleavage induced  by  
UV light, as measured by ELISA on DR4 monomers containing peptide 1 (C) or peptide 2 (D). The half-
lives of the photocleavage were 0.51 min and the 0.57 min for the N-terminally and C-terminally labeled 
peptides, respectively. One representative experiment (out of  ≥ two) is shown. 
To test and validate this strategy, we either UV-irradiated or not immunopure, biotinylated 
DR4/HA306-318 monomers containing a N- or C-terminal conditional peptide His-tag for 10 
minutes, prepared PE-labeled multimers and performed binding isotherms on four different 
DR4/HA306-318-specific clones (Figs 3.12A-D and Table 3.1). Clones 2 and 9 were of high 
and clones 15 and 8 were of low avidity. Levels of surface-expressed TCR, CD4 and their 
functional avidities are listed in Table 3.2. Multimers from N-terminally His-tagged 
DR4/HA306-318 complexes stained more efficiently in all cases than the C-terminally His-
tagged complexes and both stained more avidly than conventional multimers. 
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Figure 3.12 Photolytic removal of peptide His-tag and its impact on multimer binding. A-D, Binding 
isotherms of “immunopure” DR4/HA306-318 multimers (blue and green), and conventional multimers (red) 
on DR4/HA306-318-specific clones. Binding of multimers prepared from non-irradiated complexes with N-
terminal His-tags (dark blue) and irradiated N-terminal complexes (light blue), were compared to 
binding of multimers prepared from non-irradiated C-terminal His-tagged complexes (bright green) and 
UV-irradiated C-terminal His-tagged complexes (light green). Multimer binding was performed for 1 
hour at 37 
o
C. Scatchard plots are displayed as inserts in graphs A and C. Due to low binding, no 
conclusive Scatchard plots could be derived for B and D. A DR4/Flu-MP61-72 clone was used to evaluate 
non-specific background binding for each reagent and the value of this background was subtracted. 
Inferred KD and Bmax values are compiled in Table 3.1. Experiments were performed twice. 
Representative experiments are shown. 
Table 3.1 KD and Bmax values from Fig. 3.12 
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Moreover, there was a slight, but significant decrease in staining efficiency in multimer 
staining from UV-irradiated complexes, as reflected in slight changes in KD and Bmax values 
(Table 3.1). For the low binding affinity clones 8 and 15 reliable nonlinear regression and 
Scatchard analyses were not feasible because saturation was not reached. In conclusion, our 
comparative tetramer binding studies indicated that:  i) compared to conventional tetramers, 
those made of “immunopure” monomers stained antigen-specific CD4+ T cells much more 
efficiently, in particular low avidity ones; and ii) N-terminal and to a lesser degree C-terminal 
His-tags may artificially increase binding and that this can be circumvented by photochemical 
removal of the tags.  
Table 3.2 Characterization of DR4/HA306-318 clones from Fig. 3.12 
                                 
3.1.3.3 Purification of MHC-peptide monomers via N-terminal acidic tags 
 
While the isolation of “immunopure” MHC-peptide monomers by means of peptide His-tag 
has advantages such as providing good peptide solubility and gentle isolation procedures, it 
necessitated purification of recombinant MHC class II molecules by immunoaffinity 
chromatography and conjugate formation via irreversible biotin-streptavidin interactions. As 
this is not compatible with the novel staining reagents referred to as NTAmers (presented in 
section 3.1.4), it was necessary to establish another strategy to purify cognate MHC-peptide 
monomers. 
Polyanion tags containing multiple glutamate and/or aspartate residues have been used 
successfully to purify recombinant proteins by anion exchange chromatography (Le Borgne 
et al., 1995; Stubenrauch et al., 2000; Suominen et al., 1992). As a model system to test the 
feasibility of using polyanionic tags for purification of MHC-peptide monomers of interest, 
Cy5.5, a blue fluorescent moiety containing four negatively charged SO3
-
 groups, was tested 
as a purification tag (Fig. 3.13). After loading of the soluble DR4 molecules with the Cy5.5-
HA306-318 peptide, the blue DR4/Cy5.5-HA306-318 complexes (peak 2) were clearly resolved 
from colorless material (peak 1) (Fig. 3.13A). The blue DR4/Cy5.5-HA306-318 complexes 
were characterized by a strong absorption of Cy5.5 at 675 nm (Fig. 3.13B). The DR4/Cy5.5-
HA306-318 complexes were predominantly monomeric as verified by gel filtration 
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chromatography (Fig. 3.13C) and SDS-PAGE analysis (Fig. 3.13D). Fluorescent multimers 
prepared from these monomers bound more avidly to a DR4/HA306-318-specific CD4+ T cell 
clone (Fig. 3.13E) and also elicited a stronger IL-2 response when bound to a plastic surface 
at the same concentration than DR4/HA306-318 complexes prepared by conventional peptide 
loading (Fig. 3.13F). However, use of Cy5.5 as a purification tag had serious disadvantages, 
such as: i) solubility problems and non-specific binding; ii) the use of photosensitive linkers 
for subsequent removal of the peptide tag was not applicable, due to the high UV absorption 
of Cy5.5 and iii) highly expensive and often difficult syntheses.  
 
To determine the minimal peptidic polyanionic tag length allowing effective separation of 
specific MHC-peptide complexes of interest from the remaining MHC molecules, we 
examined the different variants of the HA306-318 peptide shown in Table 3.3. To facilitate 
detection of the tagged MHC-peptide monomers in chromatographic fractions by ELISA, the 
peptide’s N-terminus was capped with a phosphotyrosine (pY) or sulfotyrosine (sY), for 
which there exist antibodies. After loading, excess peptide was eliminated by gel filtration 
and MHC-peptide monomers resolved on anion-exchange chromatography. Fractions were 
assayed for peptide (pY, red and sY, purple) and DR protein in two separate ELISA. Peptide 
tags carrying four (Fig. 3.14A) and six aspartates (Fig. 3.14B) insufficiently separated 
specific (peak 2) and non-specific MHC-peptide complexes (peak 1), i.e. the peaks largely 
overlapped. By spacing the six negatively charged aspartates over ten residues (Fig. 3.14C) or 
by using eight glutamate residues (Fig. 3.14C-E), a clear separation of specific MHC-peptide 
monomers from the irrelevant MHCs was achieved. The octaglutamate tag (E8), 
irrespectively of glutamate linkage via the α-carbon (pY-E8) or via the γ-carbon atom (pY-E8) 
gave the best separation. The functionality of the complexes was verified by multimer 
staining (Fig. 3.14G). However, the usefulness of the E8 peptide tag was found to be limited 
to very stable complexes, e.g. DR4 (or DR1)/HA306-318. For less stable complexes, such as 
DR1 or DR4/NY-ESO-1119-143, aggregate formation was observed after purification due to the 
high salt conditions (>0.5M) needed for elution (data not shown). Another drawback of this 
strategy was the frequently high contamination of the thus isolated cognate monomers with 
diverse impurity, especially when the MHC class II molecules were isolated first by chelation 
and not by immunoaffinity chromatography (data not shown). 
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Figure 3.13 Purification of DR4/Cy5.5-HA306-318 complexes and their proprieties. A, Resolution of 
DR4/Cy5.5-HA306-318 from non-specific complexes by anion-exchange chromatography, referred to as 
peak 1 and 2, respectively. B, UV/VIS spectrophotometric analysis of peak 1 and 2. C, Gel filtration on a 
Superdex S200 column of the material corresponding to peak 2. D, SDS-PAGE (12%) of DR4/Cy5.5-
HA306-318 (lanes 1,4), DR4/HA306-318 (lanes 2,5), DR4/CLIP (lanes 3,6) complexes under non-reducing (lanes 
1,2,3) and reducing (lanes 4,5,6) conditions. M labels the molecular weight marker. E, Binding isotherm 
at 37 
o
C on a DR4/HA306-318-specific clone with PE-labeled DR4/Cy5.5-HA306-318 multimers (squares) and 
DR4/HA306-318 multimers (circles). F, IL-2 production from a CD4+ T-cell DR4/HA306-318 clone stimulated 
with plate-bound (100 ng/well) biotinylated complexes. IL-2 quantification was performed by ELISA. A 
representative experiment is shows out of two. Error bars represent SEMs from triplicates. 
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Figure 3.14 Isolation of “immunopure” MHC-peptide complexes via peptide polyanion tags. A-E, Empty 
DR4 molecules were loaded with HA306-318 peptides with the negatively charged N-terminal extensions 
listed in Table 3.3. After elimination of unbound peptide, DR4/peptide complexes were separated with 
anion-exchange chromatography on a NaCl gradient (0-1 M, 20 CV). F, As the negative control, the 
empty DR4 protein was subjected to anion-exchange chromatography under the same conditions. G, 
Staining of a DR4/HA306-318-specific CD4+ T cell line with PE-labeled DR4/pY-E8-HA306-318 (9.3 nM or 5 
μg/ml) (red histogram). The black histogram represents cells stained with the same concentration of PE-
labeled DR4/CLIP multimer. On all chromatograms, peak 1 represents DR4 without the peptide of 
interest, and peak 2 corresponds to DR4 complexes with the target peptides. Peak assignment was based 
on the ELISA analysis of fractions for the presence of the N-terminal pY (red) or sY (magenta) tag or the 
DR4 protein (green). 
Table 3.3 Polyanion tags for purification of MHC class II-peptide complexes. pY and sY stands for 
phosphotyrosine and sulfotyrosine, respectively. E stands for glutamate where peptide linkage is achieved 
through the γ-carbon. All other letters are standard amino-acids. 
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3.1.3.4 MHC-peptide monomer purification via a N-terminal DTB tag 
 
To find an alternative peptide tag that permits simple peptide synthesis and gentle MHC-
peptide complex isolation, we tested desthiobiotin (DTB). Desthiobiotin is a biotin analog, 
missing the sulfur atom (Fig. 3.15A). It binds less avidly to streptavidin (KD=2x10
-9
 M versus 
4x10
-14
 M for biotin, (Green, 1970) and is easily dissociated at room temperature or 37 
o
C or 
displaced with biotin. Streptactin, an engineered mutant of streptavidin (Korndörfer and 
Skerra, 2002; Voss and Skerra, 1997), is preferentially used for protein purification of 
streptag- or desthiobiotin-tagged proteins (Wu and Wong, 2004) as it can be easily displaced 
with 2-(4-hydroxyphenylazo)benzoic acid (HABA) and regenerated for repeated cycles of 
purification (Fig. 3.15B,C).          
                       
Figure 3.15 Isolation of MHC class II-peptide complexes via DTB-labeled peptides. A, Molecular structure 
of biotin and desthiobiotin. B, Cartoon representation of the DTB-HA306-318 peptide (red) or an irrelevant 
peptide (light blue) bound to the DR4 protein (black). C, Purification cycle of DTB-labeled MHC-peptide 
complexes on a streptactin column. D, Chromatogram of DR4/DTB-HA306-318 monomers eluted from a 
streptactin Sepharose column. Free DTB (50 mM) was used to elute DTB-labeled complexes from 
streptactin Sepharose. 
For a proof-of-principle, we synthesized HA306-318 with a N-terminal DTB residue separated 
from the HA306-318 peptide by a flexible GSGS peptide linker and loaded this onto 
recombinant DR4 protein. Elution of the DR4/DTB-HA306-318 complexes with excess ligand 
(50 mM DTB) at neutral pH was efficient (>70% recovery) and resulted in a sharp peak (Fig. 
3.15D). The validity of this strategy was confirmed by extending this experiment to DR1, 
DR4 and DP4 MHC class II complexes with a wide range of different peptides. 
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3.1.4 NTAmers: a novel class of reversible MHC class II-peptide staining reagents 
 
Several reasons prompted us to develop a novel strategy for the preparation of MHC class II 
–peptide multimers. First, the commonly used immunoaffinity purification is not only tedious 
and costly, but also a major source of MHC protein denaturation due to the typically harsh 
elution conditions required (pH=11.3 or 3.2 depending on the mAb). Purification via His-tags 
and chelating columns is more attractive, as it does not cause MHC II denaturation, and is 
universally applicable, economic and scalable. Second, conventional multimer preparation 
based on enzymatic biotinylation of soluble recombinant MHC-peptide complexes and 
subsequent multimer formation by conjugation with fluorescent streptavidin derivatives is 
irreversible and provides no versatility in conjugate formation. Third, besides flow cytometric 
analysis of antigen-specific CD4+ T cells, many studies require sorting of such cells.  
Sorting of antigen-specific T cells by means of conventional multimers may cause diverse 
difficulties. Upon avid binding of cell-surface TCR, MHC class I-peptide tetramers and 
dimers strongly induce T cell activation, provoking cell death and functional alterations in 
CD8+ T cells (Cebecauer et al., 2005a; Guillaume et al., 2006; Knabel et al., 2002; Schmidt 
et al., 2011). Even if the binding is performed in the cold, multimers stay on the cell surface 
and upon subsequent culturing of cells internalize and strongly activate CD8+ T cells. 
Furthermore, peptides from multimers can be transferred to cell-associated MHC molecules 
and thus enable potentially adverse T cell-T cell interactions (Ge et al., 2002; Schott et al., 
2002; Walden and Eisen, 1990). Desthiobiotin and streptactin-based reagents are stable only 
in the cold (0-4 
o
C), and hence are not applicable for sorting of CD4+ T cells, comprehensible 
staining of which requires elevated temperatures. Because there are growing interests in 
sorting antigen-specific CD4+ T cells for adoptive transfer in therapeutic settings, we devised 
a new strategy, based on the reversible Ni
2+
 NTA-His tag interaction. 
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3.1.4.1 Principles of the new strategy 
 
The first step in building a reversible reagent was to replace the essentially irreversible biotin-
streptavidin interaction (KD~10
-15
 M) between the biotinylated MHC-peptide monomers and 
the fluorescent streptavidin conjugate. As basis for this reversible interaction we chose the 
well-characterized Ni
2+
NTA:His-tag chelate complexes that are widely used, not only for 
protein purification, but also for binding of proteins to various surfaces (such as Biacore 
sensor chips or glass surfaces for protein microarrays) or even cell-surface for protein 
conjugation (Guignet et al., 2004). However, the interaction of one His-tag with Ni
2+
 NTA 
groups is not very strong (KD~10
-6
 M) and thus not adequate for stable conjugate formation. 
To strengthen this interaction, the hexahistidine tag was duplicated via a flexible 
GSGSGGGG spacer (Schmidt et al., 2011) (Fig. 3.16A). Moreover, four NTA groups were 
clustered as a dimer-of-a-dimer containing the same GSGSGGGG spacer in a linear peptide 
carrying an N-terminal biotin (Fig. 3.16C). This molecule we designated biotin-NTA4. By 
saturating the biotin binding sites of a streptavidin-phycoerythrin and adding nickel ions, the 
reversible scaffold was prepared (Fig. 3.16B). In this way, binding affinities up to 10
-12
 M 
were achieved for the Ni
2+
NTA4:2xHis pair. The tandem His-tag was appended to the C-
terminus of the MHC class II  chain, while on the β chains the C-terminal BirA-tag (BSP) 
was kept, providing an alternative tag for detection by antibody or enzymatic biotinylation 
(Fig. 3.16A). To purify correctly formed MHC-peptide monomers, DTB was used as a 
peptide tag of choice on the peptide’s N-terminus. Fluorescent streptavidin conjugates were 
prepared by mixing monomers with excess biotin-NTA4 ligands charged with NiSO4 and 
subsequently dialyzed to eliminate unbound reagents. Such fluorescent conjugates are 
referred to as SA-PE NTA4. The workflow of NTAmer preparation is outlined in Fig. 3.17. 
This strategy allows gently purification of delicate “empty” MHC class II molecules by 
chelating chromatography on IDA (iminodiacetic acid) columns, which is universally 
applicable, inexpensive and scalable.  In addition, it includes reversible use of the DTB 
peptide tag to isolate cognate MHC class II-peptide complexes after peptide loading. The 
sequential combination of these two different affinity chromatographies provides cognate 
MHC class II-peptide monomers of remarkably high purity. Finally in this strategy the 
tandem His-tag is again used for conjugate formation with SA-PE NTA4. While these 
conjugates are highly stable in the absence of imidazole, they very rapidly decay in its 
presence, i.e. they are fully switchable.   
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Figure 3.16 Components of the NTAmer. A, Cartoon representation of the 2xHis-tagged MHC complex 
loaded with a tag-labeled peptide. B, Cartoon representation of PE-labeled streptavidin saturated with 
biotin-NTA4  groups. C, Structure of biotin-NTA4 from (Schmidt et al., 2011). 
                                                  
Figure 3.17 Workflow of NTAmer preparation. “Empty” MHC class II proteins are purified from insect 
cell culture supernatants by means of IDA columns and subsequently loaded with DTB-tagged peptides. 
DTB-labeled MHC class II-peptide monomers are purified on streptactin columns and multimerized by 
mixing with SA-PE NTA4. 
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3.1.4.2 Staining performance of reversible NTAmers and staining reversibility 
 
We wished to test binding of reversible NTAmers on cells. To this end, we prepared SA-PE 
NTA4-based multimers incorporating DR42xHis/DTB-HA306-318 complexes, by mixing MHC-
peptide monomers with SA-PE NTA4. Concentrations of DR42xHis/DTB-HA306-318 and 
DR4/His-HA306-318 multimers were equalized according to their PE content and binding 
isotherms assessed on a DR4/HA306-318-specific high avidity clone 9 (Fig. 3.18A,B) and a low 
avidity clone 8 (Fig. 3.18C,D). Whereas conventional SA-PE DR4/His-HA306-318 multimers 
displayed a higher binding avidity (KD) than SA-PE NTA4 DR42xHis/DTB-HA306-318 
multimers on clone 9, the inverse was true on clone 8 (Table 3.4). On both clones  maximum 
binding (Bmax) was considerably higher for NTAmer as compared to conventional multimers. 
              
Figure 3.18 Binding of conventional (BSP) and NTAmer (NTA) on CD4+ T cell clones. A and C, Binding 
isotherms of DR42xHis/DTB-HA306-318 NTAmer (blue squares) and BSP multimers prepared from (red 
triangles). B and D, Scatchard plots for binding curves (A) and (C), respectively. Cells were stained at 37 
o
C for 1 hour with the respective multimers and cell-associated fluorescence was analyzed by flow 
cytometry. Concentrations of multimers were adjusted for PE content, by measuring absorbance at 565 
nm. A DR4/Flu-MP61-72 clone was used to assess non-specific binding for each reagent and the value of 
this background was subtracted. Curves were fit by non-linear regression. Resulting Bmax and KD values 
are reported in Table 3.4. Experiments were performed twice. Representative experiments are shown. 
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We then extended such an analysis to DR4/HA306-318-specific CD4+ T cells from a 
heterogeneous population. We compared the frequency of multimer positive cells on PBMC 
from a DR4
+
 healthy donor previously stimulated with the HA306-318 peptide and stained with 
NTA and conventional BSP multimers (Fig. 3.19A). For comparison we assessed IFNγ 
intracellular staining (Fig. 3.18B). A higher frequency (4% versus 3.1%) of antigen-specific 
cells was detected over a wide range of concentrations (up to 95 nM or ~50 μg/ml) with the 
SA-PE NTA4 DR42xHis/DTB-HA306-318 multimer compared to the immunopure DR4/His-
HA306-318 BSP multimer. NTAmers stained more avidly and detected higher frequencies of 
antigen-specific CD4+ T cells when tested at the same concentration than conventional 
multimers, at both 37 
o
C (6.23% NTA versus 4.52% BSP) and RT (5.35 NTA versus 3.30% 
BSP) (Fig. 3.19C). Similar results were observed when comparing DP42xHis/DTB-TT947-960 
NTAmers and conventional DP4/TT947-960 multimers (2.65% NTA versus 2.14% BSP in 
specific cells) on peptide stimulated PBMC (Figs. 3.19D) or with the corresponding 
DR1/NY-ESO-1119-143 multimers on a DR1/NY-ESO-1119-143 specific CD4+ T cell line (MFI  
284 versus 52.1)  (3.19E).  It should be noted that higher non-specific staining was observed 
with SA-PE NTA4-based multimers than with the BSP multimers in the experiment shown in 
Fig. 3.19C. This may be explained, at least in part, by the fact that the PBMC of this 
particular donor had significant frequency of DR4/TT947-960-specific CD4+ T cells. 
Table 3.4 Bmax and KD values from Fig. 3.18 
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Figure 3.19 Comparative staining of NTAmer and BSP multimer. A, Binding isotherms were assessed at 37 
o
C on HA306-318-stimulated PBMC from a DR4
+
 healthy donor with conventional SA-PE DR4/His-HA306-318 
multimers (squares) and SA-PE NTA4 DR42xHis/DTB-HA306-318 (circles). B, Intracellular IFNγ staining of 
of DR4/HA306-318-peptide stimulated PBMC. C, Staining of PBMC stimulated previously with 2 μM of 
HA306-318 or TT947-960 peptide with conventional SA-PE DR4/His-HA306-318 multimers (multimer) and SA-
PE NTA4 DR42xHis/DTB-HA306-318  (SA-PE NTA4) at 18.5 nM (10 μg/ml) for 1 hour at 37 
o
C or room 
temperature (RT). D, Staining of PBMC stimulated with 2 µM HA306-318 or TT947-960 peptide with 
conventional SA-PE DP4/TT947-960 multimers (multimer) and SA-PE NTA4 DP42xHis/DTB-TT947-960  (SA-PE 
NTA4) at 18.5 nM (10 μg/ml) for 1 hour at 37
o
C. E, Staining of a DR1/NY-ESO-1119-143 cell line with 
conventional SA-PE DR1/His-NY-ESO-1119-143 multimers (multimer) and SA-PE NTA4 DR12xHis/DTB-NY-
ESO-1119-143 (SA-PE NTA4) at 18.5 nM (10 μg/ml) for 1 hour. F, PBMC stimulated with 2 μM HA306-318 
peptide (from C) were stained with 18.5 nM (10 μg/ml) conventional SA-PE DR4/His-HA306-318 multimer 
(triangles) or SA-PE NTA4 DR42xHis/HA306-318 multimer (squares), washed and analyzed by flow 
cytometry. The initial frequency of tetramer+ cells was normalized to 100%. Upon the addition of 100 
mM imidazole, the frequency of tetramer+ events was measured at 1, 3, 5 and 10 minutes and converted 
to percentages of initial frequencies. As a control, cells were stained with SA-PE NTA4 DR42xHis/HA306-318 
multimer and left untreated (circles). Mean values and SD were calculated from two experiments. 
A key feature of the NTA-based multimers is their reversibility, i.e. they quickly disintegrate 
upon addition of 100 mM imidazole in the cold (4 
o
C), which allows sorting of “untouched” 
T cells. To confirm staining reversibility with SA-PE NTA4 DR42xHis/DTB-HA306-318 
multimers, we subjected cold-stained peptide-stimulated PBMC to imidazole treatment and 
assessed the count of antigen-specific cells over time (Fig. 3.19F). After one minute of 
incubation, >90% of NTA-mer stained cells disappeared and complete loss of specific 
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staining was reached after 5 minutes. In the absence of imidazole, staining remained stable. 
Conventional multimers were insensitive to the presence of imidazole, as expected.  
3.1.5 Improving peptide loading of MHC class II molecules via conditional peptide 
ligands   
 
As described above (section 3.1.2) loading of “empty” MHC class II molecules with some 
peptides, namely viral epitopes,  is quite efficient (~80%), whereas for others, many of which 
derived from tumor-associated antigens, is inefficient (~20%). Because MHC proteins are 
precious, we explored whether the loading efficiency of the latter peptides can be 
significantly increased by means of conditional peptide ligands. The idea was to design a 
photocleavable peptide that can be efficiently loaded onto given MHC class II molecules and 
subsequently be exchanged with a peptide of interest by means of photocleavage of the 
conditional peptide. 
3.1.5.1 Design of conditional photocleavable peptide ligands 
 
The crystal structure of DR4 with the HA306-318 peptide bound to the HA1.7 TCR (Hennecke 
and Wiley, 2002) was used to design suitable photocleavable peptide ligands. HA306-318 is a 
peptide derived from the influenza A virus hemagglutinin protein with a low nanomolar 
affinity for many HLA-DR proteins (e.g. DR1, DR4, DR7, DR52b and many others (Posch et 
al., 1996)) ensuring a broad applicability of an optimal photocleavable ligand, unlike the 
photosensitive MBP-P4* derivative of MBP85-99 peptide which is specific only for DR2 
(Grotenbreg et al., 2007). Peptides bound to MHC class II proteins assume a poly-proline II 
helix-like, extended conformation and form a network of hydrogen bonds with the MHC 
protein backbone. In addition, several side chains act as “anchors” occupying deep pockets, 
namely P1, P4, P6 and P9. 
In the DR4\HA306-318 complex the Tyr308 side chain occupies the principal, deep 
hydrophobic pocket P1, and those of Gln311, Thr313 and Leu316 the pockets P4, P6 and P9 
respectively. Residues Lys307, Val309, Lys310, Asn312, Leu 314 and Lys315 are oriented 
towards the TCR (Fig. 3.20A). 
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Figure 3.20 Design of photocleavable peptide ligands. A, Structure of the HA306-318 peptide from the 
DR4/HA306-318:HA1.7 TCR crystal structure (PDB file ID code 1J8H) with TCR and MHC-facing side-
chains indicated by arrows. Carbon atoms are yellow, nitrogen atoms blue and oxygen atoms red. B, 
Peptide variants generated from the HA306-318 peptide where a photolabile β-(2-nitro)phenylglycine 
residue (represented by a red X) was introduced in positions 2,3,5 or 8. 
Based on this, we replaced amino acid residues at positions 2 (Val309), 3 (Lys310), 5 
(Asn312) or 8 (Leu 314) by β-(2-nitro)phenylglycine (βNPG), a UV-labile residue, 
generating a set of four photocleavable HA306-318-derived peptides referred to as HA*2, 
HA*3, HA*5 and HA*8 (Fig. 3.20B). We selected the residues whose side chains are 
solvent-exposed and whose replacement hence should not interfere with the binding of the 
peptide to the DR4 protein. Upon irradiation at 365 nm, βNPG undergoes a rearrangement 
resulting in the cleavage of the N-proximal peptide bond (Fig. 3.11B). The aim was to 
generate, upon photolysis, two peptide fragments that have dramatically reduced binding to 
DR4 and hence can be readily exchanged for a peptide of interest. Hexahistidine tags were 
added to the N-terminus of the photocleavable ligands through a SGSG spacer to allow 
isolation of homogeneous DR4/HA* complexes. 
3.1.5.2 Relative affinity of conditional peptide ligands for DR4 and efficiency of 
photocleavage 
 
To determine the best candidate for the photosensitive DR4 complexes, we performed a 
competition assay to determine the relative binding affinities of the conditional peptide 
ligands for the DR4 protein (Fig. 3.21A). Two peptides, HA*3 and HA*5, had equal (~6 μM) 
or better (~2 μM) affinity (IC50), respectively, for DR4 than the wild-type HA306-318 peptide. 
Another two candidate peptides (HA*2, HA*8) bound ~10-fold less avidly (as judged by 
their IC50) than the parental peptide and were excluded from further analyses. The HA*3 
ligand was also excluded from further analyses due to its inability to be exchanged after UV 
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irradiation (data not shown). To verify that UV light induced fragmentation of the HA*5 
peptide ligand occurred as expected (Fig. 3.21B), the HA*5 peptide (2676 Da) (Fig. 3.21C) 
was UV-irradiated for an extended period of time to ensure completion of UV-induced 
fragmentation (60 min); this indeed resulted in the appearance of the expected fragments 
(1870 Da and 806 Da) as detected by MALDI-TOF (Fig. 3.21D).  
 
Figure 3.21 Characterization of photocleavable peptide ligands. A, Four photosensitive HA306-318 peptide 
derivatives (HA*2, HA*3, HA*5, HA*8) were compared to the HA306-318 peptide for their ability to 
compete with biotin-HA306-318 for binding to DR4. Oxy272-284 is the negative control. Data are an average of 
three experiments. Error bars represent SD. B, Structure of the HA*5 peptide and the predicted 
photocleavage fragments resulting after UV irradiation. Inserted numbers indicate the predicted 
molecular weights. Molecular structure drawn by Julien Schmidt. C, Verification of molecular weight of 
HA*5 with MALDI MS. D, Detection of HA*5 photocleavage fragments after 1 hour of irradiation with 
UV at 365 nm by MALDI MS. The mass spectrometry data were collected by Julien Schmidt. The 
experiment was performed twice. A representative experiment is shown. 
3.1.5.3 Dissociation of photocleaved peptide depends on temperature and pH 
 
Loading of a peptide of interest onto the MHC molecule harboring a conditional peptide 
ligand is expected to depend on the dissociation of the peptide fragments upon its photolytic 
cleavage. UV-induced decay kinetics was first examined on free HA*5 peptide in PBS (Fig. 
3.22A), exhibiting a half-life (t1/2) of 2.05 min. The UV-induced decay was rapid, with the 
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peptide being >98% fragmented after 10 minutes of irradiation and not detectable after 30 
minutes.  
 
Figure 3.22 Photocleavage kinetics of HA*5 peptide. A, Photoclevage kinetics of the free HA*5 peptide 
measured by HPLC on C18 columns. Area under the peaks corresponding to the intact HA*5 peptide 
were integrated at designated time points, and normalized to those of non-irradiated HA*5 peptide. B, 
Photocleavage kinetics of DR4/HA*5 complexes, where the His-tag is detected by ELISA. Kinetics 
experiments were performed in the presence (right) or the absence (left) of 10 μM Flu-MP61-72 peptide at 
pH 6.0, 7.4, 9.0. The percentage of residual DR4-bound, heavier His-tag peptide fragment, is indicated in 
italic. Peptide half-lives (free and in complex with DR4), were calculated by fitting the data with an 
exponential decay curve and are indicated as t1/2. The experiments were performed twice. Representative 
experiments are shown. 
To assess the photocleavage kinetics of His-tagged HA*5 bound to an MHC protein, the 
DR4/HA*5 monomers were prepared, purified over Ni
2+
-NTA column to homogeneity and 
subjected to UV irradiation for indicated periods of time in the presence or absence of Flu-
MP61-72 peptide at three different pH. The remaining DR4-associated His-tag peptide 
fragment was detected by ELISA using serial dilutions (Fig. 3.22B). The half-lives of HA*5 
bound to DR4 (t1/2 from 0.87 to 3.01 min) were comparable to the half-life measured on the 
free peptide. The observed half-lives were pH dependent, namely were shorter at low than at 
high pH. Furthermore, in the presence of a strongly binding competitor, the half-lives were 
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shorter at pH 6 and pH 7.4, but not at pH 9, where the peptide exchange is scant. Although 
photoclevage of the free peptide was complete after 10 minutes, 24-53% of the His-tagged 
HA*5 peptide fragment remained DR4-associated after UV irradiation. Possible explanations 
for this include: i) the photocleavage of DR4-bound, as opposed to free, HA*5 peptide may 
not be complete; ii) the His-tagged N-terminal HA*5 peptide fragment, being rather large 
(1870 Da), may not completely dissociate at room temperature. Indeed, it is generally 
accepted that efficient peptide loading requires elevated temperatures and this may be due to 
more efficient dissociation of MHC-bound peptides. 
3.1.5.4 Increased peptide binding of UV-irradiated, photosensitive DR4/HA*5 peptide 
complexes 
 
Recombinant MHC class II proteins without covalently bound peptide cargo expressed by 
Drosophila cells are capable of binding antigenic peptides. However, as described above (see 
section 3.1.2), direct loading of such “empty” MHC class II molecules with peptides of 
interest, namely peptides derived from tumor-associated or self-antigens, is often remarkably 
inefficient. This may be explained by that they have either bound unknown peptides or are 
conformationally heterogeneous, i.e. contain peptide-receptive and non-receptive conformers 
that can interconvert. To find out whether loading of such peptides can be improved by 
means of conditional peptide ligands, DR4/HA*5 complexes were incubated with DTB-NY-
ESO-1119-143 peptide and the desthiobiotin (DTB) bound to DR4 measured by ELISA (Fig. 
3.23). After UV-irradiation of DR4/HA*5 complexes extensive DTB-NY-ESO-1119-143 
peptide binding was observed, whereas barely detectable binding was detected in the absence 
of UV-irradiation (Fig. 3.23). By comparison, peptide binding on “empty” DR4 molecules 
was slower and less efficient, with no differences between UV-irradiated and non-irradiated 
molecules.  
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Figure 3.23 Binding kinetics of the DTB-NY-ESO-1119-143  peptide onto UV-irradiated DR4/HA*5 complexes. 
Kinetics of DTB-NY-ESO-1119-143 peptide binding on DR4/HA*5 complexes (circles) or “empty” DR4 
molecules (squares),  UV-irradiated (red) or not (blue) for 10 minutes on ice and subsequently incubated 
1, 6, 12 and 24 hours at 37 
o
C in the presence of 10 μM DTB-NY-ESO-1119-143 peptide. The percentages of 
DTB-containing DR4 complexes were measured by ELISA specific for DTB. Data were normalized to the 
signal from DR4/DTB-NY-ESO-1119-143 complexes after 24 hours taken as 100%. A representative 
experiment out of three is shown. Error bars represent SEM from triplicates.  
3.1.5.5 Detection of antigen-specific T cells with peptide exchange multimers 
 
To optimize time and temperature parameters for peptide exchange, affinity-purified DR4 
HA*5 complexes were UV-irradiated or not and incubated with 10 μM Flu-MP61-72 peptide 
for up to 24 hours. After incubations of the samples they were diluted with FACS buffer, 
multimers prepared with SA-PE, and the sample directly used to stain DR4/Flu-MP61-72-
specific cloned cells (Fig. 3.24). The optimal conditions for peptide exchange were clearly 
24h at 37 
o
C. To test whether DR4-peptide complexes created by peptide exchange via the 
UV-irradiated photolabile precursor can used to produce functional fluorescent multimers, as 
previously demonstrated on MHC class I HLA-A1, -A3, -A11 and -B7 alleles (Bakker et al., 
2008), biotinylated DR4/HA*5 complexes were irradiated and exchanged with Flu-MP61-72, 
HA306-318 or NY-ESO-1119-143 peptides, multimerized with SA-PE and used to stain specific 
CD4+ T cells (Fig. 3.24 A-C).  
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Figure 3.24 Optimization of peptide exchange conditions of DR4/HA*5 complexes by multimer staining. A, 1 
μg biotinylated DR4/HA*5 complexes in 50 μl at pH 6.0 were irradiated (+UV) or not (-UV) for 10 min at 
365 nm on ice and incubated for 1, 6 or 24 hours at 4 
o
C, RT or 37 
oC with 10 μM Flu-MP61-72 peptide at 
pH 6.0, diluted with 50 mM Tris pH 9.0 and multimerized with SA-PE. A DR4/Flu-MP61-72-specific clone 
was stained with the resulting multimers for 1 hour at 37 
o
C and analyzed by flow cytometry. Inserted 
numbers indicate mean fluorescence intensities of cell-associated multimer. Black histograms refer to the 
DR4/CLIP multimer staining. The experiment was performed twice. A representative experiment is 
shown. 
Multimers prepared with affinity-purified DR4 complexes via N-terminal peptide His-tags 
were used for comparison. Peptide-exchanged DR4 multimers were less efficient in staining 
specific cells than multimers made from affinity-purified DR4 complexes used at the same 
concentration. Peptide-exchanged multimers prepared with peptides at 0.1, 1 and 10 μM had 
nearly identical staining patterns when applied at the same concentration, while more 
efficient staining was obtained when the exchange peptide at 100 μM was used (Fig. 3.25). 
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Figure 3.25 Staining of antigen-specific CD4+ T cell clones with peptide-exchanged multimers. A-C, 3 μg/ml 
of SA-PE multimers prepared with photosensitive biotinylated DR4/HA*5 complexes and loaded with 
different concentrations of Flu-MP61-72 (left), HA306-318 (center), or NY-ESO-1119-143 (right) peptides (from 
0.1 µM in dark green to 100 µM in yellow). Non-specific background staining was assessed by using 3 
μg/ml DR4/HA*5 multimers (black histograms). As positive controls immunopure multimers were used 
(red histograms). A representative experiment out of two is shown.  
Taken collectively these results indicate that the use of conditional peptide ligands is a viable 
and attractive means to substantially increase loading of peptides to MHC class II molecules, 
especially of peptides that inefficiently bind to empty molecules. We argue that combination 
of this strategy with the use of conditional N-terminal DTB peptide tags and affinity 
purification of bona fide cognate MHC class II-peptide monomers is a preferred method to 
produce high quality MHC class II-peptide multimers. 
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3.2 Discussion 
 
The present study unequivocally demonstrates that peptide loading of “empty” recombinant 
HLA class II proteins is erratic and for some peptides (e.g. NY-ESO-1119-143) remarkably 
inefficient and that this can dramatically impair staining performance of fluorescent 
multimers prepared with such monomers (Fig. 3.9). Factors that contribute to incomplete and 
erratic peptide loading of “empty” HLA class II molecules include: 1) MHC class II 
molecules are typically purified by immunoaffinity chromatography, which require extreme 
pH for elution (pH=11.5 or pH 3.2, depending on the antibody). MHC class II proteins, 
especially “empty” ones, are prone to rapidly denature under such conditions and thereby lose 
their ability to bind peptide. 2) The ability of antigenic peptides to be loaded onto “empty” 
MHC molecules can vary considerably from peptide to peptide and may not correlate with 
the binding affinity of the peptide (Fig. 3.5). 
In order to produce homogenous MHC class II-peptide complexes, small tags, such as 
dinitrophenyl (DNP), His-tag or biotin were added onto the peptide to allow affinity 
purification of correctly peptide-loaded complexes (Day et al., 2003; Demotz et al., 1991; 
Nag et al., 1994). However, none of these techniques gained broader acceptance for the 
preparation of fluorescent MHC-peptide multimers, partly because some tags (e.g. DNP) 
tended to worsen peptide solubility and caused concerns for MHC and/or TCR binding.          
Based on these findings and in order to produce high quality MHC class II-peptide staining 
reagents we examined different peptide tags for their suitability to isolate molecularly 
defined, also referred to as “immunopure”, MHC class II-peptide monomers. From those 
published previously, only the His-tag turned out to be practically useful. Using a His-tag 
added on the peptide’s N- or C-termini, homogeneous complexes could be purified (referred 
to as “immunopure”) and staining of specific cells with resulting multimers was improved, 
sometimes dramatically, as demonstrated in the case of DR4 or DR52b/His-NY-ESO-1119-143 
(Fig. 3.9). By analyzing binding of mixed multimers (Fig 3.6) and multimer binding 
isotherms (Fig 3.12) on a panel of DR4/HA306-318-specific clones, we demonstrated MHC 
class II-peptide complex heterogeneity, due to incomplete peptide loading of MHC 
molecules, precluded reliable detection of low-avidity clonotypes, which can be very frequent 
in CD4+ T-cell responses (Gebe et al., 2003; Sabatino et al., 2011).  
We successfully applied this strategy to different HLA class II alleles (DR1, DR4, DR52b 
and DP4) and peptides, demonstrating the general applicability of this strategy (Fig. 3.9) and 
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unpublished data (Ayyoub et al., 2010a; Ayyoub et al., 2010b). As shown for DR52b/His-
NY-ESO119-143, the use of immunopure multimer could dramatically improve staining of NY-
ESO-1-specific CD4+ T cells in PBMC from melanoma patients as compared to conventional 
multimers (Fig. 3.9, 3.10) (Ayyoub et al., 2010a). In particular, it made possible for the first 
time a direct analysis of ex vivo analysis of such cells.  
Because it has been shown that peptide residues flanking the core of CD4+ T cell epitopes 
could influence TCR recognition (Carson et al., 1997), as well as peptide binding to MHC 
class II molecules (Adams and Humphreys, 1995; Rötzschke et al., 1999), a caveat of this 
strategy is that the added peptide tag may bias multimer staining. To circumvent this, we 
linked the His-tag to the peptide via a linker containing photosensitive β-(2-
nitro)phenylglycine to allow its removal by irradiation at 365 nm (Fig. 3.11). This UV 
irradiation is safe for MHC class II peptide complexes, which do not absorb light at this 
wavelength, as demonstrated by multimer binding experiments (Fig. 3.12). 
It is noteworthy that we unsuccessfully tried to apply the same strategy to murine MHC class 
II molecules, namely I-A
b
. Unlike HLA class II molecules, especially HLA-DR, I-A
b
 was 
found not to be stable as “empty” molecule. In fact, to our knowledge, not a single murine 
MHC class II peptide complex has ever been made via peptide loading of “empty” soluble 
recombinant H-2 molecules. The only strategy that allows preparation of H-2 class II 
tetramers consist in tethering the peptide of interest on the N-terminus of the MHC class II β- 
chain via a long and flexible linker (Fremont et al., 1996a). It should be cautioned, however, 
that although this way the peptide is part of the molecule, this is no guarantee that it is 
properly nested in the MHC peptide binding groove (Landais et al., 2009). Therefore, this 
strategy has the same problem of not knowing the extent of nominal peptide loading, as has 
the conventional peptide loading of empty HLA class II molecules. 
We successfully adapted the NTAmer multimer format (Figs. 3.16, 3.17) (Schmidt et al., 
2011) for MHC class II-peptide complexes and thus created reversible MHC class II-peptide 
multimers, providing equal or better staining than the conventional or “immunopure” SA-PE 
multimers (Figs. 3.18, 3.19). The use of a tandem His-tag to bind MHC class II-peptide 
monomers to the SA-PE NTA4 precluded the use of the His-tag for MHC-peptide isolation. 
We therefore tested various N-terminal polyanion sequences (Fig. 3.14 and Table 3.3) and 
desthiobiotin (Fig. 3.15), as alternative purification tags; both of which have been used 
successfully to isolate recombinant proteins (Stubenrauch et al., 2000; Suominen et al., 1992; 
Wu and Wong, 2004). The polyanionic tags (E8 and E8) were able to well separate MHC-
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peptide complexes of interest, but required elution conditions which proved to be deleterious 
for their integrity. In addition, the synthesis of peptides with polyanionic tags was often 
difficult, costly and with poor yields. On the other hand, we demonstrated that the 
desthiobiotin tag was best suited because of mild elution conditions (pH 7.4) which preserved 
the integrity of the MHC-peptide complexes; in addition the synthesis of DTB-tagged 
peptides was facile. We found the MHC class II NTAmers to be stable at a wide range of 
temperatures, unlike reversible multimer formats developed for the MHC class I-peptides 
which can be used only at 4 
o
C (Guillaume et al., 2006; Knabel et al., 2002). We and others 
have confirmed that optimal MHC class II-peptide multimer staining requires plasma 
membrane fluidity, active cellular processes and desialylation (Figs. 3.2, 3.3, 3.4) (Cameron 
et al., 2001; Cecconi et al., 2008; Novak et al., 2001; Reddy et al., 2003). It is interesting to 
note that human DR4/HA306-318-specific cells are able to separate Cy5-labeled HA306-318 from 
internalized DR4/Cy5-HA306-318 complexes (Fig. 3.3). This indicated that these cells could 
potentially cross-present the internalized peptide and induce adverse T cell-T cell 
interactions. NTAmers could therefore prove especially useful for isolation of untouched 
antigen-specific CD4+ T cells for basic research and clinical applications. 
While the use of conditional peptide tags allows the preparation of “immunopure”, bona fide 
HLA class II-peptide complexes, depending on the allele and peptide can be low (≤20%) due 
to inefficient peptide loading. We therefore investigated whether peptide loading can be 
substantially increased by means of conditional peptide ligands. For HLA class I molecules, 
UV-mediated ligand exchange technology is well established (Bakker et al., 2008; Toebes et 
al., 2006) and allows the generation of a vast diversity of MHC-peptide multimers with 
minimal effort. We reasoned that this strategy should also be applicable to HLA class II 
peptide complexes and should allow substantial increase of peptide loading efficiency of 
some peptides (e.g. NY-ESO-1119-143) when using a strongly loading conditional peptide (e.g. 
a HA306-318 peptide derivative HA*5 (Figs. 3.20, 3.21)). Suitable conditional, i.e. UV-
photocleavable ligands should fulfill the following criteria: i) they should bind to given HLA 
class II molecules with high efficiency and should exhibit broad binding specificity, i.e. 
should bind to multiple alleles, e.g. like the HA306-318 peptide that very efficiently binds to 
nearly all HLA-DR molecules; ii) upon UV irradiation they should disintegrate, i.e. photolyse 
rapidly;  iii) photolysis fragments should dissociate rapidly to generate intermediate “empty” 
HLA class II molecules that avidly binding peptides. As a proof of principle a structure-based 
approach was used to identify a suitable photocleavable derivative of the HA306-318 peptide, 
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similar as has been described for DR2/MBP85-99 (Grotenbreg et al., 2007). Out of four 
candidate peptide variants examined, only one satisfied all three criteria (Figs 3.27, 3.28, 
3.29). However, the third criterion was satisfied only partially, because 24-54% of the peptide 
remained bound to the DR4 protein, even though the photolysis was apparently complete. 
Systematic evaluation of peptide loading conditions indicated as optimal ones incubated for 
24 hours at 37 
o
C and pH 6.0, which facilitate peptide exchange due to the “open” 
conformation of MHC class II molecules (Boniface et al., 1996; Runnels et al., 1996; Sette et 
al., 1992). DR4/HA*5 complexes allowed for substantially improved loading of problematic 
peptides, as demonstrated for DTB-NY-ESO-1119-143 (Fig. 3.29). For the HA306-318, Flu-MP61-
72 and NY-ESO-1119-143 peptides it was possible to obtain peptide-exchanged multimers that 
stained specific cells, and the quality of staining depended on the concentration of the peptide 
used for exchange. 
3.3 Conclusion and perspectives 
 
MHC class II-peptide multimers are important tools for detection, enumeration and isolation 
of antigen-specific CD4+ T-cells. Their erratic performance prevented widespread use and 
consequently they had limited impact on the study of CD4+ T cell responses. We found that a 
major obstacle for this was in the quality of recombinant MHC class II-peptide complexes, 
frequently prepared by peptide loading. We observed that the affinity of the peptide for the 
MHC class II molecule is not necessarily related to the extent of peptide loading. By adding a 
His-tag or desthiobiotin to the N-terminus of the MHC class II-binding peptides and 
subsequently isolating “immunopure” MHC class II-peptide monomers by affinity 
chromatography we could significantly, sometimes dramatically, improve staining of antigen-
specific CD4+ T cells. Inserting a photolabile β-(2-nitro)phenylglycine residue between the 
tag and the MHC-binding peptide, allowed the removal of the tag from the “immunopure” 
MHC class II-peptide complex, thereby eliminating potential concerns for interference with 
TCR binding. We also successfully adapted the NTAmer multimer format, originally 
developed for MHC class I-peptide multimers for MHC class II-peptide complexes. Finally, 
by replacing the Asn312 in the HA306-318 peptide from influenza A hemagglutinin we 
generated a broadly applicable photocleavable peptide, HA*5, and showed that DR4/HA*5 
complexes exhibit improved, UV-dependent loading, opening new perspectives for the 
future. Currently developed for the fluorescence-based flow cytometry, NTAmers can be 
easily modified to suit the needs of the emerging, more powerful, time-of-flight cytometry 
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(Newell et al., 2012). With the ever-greater realization of the role that CD4+ T cells play in 
cancer and antiviral immunity, and in particular cytotoxic CD4+ T cells (Quezada et al., 
2010; Xie et al., 2010), the reversible “immunopure” NTAmers should be most useful tools 
for future CD4+ T cell sorting and analysis. 
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4. Essential role of the CD8α transmembrane domain for efficient CD8 
coreceptor function 
4.1 Results 
4.1.1 Role of transmembrane domains for CD8 coreceptor function 
 
Transmembrane domains (TMDs) of membrane proteins play important roles besides 
providing anchors for the lipid bilayer of the plasma membrane. Assembly or oligomerization 
of receptors is at least in part driven by TMD-TMD interactions and is important for their 
signaling function; inhibition of such interactions can lead to different pathological disorders 
(Fink et al., 2012). Assembly of MHC class II proteins (Cosson and Bonifacino, 1992), the 
TCR:CD3 complex (Call and Wucherpfennig, 2005) and CD8 (Hennecke and Cosson, 1993) 
are all driven by TMD-TMD interactions. Such interactions are mediated mainly by Van der 
Waals contacts, but hydrogen bonds bridging polar residues and aromatic residues capable of 
π-π stacking provide important contributions. Analyses of TMD sequences revealed the 
existence of numerous motifs mediating such interactions: i) the most common, GxxxG 
motif; ii) leucine heptad motif; iii) the Polar-xx-Polar motif, where polar amino acids can be 
Ser, Thr, Glu, Gln, Asp and Asn; iv) Aromatic-xx-Aromatic motif; v) a Gly zipper 
(GxxxGxxxG) motif; vi) Leu zipper and vii) Ser/Thr rich sequences. A special motif present 
in immune receptors encompassing the combination of polar and aromatic residues, called 
CART, has been postulated to play a role in T cell signaling (Campbell et al., 1994). It has 
been previously shown that for homodimerization of murine CD8 , the TMD of CD8  plays 
an important role together with the extracellular part of CD8  (Hennecke and Cosson, 1993). 
Conversely, formation of the CD8  heterodimer is entirely driven by interactions of the 
chain’s extracellular domains, which is also true for the human CD8  (Pang et al., 2007). 
The TMD of CD8  apparently is not involved in CD8β homo- or heterodimerization. Thus, 
in a CD8  heterodimer, the CD8  TMD is free to interact with CD8  TMD of another 
CD8  and to thus form CD8  dimers. To investigate the functional significance of CD8  
TMD, we generated a mutant, CD8 Tac, in which the CD8  TMD was replaced with the one 
from the partially monomerizing (44.5±14% monomer) interleukin-2 receptor  chain (Tac) 
(Hennecke and Cosson, 1993). We investigated molecular and functional implications using 
T1 T cell hybridomas. The T1 TCR has been cloned from CD8+ CTLs derived from mice 
immunized with the PbCS(ABA) peptide (SYIPSAE(ABA)I). In this system, UV-irradiation 
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at 312 nm the ABA group (4-azido-benzoic acid) to cross-link to bound TCR (photoaffinity 
labeling), which allows binding studies with monomers to be performed on living cells. The 
T1 TCR is CD8-independent for the recognition of the PbCS(ABA) peptide, but not for the 
its weak agonist P255A (Luescher et al., 1995a; Luescher et al., 1992; Luescher et al., 1991). 
4.1.2 Cell surface expression of CD8α and CD8αTac on T1 T cell hybridomas 
 
Alignment of the CD8α TMDs for a variety of mammalian species (Fig. 4.1A) revealed 
highly conserved sequence motifs. The alignment of CD8β TMDs, conserved to a modest 
degree, is shown for comparison (Fig. 4.1B). Sequence conservation is visualized by the 
sequence logo of each alignment (Fig. 4.1C). 
                                  
Figure 4.1 Sequence alignments of transmembrane domains of CD8α and CD8β. Transmembrane domains 
of CD8α (A), and CD8β (B) from selected mammalian species. Completely conserved residues are shown 
in orange, while differing residues are shown in blue. C, The consensus sequence is shown in logo cartoon 
format with black capital letters indicating absolutely conserved residues, and smaller sized letters in 
black, green and blue indicating a lesser degree of sequence conservation. 
The expression of wild type CD8α and mutant CD8αTac was examined on the T1.4 (T1 TCR+ 
CD8α- CD8β-) T cell hybridoma transduced with lentiviral constructs for CD8α and 
CD8αTac, respectively and FACS sorted. The CD8α and CD8αTac were expressed at 
comparable, high levels (Fig. 4.2A). The expression of CD8α insignificantly affected TCR 
expression, while the cells remained negative for CD8β. Following introduction of a lentiviral 
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construct for CD8β-YFP into cells expressing CD8α or CD8αTac and subsequent FACS 
sorting, cells expressing similar levels of YFP were obtained (Fig. 4.2B). Thus, a set of four 
cell types was generated to investigate the role of TMD replacement. All cells derived from 
T1.4 maintained similar levels of the T1 TCR, CD8α and CD8β (Table 4.1). 
 
Figure 4.2 Characterization of T1 hybridomas expressing CD8α or CD8αTac. A, Cells were stained with PE-
labeled anti-CD8α, anti-CD8β, or Alexa 647-labeled anti-Vβ8.2 antibodies and fluorescence levels 
measured by flow cytometry. T1.4 cells express the T1 TCR but no CD8α or CD8β chains. Cells 
expressing the CD8α or CD8αTac, but no CD8β, are referred to as T1.wt and T1.Tac, respectively. 
Alternatively, if CD8β is expressed in the form of the CD8β-eYFP fusion protein, cells are referred to as 
T1.wt.bYFP and T1.Tac.bYFP. A representative experiment is shown out of at least two independent 
ones. Errors in Table 4.1 represent SD. B, Levels of eYFP measured by flow cytometry are shown in 
histograms. A representative experiment is shown out of at least two independent ones. 
 
Table 4.1 Surface expression of CD8α, CD8β and TCR on T1 hybridomas.  
                  
4.1.3 K
d
/PbCS(ABA) multimer binding 
 
To examine whether replacement of the CD8α TMD affected ligand binding, we measured 
multimer binding at room temperature on CD8β+ cells expressing CD8α (T1.wt.bYFP) or 
CD8αTac (T1.Tac.bYFP). To this end, the cells were incubated with PE-labeled K
d
/peptide 
multimers. Two different peptide ligands were used; the high affinity PbCS(ABA) ligand and 
its variant, P255A, which has a lower affinity for the T1 TCR (Luescher et al., 1995a). To 
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gauge the contribution of CD8 to multimer binding, we used complexes of CD8-binding 
deficient K
d
 Q226A/D227K (K
d
226/227) mutant multimers containing PbCS(ABA) (Fig. 4.3A, 
D) or blocking anti-CD8  mAb H35 (Fig. 4.3B,C,E,F). Dissociation constants (KD) were 
determined by nonlinear regression analysis of the MFI values of bound multimers (Table 
4.2). CD8αTacβ hybridomas bound K
d
/PbCS(ABA) multimers with modestly weaker avidity 
as compared to CD8αβ hybridomas (KD=3.0±0.3 versus 2.5±0.3). Moreover, the difference in 
binding avidity (ΔKD) between the K
d
 wild-type PbCS(ABA) and K
d
226/227/PbCS(ABA) 
multimers was greater for CD8αβ hybridomas (3.8-fold) than for CD8αTac β hybridomas (1.5-
fold), indicating a lesser contribution of the CD8 coreceptor to multimer binding. The 
difference in maximal binding of K
d
/PbCS(ABA) P255A multimers was dramatic, as 
CD8αTacβ hybridomas exhibited only ~8% of maximal binding of K
d
/PbCS(ABA) multimers 
(Fig. 4.3F) while the CD8αβ hybridomas reached ~50% of maximal binding of 
K
d
/PbCS(ABA) multimers (Fig. 4.3C). The binding experiments were repeated in the 
presence of an anti-CD8β blocking antibody (H35). The H35 mAb strongly reduced maximal 
binding (Bmax) of K
d
/PbCS(ABA) multimers, which was essentially halved in CD8αβ (53%) 
and CD8αTacβ hybridomas (46%) with little changes of KD values (3.1±0.2 and 4.0±0.2 for 
CD8αβ and CD8αTacβ hybridomas, respectively) (Fig. 4.3B,E and Table 4.2). For 
K
d
/PbCS(ABA) P255A multimers, the binding difference between the two hybridomas was 
dramatic (Figs. 4.3C,F) and completely ablated in the presence of H35 mAb, indicating that 
the binding of K
d
/PbCS(ABA) P255A multimers was entirely CD8β-dependent. Collectively 
our data indicated that replacement of the TMD of the CD8  with the one of Tac, reduced the 
CD8 β-mediated increase in multimer binding, in particular of the weak agonist 
K
d
/PbCS(ABA) P255A multimers; in other words this mutation affected the ability of CD8 to 
strengthten the MHC-peptide binding, which is an important aspect of CD8 coreceptor 
function.  
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Figure 4.3 K
d
/PbCS(ABA) multimer binding on T cell hybridomas. Room temperature binding isotherms of 
PE-labeled multimeric K
d
/PbCS(ABA), K
d
226/227/PbCS(ABA) and K
d
/PbCS(ABA) P255A ligands labeled 
WT (red), 226/227 (blue) and 3A (green) on T1.wt.bYFP (A-C) and T1.Tac.bYFP (D-F). Binding data 
were normalized by taking Bmax of the K
d
/PbCS(ABA) multimer binding isotherm as 100%. Room 
temperature binding isotherms of K
d
/PbCS(ABA) (B and E) and K
d
/PbCS(ABA) P255A (C and F) in the 
presence (squares) or absence (circles) of anti-CD8β mAb H35 blocking antibody (20 μg/ml) on 
T1.wt.bYFP and T1.Tac.bYFP cells. Representative data from two experiments are shown. Error bars 
represent SEM from duplicates. 
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Table 4.2 KD and Bmax values from K
d
/PbCS(ABA) multimer binding. 
                      
4.1.4 Calcium flux and IL-2 production is impaired on hybridomas expressing CD8αTac 
 
To examine the effect of CD8α TMD replacement on functional responses, we measured 
intracellular calcium flux upon incubation of the hybridomas with PbCS(ABA)-pulsed P815 
cells. CD8β+ T1 hybridomas expressing wild type CD8  (T1.wt.bYFP) exhibited high 
intracellular Ca
2+
 flux (67% positive cells), whereas CD8β+ hybridoma expressing the 
CD8αTac mutant (T1.Tac.bYFP) displayed a significantly reduced response (41% positive 
cells) and T1.4 (CD8 - CD8β-) hybridoma even less (11% positive cells) (Fig. 4.4A). We 
next assessed the IL-2 responses of the CD8β+ hybridomas upon incubation with P815 cells 
pulsed with graded concentrations of the PbCS(ABA) peptide. As shown in Fig. 4.4B and 
Table 4.3, the CD8αTacβ hybridoma were less responsive than the CD8αβ hybridoma 
(EC50=764.8 pM versus 25.9 pM, respectively). The presence of the anti-CD8  mAb H35 
significantly impaired sensitivity of IL-2 production by CD8αβ hybridomas (EC50=465.7 pM, 
ΔEC50~18-fold), and to a lesser degree in CD8αTacβ hybridomas (EC50=4545 pM, ΔEC50~6-
fold). We previously observed that CD8 was essential for K
d
/PbCS(ABA) P255A multimer 
binding, and therefore we expected IL-2 production to follow suit. This proved to be indeed 
the case. CD8αβ hybridomas produced IL-2 upon incubation with PbCS(ABA) P255A 
peptide pulsed APCs, however considerably less efficiently as compared to PbCS(ABA) 
pulsed APC (EC50=1160 pM) (Fig. 4.4B). By contrast, CD8αTacβ hybridomas failed to 
produce any detectable IL-2 in response to any concentration of the PbCS(ABA) P255A 
peptide tested, regardless of the presence or absence of the anti-CD8  mAb H35.  
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Figure 4.4 Intracellular calcium flux and IL-2 production of CD8 Tacβ hybridomas are impaired. A, 
Calcium flux of Indo-1 loaded T1.4, T1.wt.bYFP and T1.Tac.bYFP cells when stimulated with P815 cells 
pulsed (WT) or not (no peptide) with 1 μM PbCS(ABA) peptide. B, IL-2 production of T1.wt.bYFP and 
T1.Tac.bYFP cells with P815 cells pulsed with graded concentrations of PbCS(ABA) (WT) or its P255A 
variant (3A) peptide in the presence (squares) or absence (circles) of anti-CD8β mAb H35 blocking 
antibody was measured by ELISA. Representative experiments from at least two independent 
experiments are shown. Values are normalized to maximal IL-2 secretion of T1.wt.bYFP cells taken as 
100%.  
Table 4.3 EC50 values of IL-2 secretion 
                      
4.1.5 Assessment of the proximity of CD8 and TCR:CD3 by FRET 
 
We wished to assess the proximity of CD8 to TCR:CD3 by FRET on CDβ+ T1 hybridomas 
expressing CD8α or CD8αTac. First, the proximity was measured in the absence of MHC-
peptide (Fig. 4.5A) by co-staining CD8αβ and CD8αTacβ hybridomas with the PE-labeled 
anti-CD3ε mAb 17A2 or anti-TCR  mAb H57 and Cy5-labeled anti-CD8β mAb KT112. We 
observed more CD3ε-CD8β FRET (FRET units=3.7±0.1) and TCR-CD8β (FRET 
units=2.3±0.2) on CD8αβ hybridomas than on CD8αTacβ hybridomas (CD3ε-CD8β FRET 
units=2.0±0.1 and TCR-CD8β FRET units=1.1±0.1). Moreover, when PE-labeled 
K
d
/PbCS(ABA) multimers were used as FRET donors, much stronger FRET was observed 
between the multimer and CD8β than between the multimer and CD8α in both CD8αβ 
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hybridomas (multimer-CD8β FRET units=126.6±27.4 versus multimer-CD8  FRET 
units=50.2±11.8) and CD8αTacβ hybridoma (multimer-CD8β FRET units=65.7±25.2 versus 
multimer-CD8  FRET units=34.6±13.1) (Fig. 4.5B). Importantly, multimer-CD8β FRET 
observed on CD8 αTacβ hybridomas was significantly weaker than on the CD8αβ hybridomas, 
indicating that CD8 αTacβ associates with the TCR:CD3 less efficiently. 
       
Figure 4.5 CD8 Tacβ associates inefficiently with TCR:CD3. A, T1 hybridomas expressing CD8β-eYFP and 
CD8α or CD8αTac were stained in the cold with PE-labeled anti-CD3ε mAb 17A2 or anti-TCRβ mAb H57 
and Cy5-labeled anti-CD8β mAb KT112. B, Alternatively, staining was performed with PE-labeled 
K
d
/PbCS(ABA) multimers and Cy5-labeled anti-CD8β mAb KT112 or anti-CD8α mAb 53.6.72. C, T1 
hybridomas expressing wild-type CD8α or CD8αTac were stained with PE-labeled anti-CD90.1 mAb 
HIS51 and Cy5-labeled CD8α mAb 53.6.72. Cells were analyzed by FACS using excitation at 488 and 630 
nm. FRET units were calculated from the fluorescence emissions at 580 and 670 nm (see “Materials and 
methods”). For B and C, mean values and SD were calculated from three experiments, each performed in 
duplicate, while for A from two experiments.  
By virtue of palmitoylation at its tail cysteine residue (Cys198), CD8β confers lipid raft 
association to the CD8 β, thus strengthtening its association with p56Lck that also partitions 
to lipid rafts by virtue of its N-terminal palmitoyl and myristoyl modifications (Arcaro et al., 
2000). CD8αTac confers partial monomerization of CD8α normally present in CD8αα 
homodimers or CD8αβ heterodimers at the cell surface. To compare the extent of raft 
association of CD8αβ and CD8αTacβ, we measured FRET between Thy-1.1 (PE-labeled anti-
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Thy-1.1 (CD90.1) mAb HIS51), a constitutive raft marker and CD8α (Cy5-labeled anti-CD8α 
mAb 53.6.72). Indeed, the Thy-1.1-CD8α FRET was lower on CD8αTac hybridomas (FRET 
units=107.4±31.7) than on CD8  hybridomas (FRET units=60.2±19.5) (Fig. 4.5C).  
4.1.6 Multimer and CD8β co-localize on CD8αβ and CD8αTacβ hybridomas 
 
While co-localization does not necessarily imply interaction between two proteins, the 
reverse holds true, i.e. if there is no association, two proteins do not co-localize. Having 
measured more intense FRET between PE-labeled K
d
/PbCS(ABA) multimers and Cy5-
labeled anti-CD8β mAb KT112, we examined co-localization of PE and YFP fluorescence on 
the plasma membrane (Fig. 4.6). To this end, CD8αβ and CD8αTacβ hybridomas were stained 
with PE-labeled K
d
/PbCS(ABA) multimers in the cold and fixed. Membrane distribution of 
PE and YFP was imaged by fluorescence microscopy. Examination of fluorescence 
micrographs showed that multimers induced large patches on T1.wt.bYFP and T1.Tac.bYFP 
hybridomas in which CD8 -YFP and multimers co-localized to comparable degrees (Fig. 
4.6A). This was confirmed by co-localization metrics, indicating similar Pearson’s 
correlation coefficient (0.999 for T1.wt.bYFP and 0.987 for the T1.Tac.bYFP) between YFP 
and PE pixels and the cytofluorogram showed no difference in co-localization (Fig. 4.6B). 
The population of pixels parallel to the diagonal, but shifted towards higher YFP values came 
from multimer patches containing with more accumulated CD8β-YFP. 
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Figure 4.6 Similar co-localization of K
d
/PbCS(ABA) multimer and CD8β on CD8αβ and CD8αTacβ cells. A, 
T1.wt.bYFP and T1.Tac.bYFP hybridomas were stained with ~40 nM PE-labeled K
d
 PbCS(ABA) 
multimer at 4 
o
C, fixed and imaged by fluorescence microscopy where PE and YFP fluorescence were 
recorded in separate channels. B, Cytofluorograms of each image are labeled appropriately; images were 
processed so that only pixels representing cell-surface features were taken into account. Pearson’s 
correlation coefficients were 0.999 for the T1.wt.bYFP image and 0.987 for the T1.Tac.bYFP image. 
Cytofluorograms and Pearson’s correlation coefficients were calculated by the JACoP plugin of the 
ImageJ program. A representative experiment is shown out of the two. 
4.1.7 Expression of CD3ζ-CFP in hybridomas harboring CD8β-YFP and CD8α or 
CD8αTac 
 
Multimer binding, calcium flux and IL-2 production data indicated a functional impairment 
of hybridomas expressing CD8αTacβ compared to those expressing CD8 β. Because 
interaction of the CD8 coreceptor with TCR:CD3 is crucial for initiation of TCR signaling, 
we wished to assess this interaction in contact areas (immunological synapses) between the 
hybridoma cell and the peptide-pulsed APC. To this end, we transduced T1 TCR hybridomas 
expressing CD8β-YFP and CD8α or CD8αTac with the CD3ζ-eCFP fusion protein. The 
resulting T cell hybridomas were FACS-sorted and cloned. Clones were selected for 
comparable surface expression of the T1 TCR, CD8α, CD8β-YFP and CD3ζ-CFP (Fig. 
4.7A). We next analyzed these cells by flow cytometry for CD3ζ-CFP and CD8β-YFP 
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fluorescence and found that while the latter exhibited comparable expression, the former 
showed clearly higher expression on T1.Tac.bYFP.zCFP (Fig. 4.7B,C). This seems at 
variance with the TCR surface expression, this divergence is explained, at least in part by that  
CD3ζ-CFP transfectants express endogenous CD3ζ and that only a fraction of CD3ζ is 
associated with TCR (Yachi et al., 2005b). Moreover, examination by fluorescence 
microscopy of the hybridomas showed that most of the CD3ζ-CFP and CD8β-YFP 
fluorescence was membrane-associated on both cell types, but that on the T1.Tac.bYFP.zCFP 
cells there was also a significant fraction of intracellular, perinuclear fluorescence.  
 
Figure 4.7 Characterization of CD3ζ-CFP+ CD8β-YFP+ hybridomas. A, Surface expression of CD8α, CD8β 
and the T1 TCR on T1.wt.bYFP.zCFP and T1.Tac.bYFP.zCFP hybridomas by staining with PE-labeled 
anti-CD8α mAb 53.6.72, PE-labeled anti-CD8β H35 and Alexa 647 labeled anti-Vβ8.2. B, Levels of 
expression of CFP and YFP on T1.wt.bYFP.zCFP and T1.Tac.bYFP.zCFP hybridomas measured by flow 
cytometry. C, Fluorescence micrographs of CFP and YFP in T1.wt.bYFP.zCFP and T1.Tac.bYFP.zCFP 
hybridoma. Cells were fixed before imaging. YFP and CFP channels were recorded separately. 
Calculated MFI values are displayed in the associated histograms. Representative data of two or more 
experiments.  
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4.1.8 Antigen-dependent responses of hybridomas expressing CD8β-YFP, CD3ζ-CFP 
and CD8α or CD8αTac 
 
To assess functionality of a new pair of hybridoma cells and to verify whether the 
introduction of CD3ζ-CFP altered previous conclusions, we tested fluorescent CD3ζ-CFP+ 
T1 TCR hybridomas for their ability to form conjugates, internalize plasma membrane-bound 
TCRs and to produce IL-2 upon incubation with peptide-loaded APCs. As APCs, P815 cells 
were used. CD8αβ hybridomas (T1.wt.bYFP.zCFP) were able to form conjugates with P815 
cells pulsed with the wild-type (WT) peptide, PbCS(ABA), in a time-dependent manner, 
attaining a maximal frequency of 40%±11% after 10 minutes, followed by a gradual decrease 
after 20 minutes to 28%±7% at 60 minutes (Fig. 4.8A). With the weak agonist peptide, 
PbCS(ABA) P255A (3A), the maximal frequency of conjugates was significantly reduced 
(25%±2%) and was reached only after 20 minutes, thereafter rapidly falling to 11%±3% after 
60 minutes (Fig. 4.8A).  
        
Figure 4.8 Conjugate formation, but not TCR downregulation is impaired in T1.Tac.bYFP.zCFP 
hybridomas. A,C Time course of conjugate formation of T1.wt.bYFP.zCFP (A) or T1.Tac.bYFP.zCFP (C) 
with NHS-Cy5 surface labeled P815 cells pulsed with 1 µM of PbCS(ABA) (WT, circles), PbCS(ABA) 
P255A (3A, squares) or JAK1 (NULL, triangles). Data are an average of three independent experiments. 
Error bars represent SD. B,D TCR downregulation of T1.wt.bYFP.zCFP (B) or T1.Tac.bYFP.zCFP (D) 
with P815 cells pulsed with 1 µM of PbCS(ABA) (WT, circles), PbCS(ABA) P255A (3A, squares) or JAK1 
(NULL, triangles). Average of three independent experiments is shown. Error bars represent SD. 
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P815 pulsed with the irrelevant JAK1 peptide (NULL) also formed conjugates, albeit 
inefficiently, in a time dependent manner, peaking after 20 minutes (7%±4%) and slowly 
decreasing to 4%±1%. These conjugates reflected non-specific adhesion that is at least in part 
CD8-mediated. CD8αTacβ hybridomas (T1.Tac.bYFP.zCFP) attained the maximal frequency 
of conjugates with the PbCS(ABA)-pulsed P815 cells (WT) after 15 minutes, i.e. 5 minutes 
later than the cells with wild-type CD8 , and at lower frequency (26%±4%) than their wild-
type CD8α counterparts, which fell to 18%±3% after 60 minutes (Fig. 4.8C). The conjugate 
frequencies with P815 cells pulsed with the PbCS(ABA) P255A (3A) peptide were similar 
(7%±2% after 20 minutes) to P815 cells pulsed with JAK1 peptide (6%±2% after 20 minutes) 
and changed very little 30 minutes later (6%±2% for 3A and 6%±3% for JAK1). These 
findings are in accordance with the multimer binding, calcium flux and IL-2 data (Figs 4.3 
and 4.4). The high affinity ligand, PbCS(ABA) (WT), pulsed on P815 cells induced 
endocytosis of ~36%) and ~47% of cell surface TCR after 60 minutes of incubation on wild-
type CD8α and CD8 Tac cells, respectively (Fig. 4.8B, D). 
The low affinity PbCS(ABA) P255A and the non-cognate JAK1 peptide failed to induce any 
significant internalization of surface TCR on the hybridomas tested. For a late functional 
response, IL-2 secretion was examined. The strong peptide agonist, PbCS(ABA) (WT) 
induced IL-2 production from T1.wt.bYFP.zCFP hybridoma (EC50=39.5 pM), and with 
weaker sensitivity (EC50=5042 pM) and lower maximal levels (~80% of maximum observed 
in T1.wt.bYFP.zCFP hybridoma) from CD8αTacβ hybridoma (Fig. 4.9C and Table 4.4). In 
accordance with previous results, while hybridoma expressing CD8α produced IL-2 when 
stimulated with the weaker P255A ligand (EC50=2051 pM) at lower maximal levels (~75% of 
maximum of wild-type CD8α hybridoma with WT peptide), no detectable IL-2 was produced 
in hybridomas expressing CD8αTac.   
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Figure 4.9 IL-2 production is impaired in CD3ζ-CFP+ CD8 Tac hybridomas. Production of IL-2 from 
T1.wt.bYFP.zCFP (A,B) or T1.Tac.bYFP.zCFP (C,D) with P815 cells pulsed with graded amounts of 
PbCS(ABA) (WT – A,C) or PbCS(ABA) P255A (3A – B,D) in the presence (+H35) or absence (-H35) of 
the anti-CD8β blocking mAb clone H35. Maximal attained levels of IL-2 by T1.wt.bYFP.zCFP hybridoma 
in contact with PbCS(ABA)-peptide pulsed P815 cells Representative data are shown out of two 
independent experiments.  Error bars represent SEM from duplicates. 
Table 4.4 EC50 values of IL-2 secretion of CD3ζ-CFP+ T1 hybridomas 
                         
4.1.9 Antigen-induced CD8-CD3ζ interaction is reduced on CD8 Tacβ hybridoma  
 
We measured CD8-CD3ζ FRET in synapses/contact sites of T1 CD3ζ-CFP+ CD8β-YFP+ 
hybridomas expressing CD8α or CD8αTac with peptide-loaded P815 cells after 20 minutes of 
incubation at 37 
o
C (Fig. 4.10A). Two different peptide ligands were examined: the wild type 
PbCS(ABA) and PbCS(ABA) P255A. Hybridomas expressing CD8α and CD8αTac had 
increased CD8β-CD3ζ FRET to similar amounts (3.1%±0.9% and 2.9%±1.1%, respectively) 
in the contact site with P815 cells pulsed with the PbCS(ABA) peptide (Fig. 4.10B). 
Conversely, CD8β-CD3ζ FRET was lower on either hybridomas in contact with the 
PbCS(ABA) P255A-loaded P815 cells, with CD8αTac cells displaying less intense FRET 
(1.8%±0.3%) than their CD8  counterparts (2.6%±0.5%).  
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Figure 4.10 CD8αTacβ associates inefficiently with CD3ζ. A, FRET microscopy of a conjugate between a 
PbCS(ABA)-pulsed, NHS-Cy5 surface labeled P815 cell (red) and a T1.wt.bYFP.zCFP cell. The white 
arrows indicate contact sites/synapses. The image is shown in four channels – Cy5, YFP, CFP and FRET. 
Intensity of FRET is shown by a color gradient ranging from blue (lowest) to white (highest). B, 
Quantification of FRET from synapses of T1.wt.bYFP.zCFP or T1.Tac.bYFP.zCFP cells with NHS-Cy5 
surface labeled P815 cells pulsed with the PbCS(ABA) or PbCS(ABA) P255A peptide after 20 minutes of 
incubation. Error bars represent SD. Experiments were repeated twice. A representative experiment is 
shown. 
4.1.10 CD8 Tacβ associates with less p56
Lck
 and partitions less in rafts than the CD8 β 
 
Critical for CD8 coreceptor function is its ability to bring p56
Lck
, a Src tyrosine kinase, into 
close proximity of TCR-associated CD3 units, in particular the CD3ζ chains. The p56Lck 
phosphorylates ITAMs on the CD3, namely ζ chains and thus initiates the TCR signal 
transduction cascade. To find out whether in addition to impaired TCR-CD8 association there 
are other functional defects intrinsic to the CD8αTacβ, we compared the amount of p56
Lck
 
associated to the CD8β chain in hybridomas expressing CD8α or CD8αTac. Western blot 
analysis of immunoprecipitates with anti-CD8α or anti-CD8β (Fig. 4.11A) revealed markedly 
lower amounts of p56
Lck
 associated with CD8β in hybridomas expressing CD8αTac than in 
hybridomas expressing wild-type CD8α. Moreover, less CD8β was immunoprecipitated with 
anti-CD8α in hybridomas expressing CD8αTac than in those expressing wild-type CD8α. 
When p56
Lck
 was immunoprecipitated with anti-CD8β antibody, the same differences were 
observed. To examine whether weaker association of p56
Lck
 with CD8αTacβ is related to 
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differential partitioning of CD8αTacβ in lipid rafts (where p56
Lck
 is mainly located), we 
immunoprecipitated CD8β with anti-CD8α antibody from detergent soluble (M) and 
detergent insoluble fractions (DIM) of plasma membranes of cells expressing CD8  or 
CD8 Tac (Fig. 4.11B). We detected CD8β in immunoprecipitates from DIM from wild-type 
CD8  cells, but observed little or no CD8β in immunoprecipitates from DIM from T1 
hybridoma expressing CD8 Tac. 
                          
Figure 4.11 CD8αTacβ associates with less p56
Lck
 than CD8αβ because of weaker partitioning in lipid rafts. A, 
Western blots with anti-CD8β mAb KT112 and anti-p56Lck polyclonal antibody of reducing SDS-PAGE-
resolved immunoprecipitates with anti-CD8α mAb 53.6.72 or anti-CD8β H35 from T1 hybridoma. In all 
lanes of the Western blot for CD8β there is a non-specific band at 50 kDa. The specific band of the CD8β-
eYFP fusion protein can be seen on top of the non-specific band. B, Western blot with anti-CD8β mAb 
KT112 of reducing SDS-PAGE-resolved of detergent-soluble (M) and detergent insoluble (DIM) fractions 
of cellular extracts immunoprecipitated with anti-CD8α mAb 53.6.72. The arrows indicate specific bands.  
                                                   
Figure 4.12 The CD8αβ dimers are bona fide CD8 coreceptors. A, CD8αβ forms dimers-of-dimers, held 
together by CD8α TMD interactions. B, The CD8αTac mutant is greatly impaired in dimerization and such 
forms of CD8 associate weakly with lipid rafts.  
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4.2 Discussion 
 
The key finding of our study is that replacement of the strongly dimerizing CD8α TMD with 
the one of the IL-2 receptor α chain (Tac) resulted in substantial reduction of T1 hybridomas’ 
ability to form conjugates with APCs (Fig. 4.8), to flux intracellular Ca
2+ 
and to produce IL-2 
(Fig. 4.4 and 4.9) and to bind MHC-peptide multimers (Fig. 4.3). This replacement did not 
alter significantly the surface expression of CD8  homodimers or CD8 β heterodimers 
(Fig. 4.2), which rules out impaired subunit chain assembly and/or intercellular transport as 
explanations for the observed defects. 
There are two major aspects of CD8 coreceptor function: First, the association of CD8 with 
TCR:CD3. We and others have shown previously that binding of MHC-peptide complexes 
(monomers and tetramers) to CD8+ T cells is greatly strengthened by coordinate binding of 
CD8 to TCR-associated complexes (Cawthon and Alexander-Miller, 2002; Luescher et al., 
1995b; Renard et al., 1996). This binding avidity enhancement critically depends on 
association of CD8 with TCR:CD3 (Gallagher et al., 1989; Mallaun et al., 2008; Naeher et 
al., 2002; Takada and Engleman, 1987). Similar findings to ours were obtained on CD8+ T 
cells that i) lack the CD3  chain (i.e. from CD3  KO mice) (Dave et al., 1998; Delgado et al., 
2000); ii) express the αCPM variant of TCR ( IV/βIII) (Bäckström et al., 1996) or iii) 
express tailless CD8β (Arcaro et al., 2001; Irie et al., 1998; Itano et al., 1994). There is 
evidence that CD8β couples with the TCR:CD3 via CD3  (Doucey et al., 2003; Suzuki et al., 
1992). Indeed on CD8+ T cells expressing TCR containing the αCPM mutation, i.e. lacking 
the highly conserved (FETDXNLN) motif in the connecting peptide of the TCR  chain, 
CD3  cannot stably associate (Bäckström et al., 1996). While the molecular nature of the 
putative association of CD8 with CD3  remains to be elucidated, it seems unlikely the CD8  
TMD plays a role, because CD8  does not significantly associate with TCR:CD3 (Doucey 
et al., 2003; Naeher et al., 2002). In the present study we observed that K
d
/PbCS(ABA) 
multimer binding on CD8 Tacβ cells was less efficient than on CD8 β T1 hybridomas (Fig. 
4.3). Binding differences were particularly striking for multimers containing the weak agonist 
peptide Kd/PbCS(ABA) P255A, whose binding was critically dependent on CD8 (Fig. 4.3). 
Moreover and importantly, we observed that CD8αTacβ associated less strongly with 
TCR:CD3 than CD8 β as demonstrated by the lower FRET signals (Fig. 4.5). This was 
observed in the absence as well as in the presence of the MHC-peptide ligand, arguing that 
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replacement of the CD8 the one of Tac severely impairs the ability of CD8 β to associate 
with TCR:CD3. This defect is especially notable in the case of low avidity MHC-peptide 
ligands, consistent with the well-established notion that CD8 β increases the breadth and 
sensitivity of ligand recognition by the TCR:CD3. 
 
Second, efficient CD8 coreceptor function requires CD8 partitioning in lipid rafts and CD8 
association with p56
Lck 
(Arcaro et al., 2001; Doucey et al., 2001; Pang et al., 2007). These 
two aspects are intimately related, because CD8 association with Lck occurs mainly in rafts, 
due to their high p56
Lck 
content (Janes et al., 1999; Montixi et al., 1998; Moran and Miceli, 
1998; Xavier et al., 1998). Antigen-specific T cell activation is initiated by MHC-peptide 
mediated cross-linking of TCR:CD3 and CD8, resulting in activation of CD8-associated 
p56
Lck
 (Arcaro et al., 2001; Doucey et al., 2001). Because lipid rafts exclude the abundant 
phosphatases (namely CD45), they are the sites where initial p56
Lck
-mediated 
phosphorylation of CD3 ITAM take place (Arcaro et al., 2001; Doucey et al., 2001). CD8 
raft-association has been shown to be mediated by CD8β, namely by its cytoplasmic domain 
(Arcaro et al., 2000). On one hand the CD8β cytoplasmic tail harbors a membrane proximal 
palmitoylation site that when palmitolyated conveys strong raft-association (Arcaro et al., 
2000). On the other hand the short CD8β tail is extremely basic and hence promotes CD8 raft 
association by binding to acidic lipids that are highly abundant on the inner leaflet of rafts 
(Lingwood and Simons, 2010). Our results demonstrate that replacement of the CD8  TMD 
severely impairs the association of CD8 β with Lck and with lipid rafts (Fig. 4.11). 
Consistent with this is the observation that CD8 Tacβ T1 hybridomas exhibited substantially 
less intracellular Ca
2+
 flux as compared to CD8 β cells (Fig. 4.4A). Intracellular Ca2+ flux on 
CD8+ T cells has been shown to critically depend on activation of CD8-associated Lck, Lck-
mediated ITAM phosphorylation and subsequent triggering of the canonical ZAP70-LAT-
PLCγ pathway (Artyomov et al., 2010; Purbhoo et al., 2001). This activation pathway and 
intracellular Ca
2+
 elevation are also required for IL-2 production of CD8+ T cells (Stanley et 
al., 1990). This is consistent with our observation that CD8 Tacβ T1 hybridomas displayed 
reduced IL-2 responses compared to their CD8 β counterparts (Figs. 4.4B and 4.9). Again 
this difference was most striking for the weak agonist PbCS(ABA) P255A, whose IL-2 
response was entirely CD8 β dependent, i.e. was ablated by the CD8 Tac mutation (Figs. 
4.4B and 4.9).  
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It remains to be explained why replacement of the CD8  TMD with the one of Tac impairs 
partitioning of CD8 β in lipid rafts. It has been shown that a (VIL) sequence motif as present 
in the outer leaflet of the TMD of the influenza hemagglutinin protein cooperates with 
palmitoyled cysteine residues in conveying raft association (Engel et al., 2012). The CD8  
TMD contains no such VIL motif (Fig. 4.1). Another study reported the existence of a 
(VXXTLXXIY) motif in the inner leaflet of the TMD of the COPI protein p24. This motif 
was found to bind to sphingosine, a lipid abundant in rafts (Contreras et al., 2012). The CD8  
TMD contains a highly conserved IWAPLAG sequence spanning the outer and the equally 
conserved LLLSLVIT sequence in the inner leaflet (Fig. 4.1). One may argue that these 
might have analogous properties due to their similarity to cholesterol and sphingosine-
binding motifs, both lipids highly enriched in lipid rafts (Ernst et al., 2010). This, however, 
seems not plausible because CD8  does not partition in lipid rafts, unless one speculates 
that a putative CD8  TMD lipid-binding motifs might be (self)masked in CD8  
homodimers, while in CD8 β heterodimer they might be accessible for lipid binding. 
 
Alternatively and more convincingly, our results are consistent with a model according to 
which the CD8  TMD mediates the dimerization of CD8 β heterodimers (Fig. 4.12). As it 
has been demonstrated that CD8 β partitioning in lipid rafts is mediated by CD8β (Arcaro et 
al., 2000), such putative “dimers-of-dimers” containing two CD8β chains therefore are 
expected to partition in lipid rafts more effectively than CD8αβ monomers. Since CD8αTacβ is 
unable to form such putative dimers-of-dimers, this would explain the observed reduced 
partitioning into lipid rafts (Fig. 4.11). Moreover, CD8 β, but not CD8 have been shown 
to associate with the TCR:CD3, and that this is mediated by CD8β (Doucey et al., 2003). 
According to our model CD8 β dimers-of-dimers, containing CD8β are thus expected to 
associate with TCR:CD3 more avidly that CD8 β monomers. This view is consistent with 
the observation that there was less FRET between CD8 and TCR:CD3 on T1 hybridomas 
expressing CD8αβ than on those expressing CD8αTacβ (Fig. 4.5). There is biochemical 
evidence that CD8 β can form dimers, which is at variance with other studies (Ledbetter et 
al., 1981a; Ledbetter et al., 1981b). It should be noted, however, that classical biochemical 
analysis, e.g. immunoprecipation, SDS-PAGE and Western blotting fail to detect such 
CD8 β dimers-of-dimers. An intriguing implication of our CD8 β dimer-of-dimer model is 
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that these should promote dimerization of TCR:CD3, especially upon co-engagement on CD8 
and TCR:CD3 by MHC-peptide ligands, including monomers. There is indeed a substantial 
body of evidence that TCR:CD3 can form dimers (and higher oligomers) and this is critical 
for TCR triggering (Kumar et al., 2011; Minguet et al., 2007; Schamel et al., 2005).      
4.3 Conclusion and perspectives 
 
The CD8 β coreceptor plays crucial roles in thymic selection and CD8+ T cell development, 
differentiation and effector function. The CD8 β isoform expressed on the surface of CD8+ 
T cells, not the CD8 , promotes an increase in functional avidity of the TCR:CD3 complex 
by cooperatively binding to the MHC class I-peptide ligand, thereby increasing the breadth 
and sensitivity of ligand recognition by the TCR:CD3. For the coreceptor function of the 
CD8 β heterodimer it is important: 1) its ability to partition to lipid rafts where p56Lck 
resides; 2) its capacity to associate with TCR:CD3. In murine CD8 β, raft partitioning is 
achieved by the palmytoilation and the cluster of basic arginine residues at the C-terminal tail 
of the CD8β chain. We have found that by replacing the highly evolutionary conserved TMD 
of CD8  with the partially monomerizing TMD of IL-2 receptor -chain (Tac) on T cell 
hybridoma expressing the T1 TCR, we obtained surface-expressed CD8 Tacβ heterodimers 
that are severely impaired in coreceptor function. We relate this functional defect to: 1) 
reduced ability of the CD8 Tacβ to associate with TCR:CD3; 2) its diminished association 
with p56
Lck
 as a consequence of perturbed lipid rafts partitioning. We postulate that the 
replacement of CD8  TMD disrupts the formation of CD8 β dimer-of-dimers, whose 
existence would be consistent with current findings. Further studies to investigate in detail the 
contribution of the conserved sequence motifs of the CD8  TMD would be needed to 
provide conclusive evidence, uncovering yet further structural feature(s) of CD8 β.
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